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Basal cell carcinoma (BCC) is one the most common skin cancer in humans. One of the most efficacious 
drugs used in treating BCC is imiquimod, which is available as a topical cream, AldaraTM. Nevertheless, 
the drug has limited cutaneous permeation limiting its use only for the management of superficial 
BCC. The work presented in this thesis explored the utility of microneedles as a drug delivery platform 
for the intradermal delivery of imiquimod for the treatment of nodular BCC.  This was achieved by first 
comparing the insertion profiles of two commercial microneedle systems, the DermastampTM and 
Dermapen®. It was discovered that the oscillating microneedle system, the Dermapen® required less 
force than the Dermastamp™ to puncture the skin while resulting in deeper insertion in ex vivo skin 
tissue to a depth needed to treat nodular BCC. Moving forward, the effectiveness of the Dermapen® 
to improve the delivery of imiquimod into the skin was investigated. It was discovered that post-
treatment of the skin with the Dermapen® after AldaraTM application, known as “patch-and-poke”, 
enhanced the intradermal delivery of imiquimod generating a depot that that persisted for up to 24 
hours. However, such enhancement was not achieved when a “poke-and-patch” strategy was 
adopted, where skin was pre-treated with the Dermapen® prior to cream application.  
Despite the effectiveness of the “patch-and-poke” strategy in delivering imiquimod intradermally, this 
approach may not be acceptable by patients owing to the two-step nature of the treatment. In order 
to overcome this limitation a one-step drug delivery strategy utilising dissolving polymeric 
microneedles was explored. This was achieved by fabricating a dissolving microneedle system out of 
the commercial PVPVA polymer, Kollidon® VA 64. The dissolving microneedle system demonstrated 
the capability of delivering similar quantities of imiquimod but into the deeper layers of the skin, 
despite a 6-fold lower drug loading, relative to the current clinical dose of Aldara™ cream used in BCC 
treatment. Furthering this, a series of polymeric microneedles of different designs and polymer 
chemistries were manufacture from pAMPS, pNAM and pHEAM that were synthesised via free radical 
polymerisation reactions. Drug release studies into ex vivo porcine skin tissues and ex vivo patient BCC 
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tumours demonstrated that the pNAM obelisk microneedle patches were capable of achieving higher 
intradermal delivery of imiquimod relative to the commercial cream, AldaraTM. In addition, an in vivo 
tumour efficacy study using a mouse model for skin tumours highlighted that the microneedle patches 
were capable of slowing down tumour growth.  
Lastly, this thesis demonstrated the analytical capability offered by time-of-flight secondary ion mass 
spectrometry (ToF-SIMS) in evaluating the effectiveness of microneedle-based drug delivery systems. 
This is exemplified by the ability of the instrument to track the dermal distribution of active 
(imiquimod) and excipients (polymers and surfactant) from different formulations within biological 
tissues in a label free fashion. Such unprecedented analysis enabled us to demonstrate active-
excipient colocalisation thus expanding our mechanistic insight on how such delivery systems behave 
upon administration into the skin.  Overall, this thesis expanded our knowledge on how some 
microneedle systems are capable of achieving enhanced intradermal delivery while highlighting the 
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Hz Hertz 
IL Interleukin  
INF-α Interferon-alpha  
IUPAC International Union of Pure and Applied Chemistry 
LC-MS  Liquid chromatography–mass spectrometry 
Log P Logarithm of partition coefficient (octanol: water) 
m/z Mass to charge ratio 
MAL Methyl aminolevulinate 
MM Malignant melanoma 
MMS Mohs micrographic surgery 
MN Microneedle 
Mw Molecular weight 
MWCO Molecular weight cut-off 
NHS HRA  National Health Service Health Research Authority 
NICE National Institute for Health and Care Excellence 
NMSC Nonmelanoma skin cancer 
OCT Optical coherence tomography 
OCT media  Optimum cutting temperature media 
p.p.m. parts per million 
pAMPS poly (2-acrylamido-2-methyl-1-propanesulfonic acid) 
PD1 Programmed cell death protein 1 
  
 
PDMS Polydimethylsiloxane  
PDT Photodynamic therapy 
PEG Polyethylene glycol 
pHEAM Poly (N-hydroxyethyl acrylamide) 
PIX Protoporphyrin IX 
pKa Acid dissociation constant 
pNAM Poly (N-acryloylmorpholine) 
PVA Poly (vinylalcohol) 
PVP Poly (vinylpyrrolidone) 
PVPVA Poly (vinylpyrrolidone-co-vinyl acetate) 
RNA Ribonucleic acid 
RPM Revolutions per minute 
SC Stratum corneum 
SCC Squamous cell carcinoma 
SD Standard deviation 
SEC size exclusion chromatography 
SEM Standard error of mean 
SIMS Secondary ion mass spectrometry 
siRNA Small interfering RNA 
STAT3 Signal transducer and activator of transcription 3 
TA Texture analyser 
Tg Glass transition temperature 
THF Tetrahydrofuran  
TLR toll-like receptor  
TMP Meso-tetra (N-methyl-4-pyridyl) porphinetetratosylate 
  
 
TNF- α Tumour necrosis factor-alpha 
ToF-SIMS Time of flight secondary ion mass spectrometry 
UV Ultraviolet 
v/v volume by volume 
VA-044 2,2'-azobis[2-(2-imidazolin-2-yl) propane] dihydrochloride 
w/v Weight by volume 
w/w Weight by weight 






Chapter 1 General Introduction 
Parts of this introduction have been published in the following review articles: 
A.H. Sabri, J. Ogilvie, K. Abdulhamid, V. Shpadaruk, J. McKenna, J. Segal, D.J. Scurr, M. Marlow, 
Expanding the applications of microneedles in dermatology. European Journal of Pharmaceutics and 
Biopharmaceutics, 2019. 140: p. 121-140 doi: https://doi.org/10.1016/j.ejpb.2019.05.001 
• The section that has been published in this review articles are Sections 1.4.1, 1.4.2 and 1.4.4 
A.H. Sabri, Y. Kim, M. Marlow, D. Scurr, J. Segal, A.K. Banga, L. Kagan, J.B. Lee, Intradermal and 
transdermal drug delivery using microneedles – Fabrication, performance evaluation and application 
to lymphatic delivery. Advanced Drug Delivery Reviews (2020). 153: p. 195-215 doi: 
https://doi.org/10.1016/j.addr.2019.10.004 
• The section that has been published in this review articles is Section 1.4.3 
This chapter will briefly review the anatomy and function of the skin followed by routes of drug 
administration into and through the skin. Indeed, there is now a considerable body of evidence on 
how skin diseases can result in psychological problems and a poor quality of life. One of the most 
common skin diseases is skin cancer, with basal cell carcinoma (BCC) being the most common out of 
all the skin malignancies combined. Given the widespread prevalence of BCC and its impact on the 
healthcare system, this chapter will also review the limitation of current treatments for BCC and how 
microneedles can be a viable drug delivery strategy in managing the disease. The history, types and 
application of microneedles in skin cancer will also be covered in this introduction followed by a review 






1.1 Skin structure and function 
The skin is the largest organ in the human body. Besides acting as a barrier between the human body 
and the external environment, the skin also forms a part of social communication in society. This organ 
accounts for 16% of the person’s body weight and covers approximately 1.8 m2 of the total body 
surface area of an average adult. The human skin is a complex organ that is metabolically active and 
plays an essential role in thermoregulation, production of vitamin D as well as the detection of various 
sensations ranging from heat, cold, pressure, touch and pain. In addition, the human skin also plays 
an important role in conferring protection against insults from the external environment ranging from 
ultraviolet (UV), microorganism, chemicals and allergens 1. The skin is a multi-layered organ that 
comprises of three main histological layers: epidermis, dermis and hypodermis (subcutis). Besides 
that, the skin also consists appendages such as hair follicle, sebaceous glands and sweat gland as 
illustrated in Figure 1-1. 
 
Figure 1-1 Schematic illustrating the structure of the human skin. Inset highlights the details of the different 




The epidermis is a multilayer compartment of the skin that comprises of the stratum corneum, stratum 
lucidum, stratum granulosum, stratum spinosum, stratum basale and basement membrane as shown 
in Figure 1-1. This layer of the skin, the epidermis, is approximately 0.05-1 mm thick with thickness 
varying anatomically. As this layer of the skin is frequently exposed to both chemical and physical 
insults, the epidermis is in a constant regenerative state with an approximate renewal time of two 
months through the process of desquamation. 
The stratum basale consist of basal cells which serve as the stem cells within the skin. These cells are 
responsible for the regeneration and replacement of new keratinocytes which are constantly being 
shed from the skin as a result of desquamation 1. As the keratinocytes differentiate, these cells migrate 
into the stratum spinosum. Within this layer the cells establish a network of desmosomes that 
intercellularly link neighbouring keratinocytes. Upon migrating into the stratum granulosum, the cells 
begin to synthesise two types of granules which are the basophilic keratohyalin and lamellar granules. 
The basophilic keratohyalin are essentially prekeratin structures whereas the lamellar granules are 
secreted by the into extracellular space to form a lipid matrix. It is also at the stratum granulosum that 
keratinocytes begin to undergo anucleation. Within stratum lucidum, keratinocyte undergoes further 
keratinisation and becomes flattened followed by the disintegration of organelles 1. 
The outermost layer of the skin is the stratum corneum which is the main barrier to drug penetration 
into the skin. This layer is typically 10-15 µm in thickness and consist of corneocytes embedded in a 
lipid matrix. This lipid matrix of the stratum corneum consist of ceramides, cholesterol sulphates and 
sterols that are arranged in a lamellar structure 2,3. However, this lipid matrix is devoid of phospholipid 





Also known as the corium, this layer of the skin falls below the dermo-epidermal junction and is much 
thicker that the overlying epidermis which it supports. This layer of the skin is rich with collagen and 
elastin that is woven into a fibrous network that is then embedded in a matrix of proteoglycan. Due 
to this composition, the dermis confers elasticity and tensile strength to the skin. Sebaceous and sweat 
glands along with hair follicles also originates from this region 7. The dermis receives a rich blood 
supply that is derived from the hypodermis. Therefore, it is postulated that any drug that reaches this 
layer of the skin after traversing the tortuous epidermal layers, are rapidly absorbed into systemic 
circulation 4. Besides that, this layer also houses the lymphatic vessels and nerve endings. In humans, 
the dermis can be further categorised into two layers-the papillary dermis located near the epidermis 
and a deep thicker area known as the reticular dermis 6. 
1.1.3 Hypodermis 
The hypodermis also referred to as the subcutaneous layer is comprised primarily of adipocytes 
responsible for providing the body with buoyancy, insulation as well as acting as an energy reservoir. 
This subcutaneous layer consists of a network of fibrous septae that formed from collagen and large 
blood vessels. This septae anchors the adipocyte in place while providing support and structure to the 
hypodermis. The network of blood vessels that runs through these septae plays a pivotal role in 
delivering oxygen and nutrients to the hypodermis. 
1.1.4 Skin Appendages 
The skin appendages consist of sebaceous glands, eccrine glands, apocrine glands and hair follicles. 
The sebaceous glands secrete sebum which consist of a mixture of triglycerides, squalene, free fatty 
acid and wax ester 8. The secreted sebum which is in involved in moisturising the skin while providing 
homeostatic control over the skin pH which is of around pH 5.0. 
The eccrine glands, which are sometimes referred to merocine gland, are thermoresponsive to body 
temperature. The secretory coil of the eccrine gland resides in the dermis. Upon sensing a rise in body 
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temperature, these glands secrete a dilute saline solution (sweat) that evaporates thus providing 
thermoregulation to the body. The eccrine glands are distributed throughout the body but consist of 
higher density at the soles of the hand and feet. The apocrine glands which are also involved in sweat 
production reside in the hypodermis 9. 
The hair follicles consist of hair bulb and hair shaft. The hair bulb can extend as deep as 3 mm into the 
hypodermis and consist of matrix cells involved in the production of hair shaft. The hair shafts are 
produced in a regular cycle which consist of three phases- anagen, catagen and telogen 10. The density 
of skin appendages varies anatomically but accounts for approximately 0.1 % of the surface area of 
the human body 11. 
1.2 Drug delivery to and through the skin and routes of permeation 
Drug administration to the skin can be divided into topical, intradermal and transdermal delivery. A 
drug delivery system is considered as topical when the intended site of action of the dosed drug is on 
the superficial layers of the skin. On the other hand, drug delivery systems fall under the transdermal 
group when the drug is delivered through the skin and into the systemic circulation. A delivery system 
is considered intradermal when the intended target site is within the deeper layers of the skin such as 
the dermis 12. Transdermal and intradermal drug delivery systems have increasingly been used in the 
past 20 years. These systems offer various advantages over oral delivery, including avoidance of 
hepatic first-pass metabolism, localised treatment of skin pathologies, controlled drug delivery, and 
improved patient compliance 13,14. 
Advancement in the mechanistic understanding of skin permeation started to emerge in in 1943 with 
a notable review by Rothman -The Principles of Percutaneous Absorption 15. Years of research in the 
area of skin permeation culminated with the regulatory approval of first transdermal patch for the 
delivery of the antiemetic drug, scopolamine in 1979 16. Since then, along with the progress in 
biophysical techniques, our understanding of skin permeation has evolved substantially. 
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The success of transdermal and intradermal drug delivery systems is dependent on the ability of the 
drug to permeate into the skin in sufficient quantities at an acceptable concentration to achieve the 
desired therapeutic effect. However, due to the efficient barrier function of the stratum corneum, the 
range of therapeutics that are available for transdermal and intradermal delivery are limited 17. For a 
compound to conventionally traverse safely through the intact stratum corneum, a drug molecule 
should ideally possess the following attributes: Mw<600 Da, Log P: 1.0 - 3.0, low melting point, 
hydrogen bonding group ≤ 2, non-irritating and non-sensitizing 18–20. The modes of drug transport to 
and through the skin along with the permeation pathway across the stratum corneum is illustrated in 
Figure 1-2 
 
Figure 1-2 Schematic highlighting the modes of drug delivery to and through the skin. The inset highlights the 
schematic of drug penetration pathways across the stratum corneum. 
Drug molecules may permeate across the stratum corneum via four main routes which are the 
intercellular, transcellular, transglandular and transfollicular routes. The intercellular and transcellular 
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routes are collectively known as the transepidermal route while the transglandular and transfollicular 
routes are frequently called the transappendageal route.  
The transcellular is deemed the shortest route of permeation and involves the traversal of the 
permeants across alternating layers of corneocyte and the extracellular matrix. The interior of the 
corneocytes is considered hydrophilic while the extracellular matrix is lipophilic due to its’ lipid 
constituents. On the other hand, the intercellular path involves the movement of permeant via 
diffusion through the tortuous extracellular lipid matrix without traversing the corneocytes. The 
diffusional pathlength for intercellular permeation route is estimated to be approximately  
300-900 µm, which is much longer than the thickness of the stratum corneum. The majority of skin 
scientists view the intercellular route as the main route of permeation despite the longer permeation 
pathway. This is because this pathway circumvents the alternating partitioning steps between 
hydrophilic corneocytes and lipophilic extracellular matrix 21.  
The transappendageal route comprises the transport of drug molecules through the skin via sweat 
glands (transglandular) or via the hair follicles (transfollicular), therefore obviating the need to 
permeate through the stratum corneum. However, as the skin appendages only account for 
approximately 0.1 % of the total skin surface area for an adult human, the overall contribution of these 
routes to drug permeation is considered negligible 22. Nevertheless, transappendageal route is 
considered to play some role during the early phase of skin permeation before steady-state diffusion 
is established 23. In addition, these permeation pathways, particularly the transfollicular route, have 
been considered to play some role in the permeation of high molecular weight drug delivery systems 
such as nanoparticles that display low diffusion coefficients across the stratum corneum 24. 
Being the largest organ in the human body, the skin is one of the easiest organs to access in term of 
drug administration. The mode of drug delivery strategies highlighted above can be utilised not only 
for administering drug transdermally but also topically and intradermally where the intended target 
site is the skin itself. This may be of great clinical utility in managing diseased skin such as skin cancer 
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where the number of people affected by the disease is escalating globally to an increase in UV 
exposure 25.    
1.3 Basal cell carcinoma  
In general, skin cancer can be categorised into two main groups which are non-melanoma skin cancer 
(NMSC) and malignant melanoma (MM). NMSC can be further subdivided into basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC) 26. BCC is the most prevalent type of skin cancer, with the 
number of individuals affected by the disease escalating worldwide. For instance, a large US sex-
stratified cohort study by Wu et al. highlighted that the incidence rates of BCC in both men and women 
have doubled over the past 20 years 27. In addition, similar trends have been reported in Canada, Asia, 
Australia and Europe 28. Furthermore, it is anticipated that the incident rate will continue to escalate 
due to the rise in an aging population coupled with historical ultraviolet (UV) exposure  29.  
Given that UV exposure is a risk factor in developing BCC, it therefore quite common that BCC typically 
manifests on sun exposed regions of the body such as the face, arms and necks 30. The two most 
common BCC subtypes are superficial and nodular 31.  Superficial BCC generally manifests as flat red 
patches on the skin on the skin surface and proliferates parallel to the epidermis 32,33. On the other 
hand, nodular BCC manifests as a translucent pearly nodule that resides within dermis at 
approximately 400 µm below the skin surface 34,35. In addition, it has been reported that at least one-
third of nodular BCC coexists with superficial BCC 36. Despite displaying a low metastasis rate of  
0.0028 %, this form of skin cancer can lead to considerable local tissue destruction (nose, ears and 
eyelids) leading to poor cosmetic outcomes and disfigurements at the disease sites 37,38. The high 
incidence rate of the disease also forms a considerable proportion of a dermatologist’s workload 39. 
1.3.1 Current treatment strategies 
The main aim of BCC treatment is complete tumour removal with acceptable cosmetic outcome to 
surrounding tissue.  BCC tumours are treated either through surgery or non-surgical interventions. 
There are several surgical techniques that are used in the treatment of BCC such as curettage, 
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cryosurgery, carbon dioxide (CO2) laser surgery and Mohs micrographic surgery (MMS). Out of these 
surgical techniques listed, MMS is the most effective surgical procedure in managing BCC which boast 
an overall 5-year cure rate of 99% 40. MMS was first introduced in 1941 by Dr Federic E. Mohs in  
1941 41. This surgical procedure also known as margin-controlled excision involves sequential removal 
of the cancer tissue coupled with careful microscopic examination. This meticulous surgical procedure 
ensures complete tumour removal has been achieved with maximal sparing of the surrounding 
healthy skin tissue. MMS is used in the management of approximately 30 % of all BCC cases in the 
United States. Although the use of MMS in much lower in Europe, there has been a rapid rise in the 
use of this surgical procedure in the management of BCC across the UK. This is attributed to the 
National Institute for Health and Clinical Excellence (NICE) skin cancer guidelines which recommend 
one MMS specialist per skin‐cancer network across the UK 42. 
Non-surgical modalities include radiotherapy, photodynamic therapy (PDT), and topical drug  
therapy 43,44. PDT involves the eradication of cutaneous malignancy through the interaction of light of 
specific wavelength with a photosensitizing agent. Examples of photosensitising agents that are used 
in this treatment are 5-aminolevulinic acid Figure 1-3 (a) and Photofrin® Figure 1-3 (b). Upon topical 
administration, these compounds will accumulate in rapidly dividing cells. This is then followed up 
with irradiating the patient at the targeted dermal region with light of a specific wavelength that will 
elicit the generation of reactive oxygen species from the photosensitizers. The interaction of reactive 





Figure 1-3 Chemical structure of drugs used in photodynamic therapy for NMSC a) 5-aminolevulinic acid and b) 
Photofrin® 
One of the drugs that is used in the topical treatment of BCC is 5-fluorouracil (Efudix®). 5-fluorouracil 
(5-FU) Figure 1-4 on the other hand is an antimetabolite which is converted intracellularly to 
fluorodeoxyuridine monophosphate (FdUMP). This metabolite binds to the nucleoside binding site of 
thymidylate synthase and inhibits the enzyme causing a decrease in the synthesis of thymidine; a 
nucleoside essential in the DNA replication. Additionally, 5-FU may also be metabolised to other 
metabolites which are later incorporated into DNA of cancer cells leading to DNA damage and 
ultimately cell death 48. 
 
Figure 1-4: Chemical structure of 5-fluorouracil (5-FU) used in the management of non-melanoma skin cancer 
such as basal cell carcinoma 
1.3.2 Imiquimod 
Another drug that is used as a topical treatment for BCC is imiquimod, Figure 1-5. The drug is marketed 
AldaraTM cream (5% w/w imiquimod) by 3M Pharmaceuticals and was initially approved by the FDA 
for the managemental external genital and perianal warts in 1997. However, in 2004 AldaraTM was 
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approved for the management of actinic keratosis and superficial BCC. Imiquimod belongs to a class 
of drugs known as imidazoquinoline. The IUPAC name for imiquimod is 1-(2-methylpropyl)-1H-imidazo 
[4, 5- c] quinolin-4-amine (C14H16N4). This compound has a molecular weight 240.3 Daltons and display 
a relatively high melting point of 297-299 oC. The drug displays excellent chemical and physical  
stability 49. In addition, imiquimod is a hydrophobic drug that is crystalline at room temperature 
causing it to have poor aqueous solubility at neutral and basic pH and is sparingly soluble in organic 
solvents. The drug has a log P of 2.7 and  a pKa of 7.3 50. However, with a primary amine (pKa 7.3), the 
solubility and ionisation of imiquimod will ultimately be pH-dependent. In order to gauge the effect 
of pH on the ionisation of imiquimod, a log D profile of the drug as function of pH as shown in Figure 
1-5 highlights that the drug ionises and thus becomes more water soluble in acidic pH. Thus, it can be 
postulated that topical application of the drug directly on the skin will cause a significant portion of 
the drug to become ionised at the stratum corneum as this layer of the skin is relatively acidic (pH 4.5) 
relative to the viable epidermis and dermis which has a near-neutral pH (7–8) 51. The ionisation of the 
drug on the skin surface will hinder the permeation of the drug across the hydrophobic lipid rich matrix 
of the stratum corneum. 
 
Figure 1-5 (a) Chemical structure of imiquimod used in the management of non-melanoma skin cancer such as 
basal cell carcinoma (b) Log D profile of imiquimod as a function of pH predicted using ACD/I-Lab software 
Based on this Log D profile it is apparent that imiquimod displayed the highest solubility in acidic 
solution. In has been shown that the saturation solubility of imiquimod in acetate buffer pH 4.0 to be 
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as high as 1360.2 (μg/mL) 52. Based on this information, many permeation study utilised acetate buffer 
with pH ranging from 3.7-4.0 in the receptor compartment order to maintain sink  
conditions 53–55. 
Although this drug was initially developed to be use as a nucleoside analogue, it was later discovered 
that imiquimod does not have any nucleoside like activity. Instead, imiquimod is an immunomodulator 
which stimulates toll-like receptors-7 (TLR-7) on dendritic cells, macrophages and monocytes when 
applied topically. This stimulates downstream processes via the MyD88-dependent signalling pathway 
which causes an up regulation immunomodulatory gene leading to enhanced production of range of 
pro-inflammatory cytokines such as interferon-alpha (INF-α), tumour necrosis factor-alpha (TNF- α), 
interleukin (IL)-1 α, IL-1 β, IL-6, IL-8, IL-12, granulocyte-macrophage colony stimulating factor (CSF), 
granulocyte CSF, and macrophage inflammatory protein-1 α. This cytokine release results in an 
increase in the infiltration of cytotoxic T-cells and natural killer cells within the site of application which 
then elicit an antitumoral response again the BCC tumour. These proinflammatory mediators are also 
involved in inducing a Th1- dominant cellular antitumoral response again BCC. In addition, it has also 
been shown that imiquimod exerts direct pro-apoptotic effects on BCC tumour through direct 
induction of Fas receptors on the cancer cells 56. 
AldaraTM cream was licensed by the FDA for the treatment small superficial BCC. Several clinical studies 
have highlighted the efficacy of imiquimod in the management of superficial BCC 57,58. In addition, a 
randomized controlled multi-centre trial that enrolled 601 patients showed that 5 years post- 
treatment, the probability of tumour-free survival was 80.5% in patients receiving imiquimod cream 
while patients receiving methyl aminolevulinate photodynamic therapy the rate was 62.7% and those 
receiving 5-fluorouracil cream was 70.0%. This study highlighted that 5% w/w of imiquimod cream is 
superior to both methyl aminolevulinate photodynamic therapy and 5-fluorouracil cream in terms of 
efficacy for superficial BCC 59. This trial highlighted that, out of three most common drug 
pharmacotherapy available for the management of superficial BCC, imiquimod displayed superior 
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efficacy and is considered as the first choice for non-invasive management in most primary superficial 
BCC. 
1.3.3 Limitation of current treatment strategies 
It has been highlighted that surgical interventions, particularly with MMS, is the most effective 
treatment for the management of BCC which has a cure rate of 99% 40. Despite the effectiveness of 
surgical interventions, accurate detection of tumour margins prior and during surgery is pivotal in 
ensuring complete tumour resection. Such prerequisites are both time-consuming and technical, 
which are major limitations of surgical intervention 43,60–62. Furthermore, the high incidence rate of 
BCC imposes a considerable burden to the workload of dermatologists particularly in managing the 
disease 39. Therefore, it would be of great benefit if BCC can be managed via an effective non-surgical 
intervention that patients can safely self-administer at home. This would help lessen workload of 
dermatologists to enable them to manage much more severe skin conditions such as malignant 
melanoma. In addition, not all BCC patients are suitable for surgical intervention and some may opt 
for non-surgical treatment due to lower overall cost and better cosmetic outcomes 63,64.    
Non-surgical intervention such as PDT with 5-aminolevulinic acid and Photofrin® may serve as a 
solution for patients that are not suited for surgical interventions. However, as the photosensitisers 
display poor skin permeation, these drugs are frequently administered intravenously. Such delivery 
route frequently results in side effects such prolonged cutaneous photosensitivity in patients post-
treatment 45–47. Furthermore, upon intravenous administration, the photosensitising agents can take 
between 24-72 hours to accumulate in the tumour before the intended treatment site can be 
irradiated 65. Such pre-requisite may necessitate multiple visits to the dermatologist which could 
increase the workload of the clinician as well as having an impact on patients’ daily activities while 
receiving PDT.   
Due to the complications associated with PDT, topical treatment with 5-FU (Efudix®) cream may be a 
more preferred option as the patient can easily self-administered the treatment at home. However, 
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5-FU is limited to the management of superficial BCC as the drugs have poor permeation profile into 
the deeper layers of the skin for the treatment of nodular BCC which reside in the dermis. Although 
delivery of 5-FU across the stratum corneum is facilitated by its low molecular weight (130.08 Da), its 
skin permeation is limited due to its hydrophilicity (Log P −0.89) thus limiting its application for the 
management of superficial BCC 66.  
Despite possessing superior potency than 5-FU and methyl aminolevulinate photodynamic therapy, 
imiquimod also suffers poor dermal permeation thus reducing its therapeutic value to superficial  
BCC 67. William et al. highlighted that in the management of nodular BCC, it has been found that topical 
therapy with imiquimod has a much lower cure rate than surgical intervention 34. Such a finding is 
attributed to the efficient barrier function of the stratum corneum which limits the permeation of 
imiquimod into the skin 68. The location of nodular BCC that resides deep within the aqueous dermis 
presents another barrier for imiquimod delivery. The poor permeation properties of imiquimod 
deeper into the skin is attributed to the various physiochemical properties of the drug. It is suggested 
some of the ideal characteristics for a drug to permeate deeper into the skin include a Mw < 600 Da, 
a Log P 1.0 to 3.0, a low melting point, and ≤2 hydrogen bonding groups 18–20. Although imiquimod 
meets some of these criteria, the drug has a total of 4 hydrogen bonding groups. The presence of such 
hydrogen bonding groups, especially the primary amine that may interact with the anionic 
components of the stratum corneum, contributing to the poor permeation profile of imiquimod 
deeper into the skin 68. Furthermore, the drug has poor aqueous solubility which precludes the drug 
from permeating deeper into the aqueous and water rich dermal layers 50 . The combination of these 
factors presents a challenge in delivering imiquimod in a concentrated and localised fashion into the 
dermis for the treatment of nodular BCC. 
In addition, it has been reported by patients that topical treatment such as creams are often 
unfavourable as this drug delivery vehicle typically has poor cosmetic feel upon administration as well 
as exuding an unpleasant scent once applied. In addition, the restriction in daily activities post-
15 
 
application (e.g. not being able to shower and bathe after application) may result in poor  
compliance 69. Also, the likelihood of the cream spreading onto clothes and healthy skin also raises the 
issue of unwanted side effects.  
Given the limitations of current treatments for BCC specifically for the nodular variants which is the 
most common, there is an impetus to improve the delivery of therapeutic such as imiquimod into 
deeper BCC lesions. One of the early works investigating this strategy was conducted by Lee et al. The 
group evaluated the ability of fractional photothermolysis (using erbium: yttrim-aluminum-garnet 
laser) to enhance and control the delivery of imiquimod into porcine and murine skin under in vitro 
conditions 70. This study highlighted that the creation of micron sized pores enhances dermal delivery 
of imiquimod whilst having a dose-sparing property. The clinical translation of such a strategy may be 
limited however, as the use of laser-assisted delivery is both expensive and requires the technical 
expertise of healthcare professionals. However, another strategy that could be adopted to create 
micron sized pores to enhance intradermal drug delivery, in a more cost-effective manner, is via the 
use of microneedle technology. 
However, factors such as toxicity and safety ought to be considered should imiquimod be delivered 
via the use of microneedles. This is because the application of microneedle to the skin transiently 
disrupts the protective layer of the skin, the stratum corneum and this could lead to the breakthrough 
of the drug from the site of administration into the bloodstream. Such unwanted systemic exposure 
of imiquimod could lead to side effects such as influenza-like symptoms, transient shifts in leucocyte 
levels, myalgias and in some extreme cases, febrile seizure and chronic neuropathic pain 71. These 
systemic side effects would not only affect the treatment outcomes for BCC but will ultimately 
jeopardise the overall quality of life for the patients. In order to circumvent these issues, imiquimod 
ought to be delivered in a suitable vehicle that is capable of forming an intradermal depot thus 
retaining the drug within the BCC tumour while minimising systemic exposure. This can be achieved 
via the use of polymers that forms a drug-polymer matrix upon microneedle administration to the 
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skin. The embedded matrix is hypothesised to generate localised regions of enhanced viscosity that 
mitigate the permeation of the drug across the skin thus reducing unwanted systemic exposure  72,73. 
In order to achieve this delivery strategy, the polymer and excipient chosen as the drug delivery vehicle 
ought to be biocompatible and safe for clinical applications. This can be achieve by the use of FDA 
approved polymers that has been utilised for transdermal and topical applications such polylactic-co-
glycolic acid (PLGA), polyvinylpyrrolidone (PVP) and polyvinyl alcohol (PVA) 74. Besides that, the 
polymer and additive chosen must be compatible with the payload delivered, which in this case would 
be imiquimod. 
Concerns may also arise from the risk of microbial invasion into the body following the 
permeabilization of the stratum corneum through microneedle application. Nevertheless, it has been 
shown by Donnelly et al microneedle puncture resulted in lower microbial penetration into the viable 
epidermis in comparison to hypodermic needle puncture 75. Indeed, this landmark study highlighted 
that microneedle puncture was safer than conventional hypodermic injection with respect microbial 
penetration. Furthermore, it may be argued that the propensity for infection to arise via microbial 
penetration through microneedle-induced pores is further reduced due to the antimicrobial 
properties of the skin. The skin is known to produce antimicrobial peptides such as cathelicidins 76 and 
β-defensins 77,78 that function as an antimicrobial shield within the skin. In addition, the risk of infection 
could be further mitigated by aseptic fabrication and application of microneedles 79. The aseptic 
production and sterilisation of microneedle would be an important factor to consider during the 
commercialisation and translation of microneedle technology into clinical practice. However, the 
choice of sterilisation during microneedle production must be carefully selected to damaging and 




1.4.1 History and development of microneedle technology 
Described as a hybrid between hypodermic needles and transdermal patches 80, microneedles are 
biomedical microdevices consisting of rows of fine needles 81. Mark Prausnitz, one of the researchers 
who pioneered the research in the field, classified microneedles as a third-generation transdermal 
drug delivery system 16. Such devices result in micron sized pores when applied to the skin and it is 
this creation of pores through the stratum corneum that can be exploited for drug delivery. Typically, 
microneedles have a shaft length between 250-1000 μm while possessing tips sharper than those of 
hypodermic needles 82. Upon insertion, microneedles can breach the stratum corneum and improve 
the bioavailability of various therapeutics and large molecular weight compounds, a significant 
advantage relative to conventional transdermal delivery. 
The first microneedle patent was filed in 1976 by Gerstel and Place from Alza Corporation, and at the 
time it was proposed that such micron-scale needles could be utilised for transdermal drug delivery in 
a painless manner 83.  However, it was not until the emergence of microfabrication tools from the 
microelectronics industry in the 1990s that research on utilising microneedles for drug delivery started 
to gain much pace. With the help of microfabrication tools, microneedles of varying dimensions, sizes 
and material were generated to meet specific drug delivery requirements. During this period, three 
main groups from Becton Dickinson, Alza Corporation and Georgia Institute of Technology pioneered 
microneedle research for drug delivery 84.  
The first ever published paper on microneedle arrays was by Hashimi et al. in 1995 who developed a 
hollow microneedle array that injected bacterial plasmid for genetic transformation of nematodes 85.  
However, it was not until 1998 that the first publication by Sebastien Henry on the use of microneedles 
for transdermal application emerged 86. In 2004,  significant progress in the area of microneedle 
emerged when Mark Prausnitz proposed that microneedle arrays may be utilised to enhance the 
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delivery of not only small molecular weight molecules but macromolecules such as peptides, proteins, 
oligonucleotides and even supramolecular complexes 87. 
Since then, there has been an exponential rise in publications regarding microneedles for 
pharmaceutical application. It has been nearly five decades since the first patent for microneedle was 
filed. Currently, most microneedles that are available on the market are indicated for cosmetic 
purposes. More recently, microneedle devices for intradermal delivery of vaccines have been 
approved by regulatory authorities for seasonal influenza vaccination 88–93. Despite these advances, 
microneedle-based drug delivery systems are yet to make a significant impact in a clinical setting as 
most devices are still in preclinical and clinical studies. However, based on the current progress in 
microneedle research as well as the rise in the number of commercialised cosmetic microneedle 
products, it is not unreasonable to predict the emergence of therapeutic microneedle products 
indicated for the management of either acute or chronic diseases in the near future. 
1.4.2 Types of microneedles 
In general microneedles can be characterised into five main groups based on their drug delivery 
strategies: solid microneedles, coated microneedles, dissolving microneedles, hollow microneedles 




Figure 1-6 Schematic showing the different types of microneedles available for delivering drugs into and across 
the skin. The different types of microneedles are classified based on their drug delivery mechanisms. Solid 
microneedles are use as skin pre-treatment to create transient micropores, followed by topical application of the 
formulation at the application site. Coated microneedles are essentially solid microneedle that are coated with 
drug for instant delivery of therapeutic upon application into the skin. Dissolving microneedles implant the needle 
layer in the skin upon application which dissolve in the skin’s interstitial fluid over time. Hollow microneedles 
mimic the hypodermic syringe needle, after insertion into the skin, liquid formulation can be infused through the 
needle bores. Hydrogel-forming MNs imbibe skin interstitial fluid upon skin application leading to the formation 
of swollen hydrogel network. This induces drug diffusion through the aqueous hydrogel network. Drugs are often 
stored above the microneedle layer in a lyophilised wafer prior to interstitial fluid uptake 
1.4.2.1 Solid microneedles 
Solid microneedles consist of fine arrays of micron lengths needles fabricated from either silicon, 
stainless steel and even biocompatible polymers. These types of microneedles are typically used as a 
skin pre-treatment to generate microneedle channels which is then followed by the application of a 
topical formulation. With solid microneedles-based drug delivery approach, the physiochemical 
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properties of the delivered therapeutic along with the needle design play a pivotal role on the 
permeation of therapeutic into and across the skin. One of the seminal works in the field by  
Banks et al. highlighted that solid microneedle skin pre-treatment, via the “poke-and-patch” strategy, 
leads to significant enhancement in the delivery of charged hydrophilic molecules across the aqueous 
microneedle channels. In contrast, the formation of such microneedle channels did not lead enhance 
the permeation of uncharged lipophilic compounds 94.  
In the case of solid microneedles, the duration that microneedle channels remain open is a limiting 
factor for this drug delivery approach. Such limitation is attributed to the regenerative and elastic 
nature of the skin. The duration that microneedle channels remain viable using the ‘poke and patch’ 
approach has been reported to be as short as 15 minutes 95 and up to several hours 96,97. This may 
reduce the amount of drug that could be delivered with this approach. However, strategies have been 
developed to prolong pore viability for drug delivery. These include the use of non-specific 
cyclooxygenase inhibitor such as diclofenac 98, HMG-CoA reductase such as fluvastatin 99 and even 
through simple occlusion 100. 
1.4.2.2 Coated microneedles 
These are a modified version of solid microneedle that contains an additional drug-polymer coating. 
Upon insertion into the skin, the microneedles are left in place over a set period to allow the coating 
to dissolve leading to drug release. This strategy is suitable for administering a bolus dose of actives 
for dermal or transdermal delivery 101. This simple one-step application process avoids the problem of 
formulation misalignment with microneedle perforated skin as seen with the “poke-and-patch” 
strategy with solid microneedles.  
However, such microneedle strategy is not without its disadvantages. One of the downsides of such 
strategies is that only limited amount of drug could be coated onto the tip and shaft of the 
microneedles 101. Additionally, concerns have been raised on how well the coating adheres to the 
microneedle upon insertion into the skin as such coating may flake off prematurely before piercing 
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the skin leading to the unwanted loss of therapeutics. However, several strategies have been explored 
to ameliorate such drawbacks. For instance, Gill et al. found that increasing the insertion speed and 
tailoring the microneedle design (by fabricating a pocketed microneedle) may help improve coated 
microneedle delivery of therapeutics while reducing the propensity of coat flaking during insertion 101. 
1.4.2.3 Hollow microneedles 
These microneedles are reminiscent of hypodermic injection as it facilitates the flow of therapeutics 
via the microneedle bore into the skin. This approach permits more control over drug delivery rate by 
pressure driven flow 87. Through the use of hollow microneedles, one may attach the microneedle 
system to an already available injectable formulation. This would allow pneumatic-driven delivery of 
formulation similar to conventional hypodermic injection.  
However, this approach limits the selection of therapeutic to a liquid formulation. The use of liquid 
formulation in hollow microneedles also introduces the risk of leakage which can contribute to 
concerns with regards to payload delivery.  Also, the presence of a hollow bore in the design reduces 
the mechanical strength of hollow microneedle, leading to an increased risk of fracture upon insertion 
into the skin 102. In addition, hollow microneedles may be blocked by compressed dermal tissue which 
limits the available outlets for the formulation to flow out 103. Nevertheless, such problem has been 
resolved via partial microneedle retraction post-insertion which induce tissue relaxation thus 
enhancing fluid infusion 104,105. However, the retraction of microneedles to promote fluid infusion has 
been associated with increased pain sensation 106. 
1.4.2.4 Dissolving microneedles 
This category of microneedles involves encapsulating drugs within a polymeric matrix that forms the 
bulk of the microneedles. Unlike coated microneedles, the entire microneedle shaft dissolves upon 
insertion into the skin. The complete dissolution of dissolving microneedle results in no biohazardous 
sharps post insertion which is an advantage of using dissolving microneedles over solid, coated and 
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hollow designs. Also, meticulous design of the microneedle matrix permits drug delivery profile to be 
tuned for bolus or even sustained release over several weeks 107–109.  
However, in meeting such requirements, the microneedle need to be inserted into the skin for a 
specified period before being removed. Such insertion time may vary from as quick as 1 min to as long 
as an hour for effective dissolution 107,110. Furthermore, the deposition of polymer within the skin post-
insertion has raised safety concerns. This is particularly true if such systems are to be used in the 
management of chronic conditions. However, this issue may be circumvented via utilising a regulatory 
approved biodegradable polymer which degrades via hydrolysis into innocuous molecules overtime 4. 
In addition, another limitation of dissolving microneedles is that the microneedle arrays may not 
possess sufficient mechanical strength to pierce the skin causing the needle to fracture or buckle 
under pressure. Besides that, some dissolving polymeric microneedles may have a heating step in the 
manufacturing  process that may lead to degradation of the therapeutic 107,111. In order to eliminate  
this limitation, most dissolving microneedles are now made from aqueous polymer blends rather than 
hot polymer melts 112–114. 
1.4.2.5 Hydrogel forming microneedles 
Developed by Donnelly and co-workers, this is the latest class of microneedle which consist of 
microneedles fabricated from hydrogel-forming polymeric matrices. Upon skin application, this class 
of microneedles absorb interstitial fluid from surrounding skin tissue leading to hydrogel swelling 115. 
This leads to the formation of continuous, unblocked hydrogel channels which therapeutic could 
diffuse into and across the skin. Additionally, the rate of drug delivery can be tuned by the density of 
crosslinking within the hydrogel network permitting controlled drug delivery kinetics. Also, such 
microneedles have also been utilised for biodiagnostic purposes through the analysis of interstitial 
fluid that is absorbed by the microneedles upon insertion into the skin 115–117. 
This class of microneedle technology has been proposed to overcome the limitation associated with 
other classes of microneedles. The one-step application of hydrogel-forming microneedle linked to a 
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drug-loaded patch overcomes the cumbersome two-step application process associated with solid 
microneedle skin pre-treatment. It has frequently been reported that the rate of pore closure after 
solid microneedle pre-treatment differs considerably leading to considerable variation in drug 
delivery. Hydrogel-forming microneedles have the advantage of resisting pore closure while in place. 
This class of microneedle also has the added benefit of avoiding deposition of microneedle tip post-
insertion. Deposition of such debris has been a contentious issue with regards to dissolving 
microneedles as well as solid microneedles that may fracture upon insertion. The ability of such 
needles to be removed intact post insertion is attributed to viscoelastic properties conferred by the 
hydrogel materials used to fabricate the microneedles 117. However, due to the hydrophilic nature of 
the hydrogel conduit, this type of microneedle may not be suitable for the delivery of hydrophobic 
drug molecules. In addition, rapid delivery of actives may not be readily achieved with these hydrogel-
forming microneedles due to the slow diffusion of actives from the reservoir into the skin through the 
hydrogel conduits. 
There is no “one size fits all” microneedle system for the delivery of drug across and into the skin. 
Judicious selection of microneedle system tailored to the nature of the disease and physiochemical 
properties of the drug is paramount in the design of an effective microneedle system to deliver the 
payload. As an emerging pharmaceutical technology, microneedles display considerable advantages 
such as being patient friendly, easy to apply and remove, minimally invasive and painless. The 
versatility and diversity in microneedle designs allow the device to be tailored to nature of the disease 
intended to be treated. Such advantages may have a significant clinical impact in the foreseeable 
future. However, before such transition could occur, careful characterisation and evaluation of the 




1.4.3 Characterisation and evaluation of microneedles 
Microneedles vary in their dimensions and materials depending on their desired applications and 
needs. The characteristics and performance of these microneedles in drug delivery need to be 
assessed by the appropriate selection of experimental setups and analytical techniques in order to 
understand if the microneedle systems are suitable for the intended use.  
1.4.3.1 Visual Inspection and Microscopy 
The design of microneedles is dictated by a multitude of interdependent materials and fabrication 
parameters. Such micron scale needles need to possess appropriate mechanical strength, toughness 
and hardness to pierce the stratum corneum whilst at the same time be able to resist fracture and 
buckling failure. Before highlighting the methods and techniques used in evaluating the performance 
of microneedles, it would be worthwhile to illustrate the common terms which are frequently used to 
describe the architecture of a microneedle patch as shown in Figure 1-7. 
 
Figure 1-7 Common terminologies used in describing the architecture of a microneedle patch. 
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It is widely reported in the literature that microneedle geometry post-fabrication are evaluated 
through visual inspection, stereo microscopy and scanning electron microscopy (SEM) 101,118,119. Such 
characterisation permits researchers to visualise the microneedle dimension, shape, surface 
morphology and needle distribution pattern on the array post-fabrication. This inspection also permits 
the experimenter to visualise the geometry of the microneedle fabricated and estimate the radius of 
curvature (tip radius), an integral characteristic in microneedle design which dictate the efficiency of 
insertion 120,121. In addition, such examination of microneedle geometry is also critical in determining 
if the fabrication process produces needles of uniform geometry with sharp tips. The ability to clearly 
visualise microneedle geometry is illustrated in Figure 1-8 . Any heterogeneity in the microneedle 
architecture may result in poor penetration of the microneedle devices in some region of the skin.  
 
Figure 1-8 An example of a scanning electron microscopy (SEM) image of microneedle fabricated from starch-
gelatine. Microneedle and SEM image were prepared by the PhD candidate himself, Mr Akmal H Sabri. 
Microneedle tip geometry plays a pertinent role in the performance of microneedle. Early 
microneedle geometries consist mostly of cones and pyramids.   Davis et al. were the first to explore 
how hollow microneedle tip design and geometry play an essential role in microneedle insertion. The 
group, through experimental measurements along with analytical and finite element modelling, 
identified that efficient microneedle insertion may be achieved by using microneedle with a small tip 
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radius. This is attributed to a smaller contact area between microneedle and the skin, thus generating 
a higher pressure at the tip which permits improved penetration. Additionally, the group also 
discovered that a hollow microneedle tip with a thick wall endows robustness to the microneedle 
patch against fracture upon insertion 102. 
Aoyagi et al. extended the knowledge on how microneedle tip geometry influences insertion by 
systematically exploring the effect of tip geometry and needle width on the performance of 
biodegradable microneedles. The group found that biodegradable microneedles possessing low tip 
angle (15-30 o) and thin needle shaft (of 120 µm) were effective in enhancing microneedle insertion 
without causing tensile failure 122. Furthering this, Li et al. through drawing lithography and laser-
cutting techniques have fabricated microneedles of varying bevel angel (15 ° ,45 ° and 90 °) of similar 
wall thickness (30 µm). In their work, they have shown that hollow microneedles possessing a low 
angle bevel tip of 15° required the least force to pierce the skin, which is in agreement with what was 
originally reported by Davis et al. 123.  
Additionally, the geometry of the microneedle itself has been shown to impact the insertion 
behaviour. Bediz et al. have shown that solid microneedles with an obelisk design were more effective 
in enabling deeper and more reproducible insertion in comparison to pyramidial shaped microneedle. 
This was attributed to the increase in insertion force with increasing depth for pyramidial microneedle, 
an issue which was not apparent in obelisk shaped microneedles 108. However, such design parameters 
resulted in an opposite effect with hollow microneedles. This was highlighted in insertion studies by 
Chua et al. where they found that tapered/pyramidal hollow microneedle resulted in improved 
penetration in comparison to obelisk/straight hollow microneedles. In addition, the lumen of straight 
hollow microneedles were more likely to be occluded than that of tapered hollow microneedles as 
skin materials are displaced during insertion 121. 
Additionally, the use of fluorescently labelled molecules and dyes may aid the identification of 
molecules that have been successfully incorporated into the microneedle patch 124–126. Successful 
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incorporation of fluorescently labelled molecules and dyes may be visualised through the use of 
confocal laser scanning microscopy (CLSM), fluorescent microscopy or even visual inspection. Such 
inspection is pertinent as this provides the investigator with preliminary information with regards to 
the location of the incorporated molecules along the microneedle structures-tip, shaft or even the 
backing layer 127. In addition, such inspection also provides information regarding the reproducibility 
and consistency of incorporating the molecule of interest into the microneedle structure during the 
fabrication process. Figure 1-9 illustrated the use of different dyes and fluorescence in elucidating the 
location of the incorporated molecules throughout the microneedle structures.   
 
Figure 1-9(a) Utilisation of brilliant blue dye to visualise the successful and reproducible coating of microneedle 
array during fabrication process. Reproduced from Liu et al. 125. (b) An example of microneedle patch 
incorporated with fluorescently labelled inactivated polio vaccine particles and N-trimethyl chitosan chloride to 
visualise the localisation of labelled biomolecules within the patch using CLSM. Reproduced from Maaden et al.  
127 (c) Using fluorescent microscopy to visualise the successful incorporation of Nile-red loaded nanoparticles into 
microneedle shafts with the absence of nanoparticles at the tip of the microneedles. Reproduced from  
Maaden et al. 126. 
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1.4.3.2 Strength test 
In order for microneedle to perforate the skin and promote the permeation profile of therapeutics 
and cosmeceuticals, the device ought to possess sufficient mechanical strength to pierce the skin. The 
skin is well known for its inherent viscoelastic property which reduces the piercing capabilities of 
microneedles 128. Should a microneedle device possess poor mechanical property, this will result in 
skin folding around the needle tips leading to poor penetration and microneedle tip buckling 105. 
Thus, it is of great importance that strength test coupled to insertion studies are performed to 
evaluate the penetration capability of microneedles. The failure force per needle needs to exceed the 
force required for successful microneedle insertion into the skin to result in successful microneedle 
application. The successful insertion force for microneedles into skin barrier is approximately 0.098 
N/needle 129,130 to penetrate the stratum corneum. However, a study by Donnelley et al. in 2012 have 
indicated that an insertion force as low as 0.03 N per needle may suffice in piercing the stratum 
corneum 115. 
The most common test typically employed in evaluating the mechanical strength of microneedle is the 
axial compression test or the needle failure test 131. Common instrument includes the TAXT analyser. 
This analysis involves a microneedle array attached to a test probe which then presses the 
microneedle at a pre-determined speed onto a flat metal block of aluminium until a peak maximum is 
registered in the force-distance curve. This is also known as the fracture force of the microneedle 131.  
The test is frequently carried out to ascertain the mechanical strength that a microneedle could 
withstand before it deforms. This is done by measuring the maximum force registered by the texture 
analyser before microneedle is deformed. An example of a force displacement curve during a 
microneedle compression test is shown Figure 1-10. The distance travelled by the microneedles during 
the axial compression test is plotted on the X-axis while the force recorded by the probe is plotted on 
the Y-axis. It is apparent that there is a slight non-linearity to the force-displacement graph which is 
attributed to the slight inadvertent movement of the microneedles over the metal block during 
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compression as well as the minimal buckling of the microneedle itself. In the graph, the peak incident 
force is assumed to correspond the moment when all microneedles on a patch have fully fractured or 
collapsed 131. The mechanical strength of microneedles is frequently reported as “force per needle”. 
This property is calculated from the maximum force registered on the texture analyser divided by the 
number of needles per array. When performing this form of tensile strength measurement, it is 
imperative that the whole microneedle patch is flat. This is because the presence of any curvature on 
the microneedles patch may lead to uneven force distribution during the tensile strength 
measurement resulting inaccurate tensile strength measurements 131. 
 
Figure 1-10  Example of a force displacement curve during a microneedle compression test. Reproduced from 
Zhang et al. 132 
This method of evaluating the tensile strength of microneedle using the whole patch, also known as 
bulk compression, only provide an average fracture force for the microneedle with the assumption 
that all the microneedles fracture simultaneously at the peak incident force.  Such assumption may 
not be accurate as some needles in an array may buckle or break prematurely during the compression 
test. This may lead to an overestimation of the microneedle tensile strength.   Recently, Romgens et 
al. highlighted the importance of estimating the mechanical strength of microneedles using single 
needle compression test relative to evaluating a whole microneedle patch. This allows the investigator 
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to circumvent the erroneous assumption made when performing a compression test on a microneedle 
patch 133.  
In addition, the bulk compression method does not provide any insight into the variability in the 
fracture force across individual microneedles across the patch. Due to this limitation, Du et al explored 
the use of micromanipulation as a method for precise and comprehensive evaluation of the 
mechanical properties of individuals polymeric microneedles within a patch. Du et al discovered that 
indeed the mechanical strength of microneedles across one patch may vary significantly which would 
not be detected by the conventional tensile strength test currently used 134. Another limitation worth 
highlighting with the conventional tensile strength test is the difference in the force distribution along 
the length of the microneedles during test relative to actual skin insertion. When conducting the 
tensile strength test, the microneedles are pressed on a flat and rigid surface that result in most of the 
force applied to be focussed on the tip of the microneedles. In contrast, during the skin insertion the 
force are distributed over the length of the microneedles due to elastic nature of the skin that causes 
the tissue to fold around the needles as the patch is applied to the skin 135.   
In addition, most method used to evaluate the mechanical strength of microneedles only measures 
the tensile strength via axial compression. The values obtained from these tests are also known as the 
axial fracture force which represent the force needed to break the microneedles via vertical 
compression during skin insertion. It was later discovered by Gittard et al that the force experienced 
by microneedles during skin insertion is much lower than axial fracture force obtained from the 
conventional tensile strength test 135.  Despite the force required to puncture the skin being much 
lower than the axial fracture force recorded, incomplete microneedle insertion into the skin have been 
reported. This may be attributed to the heterogenous contour of the skin causing unintentional needle 
slippage during insertion that ultimately result in microneedle breakage due to shear force rather than 
axial compression  136. Therefore, another limitation of the tensile strength test is the inability of the 
test to account for the shear force needed to fracture the needles. Several research group have modify 
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the test by placing the microneedles perpendicularly to the test probe as a method to estimate the 
shear force needed to fracture the microneedles 136,137. However, a notable limitation for this variant 
of the test is the need for the investigator to manually align the probe on the microneedle during 
experiment. Such requirement is indeed challenging considering the micron scale of the needles which 
would inadvertently introduce experimental inaccuracies during the test 138. 
Nevertheless, it is worth noting that the mechanism of compression for a single needle is very different 
from the insertion profile of a microneedle array. When an array of microneedles is subjected to a 
compression test, the force applied is likely to be distributed among the needles on the array leading 
to a phenomenon known as the ‘bed of nail effect’ which reduces the force experienced by a single 
needle on the array. Such effect is not apparent during a single needle compression test. Regardless 
of the approach taken in measuring the microneedle tensile strength, it could be agreed that the 
microneedle compression test is the most commonly employed in microneedle characterisation. This 
is because the test permits the investigator to predict should the fabricated needles possess sufficient 
strength to breach the stratum corneum during insertion studies. 
1.4.3.3 Insertion studies 
It is well known in the microneedle community that complete insertion of the whole microneedle 
length is difficult to achieve due to the inherent viscoelastic properties of the skin. The depth of 
microneedle insertion falls under two categories. True depth and estimated depth. Methods which 
provide true depth include confocal microscopy, X-ray transmission computational tomography and 
optical coherence tomography (OCT). On the other hand, method such as histological cross sectioning 
and staining provide estimated depths of microneedle insertion. 
Conventionally, microneedle insertion studies are frequently carried out using excised animal  
skins 109,139,140 or human skins 101,141. This involves placing an excised skin with the stratum corneum 
face up on a flat surface such as parafilm or a wooden cork to mimic the underlying soft tissue. The 
desired treatment site is then gently stretched to even out any skin folds while microneedles are 
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manually applied into the skin. After the microneedles are inserted and removed, the investigator will 
then apply a dye to the treatment site. Common dyes used to stain microneedle channels include 
gentian violet 118, methylene blue 120 and trypan blue 141. Should successful microneedle insertion take 
place, one may observe the staining of microneedle channels. Such staining arises from the ability of 
the dye to selectively bind to the nucleus of the underlying epidermal and dermal cells over the 
anucleated stratum corneum. Alternatively, this study may be carried out in vivo using healthy human 
volunteer or animal such as nude mice models. Furthering this, the penetration success ratio of 
microneedles may be calculated by counting the number of dye-stained spots observed to the total 
number of microneedles per array 142 .  
When performed ex vivo, microneedle insertion studies may be accompanied with histological 
sectioning that allows the investigator to visualise the depth of microneedle pores and estimate the 
length of microneedle penetration. Should the fabricated microneedle contain fluorescently labelled 
molecules, the microneedle insertion site may be visualised using fluorescent or confocal microscopy 
143–145. Examples of microneedle insertion sites visualised via microscopy post histological sectioning 
are shown in Figure 1-11. Despite the popularity of visualising microneedle channels using histological 
sectioning and microscopy,  this process  is quite lengthy and cumbersome, with the propensity of 
altering the skin structure during the freezing and sectioning steps 146. 
 
Figure 1-11(a) Example of microneedle insertion site visualised by microscopy after skin cross sectioning. Image 
reproduced from Lee et al. 147 Microneedle insertion site imaged via fluorescent microscopy after sulforhodamine 
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B was deposited into the skin post insertion. Reproduced from Zhu et al. 148. Microneedle insertion site containing 
FITC-dextran visualised via fluorescent microscopy.  Reproduced from Ling et al. 144 
Due to the limitation of histological sectioning in investigating microneedle insertion, alternative 
techniques have been explored in an effort to elucidate the true depth of microneedle insertion into 
the skin in a non-invasive manner. Insertion of microneedles may be observed in real time using optical 
coherence tomography (OCT) which is a non-invasive method for characterising skin structure. In 
addition, this technique permits real time monitoring of microneedle insertion into the skin 149.  
Non-invasive diagnostic techniques such as OCT on human volunteers may be the most reliable 
method to study microneedle penetration as this overcomes the issue of architectural and biological 
differences between animal and human skin 150.   
In addition, more advance analytical technique such as computerised X-ray tomography have been 
employed to study the penetration profile of microneedles. This was first carried out by Loizidou et al. 
This non-destructive technique utilises a series of X-ray scans taken at different rotation angles that 
generate 3D volumetric data. Such techniques allow researchers to visualise microneedle insertion in 
a 3D manner. However, the method is limited for microneedle materials that display X-ray contrast 
properties such as gold 146. Examples of X-ray tomography and OCT images showing microneedle 




Figure 1-12 (a) An example of a X-ray computer tomography of a gold coated microneedle inserted into porcine 
skin which was imaged using Bruker microCT SkyScan 1174. Reproduced from Loizidou et al. 146. (b) An optical 
coherence tomography image of microneedle inserted in neonatal porcine skin. Reproduced from Vora et al. 151. 
Additionally, Larrañeta et al. have developed a simple and validated insertion model for microneedles 
using thermoplastic sheet made of olefin-type polymer. Such polymer have been shown to simulate 
the elasticity and mechanical properties of the skin allowing researchers to evaluate the insertion 
depth of various microneedles in a fast and rapid manner 151.  The insertion depth may be estimated 
by multiplying the number of layers penetrated by the microneedle to the thickness of each Parafilm 
M® layer (127 μm). Additionally, a more accurate penetration may also be evaluated using optical 
coherence tomography. The simplicity of this test that obviates the use of biological material have 
slowly gained popularity within the microneedle community 131. 
1.4.3.4 Permeation studies 
The most common in vitro method employed in studying microneedle-enhanced dermal permeation 
of compounds is through the use of diffusion cells. In general, these diffusion cells consist of a donor 
compartment and receptor compartment that is separated by a membrane (typical ex vivo human or 
animal skin, or an artificial polymeric membrane). Formulations containing the permeants of interest 
is typically introduced into the donor compartment that diffuse across the membrane of choice and 
into the receptor compartment. The permeant that has diffused into the receptor compartment are 
then analysed by means of analytical techniques such as high-performance liquid chromatography 
(HPLC). Typically, diffusion cells are classified into two main types: static (Franz-type) and flow-through 




Figure 1-13 Types of diffusion cells used in studying skin permeation (a) vertical static diffusion cell (b) side-by-
side static diffusion cell (c) flow through cell. 
In static diffusion cells, permeants partition into a fixed volume receptor compartment that is 
thermostatically controlled. In addition, the receptor media is continuously mixed via a magnetic 
stirrer bar in order to maintain a sink condition within the receptor compartment 152. Besides that, a 
defined volume of the receptor media is manually sampled at predefined intervals and replaced with 
an equal volume of fresh receptor media. Such a sampling procedure allows the investigator to plot 
the permeation profile of the investigated compound over time. Alternatively, the receptor 
compartment may be sampled at the end of the experiment to determine the cumulative amount of 
compound of interest that has permeated.  
Franz-type diffusion cells can be further sub-classified into side-by-side or upright based on how the 
skin is orientated in the diffusion cell. The earliest type of diffusion cell used in percutaneous 
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absorption studies was the side-by-side static diffusion cells. In these diffusion cells both skin surfaces- 
stratum corneum and dermis are fully immersed in donor solution and receptor media, respectively, 
with both solutions being stirred simultaneously by means of stirrer bars. However, the side-by-side 
diffusion cells is rarely used in skin permeation study nowadays as the skin is more susceptible to 
damage with such experimental set up. In addition, there is the possibility of overestimating the 
permeation profile of compounds due to excessive and prolonged hydration of the stratum corneum 
by the donor compartment. In addition, the selection of formulations that are suitable to be 
investigated in side-by-side diffusion cells is limited to simple drug solutions. Nevertheless, the side-
by-side static diffusion cells are occasionally used when evaluating drug delivery systems such as 
electroporation, iontophoresis and sonophoresis.  
Due to the limitation of the side-by-side diffusion cells, another variant of the static diffusion cells 
known as the upright diffusion cell emerged in 1975. This type of diffusion was known as the Franz 
diffusion cell which was named after Thomas James Franz who invented the apparatus 153. In this 
setup, the skin is clamped between a receptor compartment that contains the receptor media while 
the stratum corneum side faces the donor compartment and is open to the ambient laboratory 
environment. Such experimental set up aims to mimic the typical environment that the stratum 
corneum experiences 152,154.  
The second type of diffusion cells is the flow-through cells which was introduced Robert Bronough and 
Raymond Stewart in 1984. Unlike the static diffusion cells, the flow-through cells maintain a sink 
condition by utilising a peristaltic pump that ensure continuous flow of the receptor media through 
the receptor chamber. Such continuous flow beneath the skin attempts to mimics the dermal blood 
circulation that carries exogenous compound away from the absorption site. In addition, these type 
of cells employs automatic sampling that overcome labour intensive sampling time points while 
enabling continuous monitoring of absorption profile  155. Despite these advantages, the Franz-type 
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static diffusion is more commonly used in percutaneous studies as the flow-through cells are 
inherently more complex and costly thus limiting their utility 152. 
In the field of microneedle research, the Franz-type diffusion cells are the most commonly employed 
experimental setup used to study the permeation of pharmaceuticals and cosmeceutical into and 
across the skin. However, compared to the conventional way of performing in vitro Franz cell 
permeation study, microneedle application is typically applied to skin first before the donor 
compartment is mounted onto the receptor compartment 119,126,156,157. It is worth noting that a 
different set up should be adopted when designing a microneedle mediated Franz cell permeation 
study. Some may opt to exclude the process of dermatoming the skin prior to setting up the Franz 
cells as the action of dermatoming the skin may results in loss of skin tension and elasticity 158. Such 
alteration in skin biomechanical properties during the dermatome process may lead to over-
penetration of microneedle into the dermal tissue. Therefore it is of no surprise that some researchers 
opt to conduct in vitro microneedle mediated permeation study using full skin thickness in order to 
preserve the biomechanical properties of skin 66,126,151. 
In general, ex vivo human skin provides the best model to study and estimate the permeation profile 
of drug molecules across the skin 159. Nevertheless, access to ex vivo human skin is very scarce and 
expensive. This is further complicated by large sample variability in ex vivo human skin due to race, 
age, gender as well as the anatomical location where the skin was sourced. Furthermore, as large 
number of studies are typically required to access, develop and optimise pharmaceutical formulations 
means that ex vivo animal skins are usually used as surrogates to evaluate permeation of drug into 
and across the skin. Despite being more readily available than human skin, rodent skin is considered 
unsuitable as a surrogate to ex vivo human skin. This is because rodent skins have an epidermal 
thickness of less than 25 µm which is much thinner than that of human skin which have an epidermal 
thickness of 72 µm 160. Besides that, the presence of panniculus carnosus, a muscular layer in rodent 
skin that is absent in human skin leads to differences in the mechanical properties of rodent skin 
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relative to human skin. Such anatomical differences between rodent and human skin can lead to an 
overestimation in drug permeability 161.  On the other hand, porcine skin is deemed to be the most 
histologically similar to human skin and thus is widely used as a surrogate to study the permeation of 
compounds into and across the skin 162. The comparison in properties and anatomy of human and 
porcine skin can be summarised in the Table 1-1. 
Table 1-1 Comparison between the properties of ex vivo human and porcine skin as reported by Jacobi et al 162, 
Ranamukhaarachchi et al 163 and Netzlaff et al164 
Properties Human skin Porcine skin 
Average thickness of stratum corneum, 
µm  
19 21 
Average thickness of viable epidermis, µm  76 72 
Average thickness of dermis, mm 1.86  1.85  
Average hair follicle density per cm2 ≈20  ≈23  
Average depth of extension of hair follicle 
into the dermis, mm 
1.20 1.00-3.00  
Average diameter of the orifice of hair 
follicle, µm  
≈ 200 µm ≈ 170 µm 
Mechanical properties measured as 
Young’s modulus for full skin thickness, 
N/m2 
1.88 ± 1.23  1.74 ± 1.28 
Arrangement of lipid within the stratum 
corneum 
orthorhombic lattice hexagonal lattice 
Percent of dry weight of cholesterol from 
full thickness skin, (w/w) % 
0.63 ± 0.15 0.62 ± 0.42 
Percent of dry weight of cholesterol ester 
from full thickness skin, (w/w) % 
0.56 ± 0.09 0.12 ± 0.07 
Percent of dry weight of fatty acids from 
full thickness skin, (w/w) % 
0.68 ± 0.16 0.34 ± 0.25 
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Percent of dry weight of triglycerides from 
full thickness skin, (w/w) % 
5.48 ± 2.42 1.37 ± 1.02 
Percent of dry weight of ceramide from 
full thickness skin, (w/w) % 
0.65 ± 0.10 0.18 ± 0.07 
 
It can be seen that there are some similarities of between human and porcine skin as shown in Table 
1-1. This is true in terms of stratum corneum, epidermal and dermal thickness as well as the overall 
mechanical properties of the skin. Nevertheless, there are also some differences between human and 
porcine skin that is worth noting such as the differences in lipid profile (e.g cholesterol ester, 
triglycerides, fatty acid and ceramide) as well as the overall lipid arrangement within the stratum 
corneum. Despite these differences, there are a number of studies that have shown that both ex vivo 
porcine and human skin display similar permeability for both hydrophilic and lipophilic compound that 
justify the use of porcine skin as a surrogate to human skin  164,165.  
However, it is also worth highlighting that the permeation results obtained from either ex vivo human 
or porcine skin should be carefully interpreted as it has been shown that the process of freeze-thawing 
the skin samples may result in some degree of damage to the skin through the formation of ice crystal 
within the stratum corneum 166. Such damage to the stratum corneum may lead to an enhancement 
and overestimation in the permeation of compound across the skin when compared to in vivo 
conditions. However, a study by Barbero and Frasch found no significant difference in the steady 
steady-state flux of diethyl phthalate across fresh and previously frozen ex vivo skin (stored up to 18 
months), suggesting that the effect of freeze-thawing in some instance might not be significant on the 
barrier properties of the skin 167. On the other hand, it is worth highlighting that one of the major 
limitation of using freeze-thawed ex vivo skin is the inability to use these models to predict dermal 
drug metabolism as these skin samples are rendered metabolically inactive once the skin are frozen 
due to ischaemic necrosis 168. Nevertheless, the use of frozen skin after thawing indeed provide some 
level of convenience in early formulation development studies in screening the permeation of 
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compound across the skin before such formulation are evaluated further in vivo using a suitable animal 
model.  
1.4.4 Application of microneedles in skin cancers 
Research in utilising microneedles for delivery of therapeutics for the treatment of skin cancers was 
pioneered by Donnelly et al. in 2008. Through the use of solid silicon microneedles and bioadhesive 
patches containing 19 mg aminolaevulinic acid (ALA) cm−2, the group employed the ‘poke and patch’ 
strategy on a nude mouse model to enhance ALA delivery into the skin. This was the first study to 
demonstrate microneedles enhanced localised delivery of a photosensitiser to the skin. In addition, 
such a strategy also showed a reduced application time, and a reduction in the dose of ALA needed to 
elicit high-level of photosensitiser in targeted skin lesions 169. Following these studies, various groups 
have explored different microneedle designs to deliver a range of anticancer drugs to the skin. 
Examples of such drugs include methyl aminolevulinic acid (MAL) 170, meso-tetra (N-methyl-4-pyridyl) 
porphinetetratosylate (TMP) 171, itraconazole 172 and 5-FU 66. A summary of these studies is presented 
in Table 1-2. 
Table 1-2 Summary of microneedle studies focussed on intradermal delivery of therapeutics for skin cancer. 
Abbreviations: ALA (aminolaevulinic acid), TMP (meso-tetra (N-methyl-4-pyridyl) porphinetetratosylate), MAL 
(methyl aminolaevulinic acid), protoporphyrin IX (PIX), 5-Fluorouracil (5-FU) programmed cell death protein 1 










ALA and TMP Ex vivo (neonatal porcine skin) Donnelly et al.  
(2014) 173  
Solid. ALA Ex vivo (murine and porcine skin) 
In vivo (murine model) 
Donnelly et al.  
(2008) 169 
Solid. TMP Ex vivo (murine and porcine skin) 
and in vivo (murine model) 
Donnelly et al.  
(2009) 171 
Dissolving. ALA and MAL In vivo healthy human volunteer 
(n=14) 








Model to evaluate 
microneedle performance 
Ref 
Solid. ALA In vivo human with actinic 
keratosis or Bowen’s disease 
(n=3) 
Kolde et al.  
(2013)  174 
Coated. ALA Ex vivo (porcine skin) using Franz 
cell set up 
In vivo (murine model) 
Jain et al. (2016) 175 
Dissolving. anti-PD1 antibody In vivo B16F10 murine model of 
melanoma 
Wang et al. (2016) 176 
Dissolving. anti-PD1 antibody In vivo B16F10 murine melanoma 
model 
Ye et al. (2016) 177 
Solid and hollow. Itraconazole In vivo human basal cell 
carcinoma murine model 
Zhang et al. (2016) 172 
Solid. Melanoma vaccine 
microparticle 
Tumour challenge study using In 
vivo murine model  




vaccine for malignant 
melanoma (MM) 
therapy 
Tumour challenge study using In 
vivo murine model 
Hu et al. (2015) 179 
Coated. human melanoma 
antigens and adjuvant 
In vitro cell culture using dendritic 
and T cells. 
Zeng et al. (2017) 180 
  In vivo murine model  
Solid. 5-FU In vitro Franz Cell setup using 
mouse skin 
In vivo B16F10 murine model of 
melanoma 
Naguib et al.  
(2014) 66 
 
Solid. ALA In vivo hairless murine model with 
SCC induced through UV 
irradiation 
Wang et al. (2015) 181 
Dissolving. Lanthanum hexaboride 
nanoparticles and 
Doxorubicin 
In vitro drug release into (porcine 
cadaver skin). 
In vivo severe combined 
immunodeficient (SCID) murine 
model bearing 4T1 tumours. 
Chen et al. (2016) 182 
Dissolving. Doxorubicin and gold 
nanocage 
In vitro B16F10 mouse melanoma 
cell line. 
In vivo B16F10 murine model of 
melanoma 







Model to evaluate 
microneedle performance 
Ref 
Dissolving. STAT3 siRNA 
encapsulated with 
polyethylenimine 
In vitro B16F10 melanoma cells 
line. 
In vivo B16F10 murine model 
of melanoma 
Pan et al. (2018) 184 
Dissolving. RedaporfinTM In vitro Franz Cell setup using 
porcine skin 
In vivo biodistribution studies 





In vitro A375 human 
melanoma cells line. 
In vivo A375 murine model of 
melanoma 
Ruan et al. (2018) 186 
Coated. PEGylated gold 
nanorod and 
doxorubicin  
In vivo Release study in murine 
model 
In vivo A431 murine model of 
melanoma 
Hao et al. (2018) 187 
Solid. mesoporous organo- 
silica nanoparticles 
covalently linked with 
dabrafenib and 
trametinib 
Ex vivo (porcine skin) 
In vivo A375 murine model of 
melanoma 
Tham et al. (2018) 188 




indocyanine green  
In vitro viability of MG-63 
osteosarcoma cell line. 
In vivo murine model of 
osteosarcoma. 







Model to evaluate 
microneedle performance 
Ref 
Solid. Vismodegib In vitro Franz Cell setup using 
porcine skin. 
In vitro skin irritation test using 
reconstructed human 
epidermis model. 
Nguyen and Banga, 
(2018) 128 
Dissolving. 5-FU and indocyanine 
green 
In vivo A375 murine model of 
melanoma and A431 human 
squamous carcinoma model 
Hao et al. (2020) 190 
Coated. Cisplatin In vitro Franz Cell setup using 
porcine skin. 
In vivo A431 murine model of 
human squamous carcinoma 
Uddin et al. (2020) 191 
Dissolving. Doxorubicin and 
indocyanine green 
Ex vivo (porcine skin) insertion 
and drug release 
In vivo B16F10 murine model 
of melanoma 
Song et al. (2020) 192 
Dissolving. Curcumin Ex vivo (porcine skin) insertion 
and drug release 
Abdelghany et al. 
(2019) 193 
Dissolving. Cytotoxic T-cell 
epitope peptide 
In vivo B16F10 murine model 
of melanoma 







Model to evaluate 
microneedle performance 
Ref 
Dissolving HA15, an emerging 
antimelanoma drug 
In vitro Franz Cell setup using 
murine skin 
In vivo B16F10 murine model 
of melanoma 
Chen et al. (2020) 195 
 
For example, Jain et al. developed a 5-ALA coated microneedle to improve dermal delivery of the 
photosensitizer to treat skin tumours. The group showed that the 5-ALA coated microneedle patch 
allowed improved delivery of 5-ALA deeper into the tumour lesion in comparison with topical 
application of 5-ALA cream. Interestingly, the coated microneedle also displayed better efficacy in the 
in vivo murine skin tumour model despite delivering a lower dose relative to topical cream  
application 175.  
On the other hand, Naguib et al. demonstrated, using a murine model, the feasibility of using solid 
microneedles to enhance the intradermal delivery of 5-FU to treat skin tumours. In their in vitro work, 
the group demonstrated that 5-FU flux increased by 4.5-fold when 5-FU cream was applied on 
microneedle-perforated murine skin compared to cream application on intact skin. In vivo work using 
a mouse model with B16-F10 melanoma tumour showed that topical application of 5-FU cream  
(5% w/w) on microneedle-perforated skin showed significant tumour inhibition relative to intact  
skin 66. Although preliminary in nature, these studies highlight that microneedles hold great potential 
in improving intradermal delivery of antineoplastic agents to improve the treatment efficacy of skin 
cancer. More recently, several groups began to explore the strategy of delivering anti-melanoma 
vaccines as a method to treat and prevent the development of metastatic melanoma 178,179,196. 
Recently, it has been proposed that delivery of anticancer agents into superficial skin tumours via 
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dissolving microneedles may be more efficacious than nanosized carriers as microscale structures of 
microneedles enable long term retention of chemotherapeutics at tumour sites 182.  
However, it is worth highlighting that due to the metastatic nature of metastatic melanoma, 
microneedles may not be a suitable standalone intradermal therapy, unless they are used for 
transdermal delivery of antineoplastic agents for systemic management of metastatic melanoma. In 
such a setting, microneedle-based treatment for melanoma ought to be used as an adjuvant to the 
standard metastatic melanoma care plan. Therefore, should research on utilising microneedles for the 
treatment of melanoma continue, researchers in the area ought to aware of the systemic nature of 
the disease and evaluate how microneedles may be able to be used to treat the metastatic melanoma 
that has invaded to other sites of the body. If such a strategy is deemed ineffective, research on 
microneedle-based skin cancer therapy should focus on more localised tumours such as BCC or some 
variants of SCC. 
1.5 Time of flight secondary ion mass spectrometry (ToF-SIMS) in skin permeation analysis 
1.5.1 Limitations of current methods to track dermal distribution of therapeutics 
Detailed analysis of the dermal distribution of pharmaceuticals within the skin strata is paramount in 
order to evaluate the permeation enhancement effect conferred by microneedles for targeted skin 
delivery. Traditionally, chromatographic analysis (e.g., high-performance liquid chromatography, 
HPLC) is frequently implemented in microneedle permeation studies in order to evaluate the delivery 
of drugs into and across the skin. However, the tissue manipulation steps and extraction procedures 
lead to the loss of valuable spatial information regarding drug localisation within the skin tissue 197.  
In order to overcome this limitation, microneedle permeation studies frequently use fluorescently-
tagged molecules in order to track their distribution within the skin 104. This method of tracking dermal 
distribution can be achieved via the use of confocal laser scanning microscopy (CLSM). CLSM utilises 
point illumination via the use focused laser beam that is rastered across the sample of interest. The 
emitted fluorescence from the in-focus plane is passed through a pinhole onto a detector, which the 
46 
 
measures the fluorescence from the site of analysis. Any out-of-focus fluorescence is blocked by the 
pinhole, which is said to be confocal with the focal point of the objective lens. CLSM has been used to 
tracked the permeation of compounds delivered using microneedle-based delivery systems 129,132,144. 
Although this approach allows the experimenters to track drug localisation within the skin, the use of 
fluorescent tagging with this method alters the physiochemical properties of molecules leading to 
erroneous estimation of drug distribution in biological tissues 198. In addition, the need for different 
fluorescent tagging to track the dermal distribution of multiple molecules complicates the method 
even further. 
Some of the techniques that offer label-free imaging of dermal drug distribution include confocal 
Raman microscopy and stimulated Raman scattering microscopy. These techniques have been used 
to visualise the dermal distribution of several pharmaceuticals such as 5-fluorouracil 199, ketoprofen 
200, and terbinafine 200. In addition, Confocal Raman microscopy and stimulated Raman scattering 
microscopy offer the advantage of being non-destructive techniques that require minimal sample 
preparation prior to analysis 201. Although these methods offer researchers the ease and feasibility to 
visualise dermal drug distribution in a label-free manner, some compounds may not have a diagnostic 
Raman signal, thus limiting the range of molecules which could be tracked by the technique. 
Furthermore, the molecule of interest which do have a diagnostic Raman signal should be present at 
sufficient concentration to allow detection. Another issue associated with Raman-based imaging is the 
high level of autofluorescence from biological tissue which can mask the weak Raman signal thus 
limiting the utility of these techniques to map dermal drug distribution 202. Hence, there is a clear need 
for advanced analytical techniques to be utilised in the field of microneedle research to allow 
researchers to track drug distribution within skin tissues in a label-free manner with high chemical 
sensitivity for a wider range of drug molecules. 
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1.5.2 Principle of ToF-SIMS Analysis 
Time-of-flight secondary ion mass spectrometry (ToF-SIMS) is a powerful surface analytical technique 
that confers excellent mass resolution, chemical sensitivity and high spatial resolution 203,204. Analysis 
of samples using ToF-SIMS permits us to chemically map the spatial distribution of a compound of 
interest as well as providing information on how such distribution changes with depth. The general 
component of a ToF-SIMS instrument is illustrated in Figure 1-14. 
 
Figure 1-14 A general schematic of the ToF-SIMS instrument. The inset shows a close up of the sample analysis 
taking place as a result of the collision cascade (red arrows) caused by primary ion bombardment onto the sample 
surface. Adapted from Saleem & Galla 2010 205 
ToF-SIMS employs the use of a focussed primary ion beam that is rastered across the samples surface. 
Sample analysis is conducted under ultra-high vacuum (~ 10-7 Torr) as this ensure the ion beam is 
focussed leading to high spatial resolution. The bombardment of the primary ion beam on the sample 
will lead to an energy transfer process from the primary ion beam to the target surface leading to 
molecular fragmentation. In addition, such energy transfer known as the collision cascade, shown in 
48 
 
red arrows in Figure 1-14, endows the molecular species at the target surface with the ability to 
overcome the surface binding energy leading to the emission of secondary particles through a process 
known as sputtering. These desorbed secondary ions are then then extracted through a time-of-flight 
tube which separates and detects the particles based on their mass-to-charge (m/z) ratio 205,206. The 
recorded ion can be represented as a single spectrum of the analysed surface or a mass spectral image 
where each pixel is a complete mass spectrum. Such mass spectral images are of heuristic value in 
identifying how ions of interest are distributed across the analysed surface 207.  
ToF-SIMS may be operated under two different modes: static and dynamic. In static SIMS, the ion dose 
delivered is low (< 1012 cm-2) with a low flux (10 pA–5 nA) 208. The low primary-ion dose delivered results 
in approximately less than 1 % of the uppermost surface monolayer being sampled 209. With this 
operational mode, the primary ion dose delivered is below the static limit and ensures that statistically 
no region on the sample will be rastered twice during the acquisition period. This mode of analysis 
also ensures only the surface (1-2 nm) of the samples are analysed 210.  
On the other hand, dynamic SIMS describes the operation of the primary ion beam at high current flux 
while delivering the primary ions at a dose which is above the static limit. This operating parameter 
leads to sample surface erosion. This operation mode is frequently used to elucidate changes in a 
sample’s chemical composition and distribution as a function of depth 208.  
Depth profiling using ToF-SIMS may be carried out using either monoatomic ions or cluster ions. 
However, monatomic ions sources such as Ga+ and Cs+ cause much deeper damage into the sample 
upon impact with low sputter yield compared to cluster ion sources. In addition, subsurface mixing 
may ensue followed by substantial topography development. These drawbacks severely reduce the 
depth resolution that could be achieved during depth profiling 211,212. In contrast, cluster ions do not 
penetrate deep into the sample. Upon impact, the energy from cluster ions is deposited within the 
first few nanometer of the surface. This leads to high sputtering yields with minimal subsurface 
damage as well as preserving larger molecular species which may be of interest 213,214.  
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Research in the area of primary ion beams has led to development of several polyatomic ion sources. 
This includes Bin+, C60+ and Arn+. Unlike monoatomic primary ion sources, the energy associated with 
polyatomic ion source are distributed evenly between all the atoms that forms the polyatomic cluster. 
Such energy dispersion between the atoms results in low energy impacts between the primary ion 
source and the samples. Such low energy impact results in an increase in the overall secondary ions 
yield sputtered from the samples. In addition, such impacts also improved the desorption of larger 
secondary ion fragments that contain greater chemical complexity and information. Such 
enhancement in the secondary ion emitted was more noticeable in the higher mass region  
(i.e., m/z > 200) of the spectrum 215. This improvement in secondary ion yield detected from the use 
of cluster primary ion beam was of great importance as it permitted the analysis of biological samples 
which do not ionise as readily as inorganic materials. 
1.5.3 Application of ToF-SIMS imaging in drug delivery to the skin 
Since the development of cluster primary ion beams there are substantial amount of studies that have 
utilised ToF-SIMS in analysing a range of biological materials ranging from proteins 216, lipids 217 and 
even diseased tissues 218–221. Subsequently, the application of ToF-SIMS in the area of skin tissue 
analysis have also been explored 222–225. The utilisation of ToF-SIMS in the area of skin permeation 
research emerged in 2006 and was pioneered by Okamoto et al.  who studied the permeation of 
pseudo ceramide into ex vivo porcine skin 226. However, it was not until seven years later that  
Judd et al. utilised ToF-SIMS as a method to track the permeation of drug molecules such as 
chlorhexidine digluconate into ex vivo skin as shown in Figure 1-15  highlighting that most of the drug 




Figure 1-15 ToF-SIMS images of various ions fragments from ToF-SIMS analysis of skin cross-sections treated with 
2% chlorhexidine (w/v) treated onto ex vivo porcine skin. C7H4N2Cl- is the fragment ion for chlorhexidine and was 
used to track the permeation of the drug into the skin. Phosphate ion, PO2- was used to map the viable epidermis 
while CNO- is generic fragment ion for biological tissue such as skin. Field of view is 400 × 400 µm. Adapted from 
Judd et al. 223 
The most common sample types that are analysed via ToF-SIMS from a majority of skin permeation 
studies are tape strips and cross-sections. Tape strips are widely analysed using ToF-SIMS as this type 
sample allow us to gauge the permeation of compound into the stratum corneum. This form of sample 
analysis via ToF-SIMS allows us view the lateral distribution of compounds within the stratum corneum 
at a layer-by-layer level 227. In addition, tape stripping also allows us to collect in vivo human samples 
in a minimally invasive manner relative to punch biopsies. On the other hand, ToF-SIMS analysis of 
skin cross-section from ex vivo tissues enable researcher to gauge the permeation profile of a 
compound as a function skin depth following permeation experiments 68.   Following the early works 
by Okamoto et al. and Judd et al. there have been an increasing number of publications in the field 
that have utilised ToF-SIMS as an analytical tool to track the permeation of compounds into the skin 
through the analysis of samples such as skin cross-sections and tape strips. Table 1-3 summarise the 
list of publication which have utilised ToF-SIMS as analytical method to track the permeation of 





Table 1-3 Utilisation of ToF-SIMS analysis in skin permeation studies. 





Cross sections from ex 
vivo porcine skin 
25 keV Au+  Sphingolipid E and 
pseudo-sphingosine 
Okamoto et al. 
(2006) 226 
Cross sections and tape 
strips from ex vivo 
porcine skin 
25 keV Bi3+ Chlorhexidine 
digluconate 
Judd et al.  
(2013) 223 
Cross sections from ex 
vivo human skin 
25 keV Bi3+ Oleic, linoleic, lauric 
and capric acid  
 
 Kezutyte et al. 
(2013) 228 
Cross sections from in 
vivo mouse skin 
60 keV Bi32+ Chromium ions Kubo et al. (2013) 
225 
Cross sections from in 
vivo mouse skin 
25 keV Bi3+ Roflumilast, tofacitinib 
and ruxolitinib 
Sjövall et al. (2014) 
224 
Cross sections from ex 
vivo human skin 
25 keV Bi3+ Linoleic, oleic, 
palmitoleic, palmitic, 
and stearic fatty acid 
Cizinauskas et al. 
(2017) 229 
Cross sections from ex 
vivo human skin 
25 keV Bi3+ Dihydroquercetin Cizinauskas et al. 
(2017) 230 
Cross sections and tape 
strips from ex vivo 
porcine skin 
25 keV Bi3+ Chlorhexidine 
digluconate 
Holmes et al. 
(2017) 227 
Cross sections from ex 
vivo human skin 
25 keV Bi3+ Exogenous ceramide 
Carvacrol 




Full thickness ex vivo 
porcine skin 
25 keV Bi3+  
(with 20 keV Ar1900 for 
depth profiling) 
Ascorbic acid and 
ascorbyl glucoside 
Starr et al. (2019) 
197 
Tape strips and cross 
sections from ex vivo 
porcine skin 
25 keV Bi3+ Imiquimod Al-Mayahy et al. 
(2019) 68 
Tape strips from in vivo 
human volunteers 
30 keV Bi32+  
(with 5 keV Ar1000 for 
depth profiling 
Collagen tripeptide Kawashima et al. 
(2020) 232 
Cross sections from in 
vivo rat skin 
50 keV Bi32+ Metal oxide 
nanoparticles 
Matter et al. (2020) 
233 
 
It can be seen from Table 1-3 that the utilisation of ToF-SIMS analysis in the area of skin permeation 
research has slowly grown over the years. Nevertheless, the use of ToF-SIMS in skin research is 
associated with some drawbacks. One of the limitations of ToF-SIMS analysis is the inability of the 
technique to provide fully quantitative results due to a phenomenon known as the matrix effect. The 
matrix effect is a situation in which the components of the analysed sample, other than the compound 
of interest, influences the yield and intensity of the detected secondary ions 234. The matrix in this 
instance would be the surrounding skin tissue while the compound of interest would be the permeants 
that are investigated. In order to circumvent this limitation, some of the reported permeation studies 
would employ chromatographic methods such as HPLC-UV and LC-MS to support the ToF-SIMS 
analysis 68,227,231.  
Nevertheless, analysis of samples using ToF-SIMS allows chemical mapping of the distribution of a 
compound of interest by tracking the mass-to-charge ratio (m/z) of specific molecular ions from the 
mass spectra. This analytical approach allows us to track the distribution of compounds, both 
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exogenous and endogenous, within a biological milieu in a label-free manner. In addition, the ability 
of the instrument to track the topical permeation of pharmaceuticals and cosmeceuticals such as 
dihydroquercetin 230, ascorbic acid 197, fatty acids 235,  carvacrol 231 and roflumilast 224 highlights the 
value of the technique in skin research.  
Following the growing body work in the area of skin permeation analysis via ToF-SIMS,  
Al-Mayahy et al. was the first and only publication to date at the time of writing this thesis that 
reported the application of ToF-SIMS imaging as an analytical tool to monitor microneedle-based drug 
delivery strategy to the skin. Al-Mayahy et al. demonstrated for the first time using ToF-SIMS imaging 
of tape strips that the application of AldaraTM cream on microneedle pre-treated skin resulted in 
enhanced the permeation of the drug within the stratum corneum. However, ToF-SIMS analysis of the 
skin cross-sections revealed that the drug was mostly localised on the skin surface and to some degree 
into the microneedle channels within the upper epidermis as shown in Figure 1-16 68. It was apparent 
that this strategy does enhance the delivery of the drug into the skin but not to the depth needed in 
managing nodular BCC. However, this study highlights the value of ToF-SIMS imaging in understanding 
the dermal drug distribution following microneedle-based drug delivery strategies. Despite the 
powerful analytical capabilities offered by this form of mass spectrometry imaging, Al-Mayahy et al. 
did not fully explore and demonstrate the utility of ToF-SIMS imaging in evaluating the effectiveness 
of microneedle-based drug delivery systems. For instance, Al-Mayahy et al. did not evaluate if the 
instrument could detect the presence of other components of the formulation (e.g., excipients) in the 
skin following administration. In addition, there is yet any work that have evaluated the dermal 




Figure 1-16 (a) ToF-SIMS ion images of tape strip from ex vivo porcine skin treated with Aldara™ cream following 
microneedles pre-treatment. This figure shows enhances lateral permeation of imiquimod across the stratum 
corneum when Aldara™ cream is applied on microneedle pre-treated skin. The skin marker (CH4N+), the 
imiquimod marker (C14H17N4+). (b) ToF-SIMS ion distribution map of porcine skin cross sections from Aldara™ 
cream on intact skin and microneedles pre-treated skin. The overlay image of the skin marker (CH4N+) with 
imiquimod marker (C14H17N4+) indicates the localisation of imiquimod within the stratum corneum for the 
AldaraTM cream only treated skin. White arrows indicate microneedle indentations and delivery of imiquimod into 
the epidermis that still persisted after 24 h. The skin cross-section covers the microneedle-treated part of the 
skin. SC indicates stratum corneum, D indicates dermis. Reproduced from Al-Mayahy et al. 68 
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1.6 Thesis aims  
Given the impact of BCC and limitation of the current therapies, the over-arching goal of this thesis is 
to explore and develop a targeted drug delivery strategy using microneedles to improve the 
intradermal delivery of imiquimod for the treatment of nodular BCC.  
The first aim of this thesis was to investigate the utility of two commercial microneedle systems, the 
Dermapen® and the DermastampTM in improving the intradermal delivery of imiquimod into the skin.  
In order to achieve this aim, the mechanical insertion of the two commercial microneedle system was 
first evaluated using in vitro skin simulant and ex vivo porcine as highlighted in Chapter 2 of the thesis. 
Following this, the microneedle system that displayed an insertion profile capable of reaching depths 
at which nodular BCC resides was explored further. This involved investigating the effectiveness of 
using the microneedle system in combination with AldaraTM cream in order to deliver the drug into the 
dermis. This will demonstrate whether the combination existing commercial products may provide an 
elegant synergy to enhance the intradermal localisation of imiquimod for the treatment of BCC. This 
combination strategy was explored and discussed in Chapter 3 of the thesis. 
The second aim of this thesis was to develop dissolvable polymeric microneedle patches loaded with 
imiquimod to promote the intradermal delivery of the immunomodulator for BCC treatment. The 
simple and straightforward one-step application using dissolving polymeric microneedle patches 
relative to the two-step application process using solid microneedles and Aldara™ cream may be a 
more preferred treatment option for patients. Therefore, Chapter 4 of this thesis explores the 
fabrication, characterisation and evaluation of dissolving microneedles prepared using the 
commercial polymer, Kollidon® VA 64 as drug delivery system for nodular BCC. Furthering this, a range 
of polymers that have never been used in manufacturing polymeric microneedles were synthesised. 
These polymers were then evaluated and fabricated into dissolving microneedles to produce a library 
of microneedle patches of different polymeric chemistries and designs. These polymeric microneedles 
were characterised for their capability to puncture the skin and deliver imiquimod intradermally. The 
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best dissolvable polymeric microneedle system was then evaluated further in vivo using a mouse 
model for skin tumours coupled with ex vivo delivery into patients’ BCC tumours. The development 
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The protection provided by the human skin is mostly attributed to the stratum corneum. However, 
this barrier also limits the range of molecules that can be delivered into and across the skin. One of 
the methods to overcome this physiological barrier and improve the delivery of molecules into and 
across the skin is via the use of microneedles. This work evaluates the mechanical insertion of two 
different commercially available microneedle systems, Dermapen® and DermastampTM. The influence 
of biaxial skin strain on the penetration of the two microneedle systems was evaluated ex vivo using 
a biaxial stretch rig. From the skin insertion study, it was apparent that for all levels of biaxial strain 
investigated, the Dermapen® required less force than the DermastampTM to puncture the skin. In 
addition, it was observed that the oscillating microneedle system, the Dermapen®, resulted in deeper 
skin insertion ex vivo in comparison to the Dermastamp™. The use of this new biaxial stretch rig and 
the ex vivo skin insertion depth study highlights that the oscillating Dermapen® required less force to 
perforate the skin at varying biaxial strain whilst resulting in deeper skin penetration ex vivo in 
comparison to the DermastampTM. Although the Dermapen® punctured the skin deeper than the 
DermastampTM, such difference in penetration did not influence the permeation profile of imiquimod, 
a drug used in the management of basal cell carcinoma, into and across the skin as evidenced from a 











The human skin is the largest organ in the human body and is comprised of three layers; the epidermis, 
dermis and hypodermis. The epidermis is a multilayer compartment of the skin that comprises of the 
stratum corneum, stratum granulosum, stratum spinosum and stratum basale 236. The outermost layer 
of the epidermis, the stratum corneum, is avascular and has evolved to provide protection against 
physical and chemical insults. The protection provided by the stratum corneum has also resulted in a 
barrier to the delivery of compounds across the skin either for therapeutic or cosmetic purposes 68.  
Microneedles are one of the strategies explored to improve the delivery of compounds into and across 
the skin. These are minimally-invasive needles with lengths that ranging between 250-1000 µm 
capable of perforating the stratum corneum in order to promote the delivery of compound into and 
across the skin 237. Due to their size, microneedles offer painless skin insertion as they are unlikely to 
stimulate the dermal pain receptors upon application 238.  The ability of microneedles to puncture the 
skin may of great clinical utility in managing skin condition where the target disease site resides deep 
within the skin tissues such as nodular basal cell carcinoma (BCC). 
Some of the microneedle products available on the market, licensed for cosmetic use, include the 
DermastampTM and Dermapen®. The DermastampTM consists of a stamp with an array of microneedles 
arranged at the base of the device. The microneedles are inserted into the skin in one vertical motion, 
creating micron sized channels in the skin. The Dermapen® is a motor driven microneedling device 
that inserts its needles into the skin in a continuous oscillating motion at one of five programmed 
frequency levels. The use of a motor helps circumvent the issue of varying insertion force between 
users. It also features an adjustable dial to control the needle’s depth of penetration during use. 
However, little research exists evaluating the effectiveness of such a motor driven device or the 
associated advantages or disadvantages in its use in comparison to the Dermastamp™ and its single 
stamping motion.  
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In order to effectively generate microneedle channels, the skins topology must also be considered. 
The human skin features a roughened surface due to the variation in structure of the keratinocytes on 
the stratum corneum 239,240. This surface is undulating in nature, being up to 150 microns from peak to 
trough for those aged over 60 240, thus clearly demonstrating the need to smooth the skin as far as 
possible to maximise depth of penetration by the needles. To achieve smoothing, the skin must be 
stretched. It is understood that when skin is uniaxially stretched, the skin acts in a compressive fashion 
in the perpendicular direction to maintain the area of the surface, causing micro-furrows to  
develop 241.This highlights the need for biaxial stretching to mitigate against this and ensure 
microneedle insertion into the skin. Biaxial skin stretching has been performed in several  
studies 242–244 with a non-linear stiffening of skin being found as a function of strain. This relationship 
has been supported by a simulation study by Flynn and Rubin 245 however little other data appears to 
exist regarding how increase in strain affects the penetration of microneedle into the skin.  
In this work, we compare the insertion force profiles of two commercially available microneedle 
systems; DermastampTM and Dermapen®.  This study evaluates the influence of biaxial skin strain on 
the insertion force of two different commercial microneedling systems into the skin. Besides that, the 
influence of microneedle oscillation during microneedle application was evaluated using an in vitro 
and an ex vivo set up.  Lastly, the impact of these microneedle systems on the permeation profile of 
imiquimod, a compound used in the management of basal cell carcinoma, was also investigated. 
2.3 Materials 
Dermapen® (ZJChao, China) and Dermastamp™ (Teoxy Beauty, Wuhan, China). The Dermapen® is an 
oscillating microneedling pen featuring a 36-needle removable array, with tip radius of 44-68 µm and 
conical geometry. In order to mimic how the Dermapen® would be used by a patient in a real-world 
setting, the plastic ring around the microneedle cartridge was not removed for all skin insertion and 
permeation study. The Dermastamp™ is a non-oscillating microneedle stamp featuring a 42-needle 
array of 1mm length, tip radius of 21-25 µm and curved conical geometry. The geometry of the 
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microneedles from respective devices are visualised using Leica DM4000B (Leica Microsystem, 
Germany). The geometry of the microneedles is shown in Figure 2-1 
 
Figure 2-1 Close up microscopy image showing the geometry of microneedles from Dermapen® and 
DermastampTM 
Porcine skin was used to study the insertion force profile of commercial microneedles instead of ex-
vivo human skin due to its limited availability and the ethical difficulties associated with its use. Various 
studies have highlighted that porcine skin is a suitable alternative to human 246. Porcine flank skin 
samples from six-month old animals were obtained from a local abattoir, reared specifically for food. 
Skin samples were collected prior to any steam cleaning, and then prepared. The skin was washed 
with distilled water and dried using tissue. Full thickness skin was used to avoid altering the skins 
biomechanical properties, which may lead to over-penetration of microneedles into the dermal tissue 
66. After that, the skin samples were stored at -20 °C and used within six months. Gentian violet 
solution 1% w/v (De La Cruz products, USA) was used as a dye to highlight the microneedle channels 
created in porcine skin. Parafilm M® (Brand Bermis, Wertheim, Germany) of 127 µm thickness was 
used as a skin simulant in the in-vitro insertion study. Imiquimod was purchased from Cayman 
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Chemicals, USA. 5% w/w imiquimod cream (AldaraTM), MEDA Company, Sweden was purchased from 
Manor Pharmacy, UK. Sodium acetate was purchased from Sigma-Aldrich, UK. Acetonitrile (HPLC 
grade) and glacial acetic acid were obtained from Fisher Scientific, UK. Teepol solution (multipurpose 
detergent) was ordered from Scientific Laboratory Supplies, UK. D-Squame standard sampling discs 
(adhesive discs) were purchased from Cuderm corporation, USA. Deionised water was obtained from 
an ELGA reservoir, PURELAB® Ultra, ELGA, UK. All reagents were of analytical grade, unless otherwise 
stated.  
2.4 Methods 
2.4.1 Biaxial Stretch Rig Development  
Following two designs presented in literature 243,244, a low cost biaxial skin stretching rig was produced. 
The rig consists of four manual linear stages arranged as shown in Figure 2-2 on an 8 mm laser cut 
acrylic base. Further laser cut components permit clamping to be achieved using M4 Cap Head Bolts 
and 5 mm acrylic plates. Friction between the clamping plates was improved using 40 grit emery cloth, 
double sided taped to the plates. The centre of the rig, over which the microneedle array is inserted, 
consists of an acrylic block topped with a 6mm layer of natural cork to simulate the stiffness of skeletal 
muscle 247 . Aluminium foil was overlaid on the cork with a thin covering of detergent. This was 
performed to reduce the friction experienced by the skin on the cork mat during stretching thus aiding 
the amount of strain that could be achieved within the skin.  In addition, a laser cut jig for locating the 
biaxial stretch rig on the bed of a Texture Analyser (TA), (Stable Micro Systems, Surrey, UK) was also 
prepared to ensure consistency of the location of insertion of the microneedle array. Zero strain was 




Figure 2-2 A schematic of the conceived manual biaxial stretch rig 
2.4.2 Biaxial strain on microneedle skin insertion force  
In order to investigate the effect of biaxial stretching on microneedle puncture performance of the 
Dermapen® and DermastampTM, an insertion experiment was performed. The prepared porcine skin 
was inserted into the biaxial stretch rig and clamped, Figure 2-3 (a). The skin samples were then 
subjected to five levels of biaxial strain; 1.00, 1.0625, 1.125, 1.875 and 1.25 (i.e., a biaxial stretch of 
0mm, 2.5mm, 5mm, 7.5mm and 10mm of a 40x40 mm grid). The level of biaxial strain was measured 
using a 40x40 mm grid of 5 mm squares ink-stamped onto the skin samples, Figure 2-3 (a). The skin 
sample was biaxially stretched and a pair of Vernier callipers used to measure the level of stretch i.e., 




ε =  Δl/l 
Equation 2-1 Equation for strain where ε is strain, l is length, and Δl is the change in length of skin. ε strain, has 
no unit as the units from Δl and l cancel each other out. 
The skin-loaded rig was then placed under the probe of the TA, using a laser cut jig to align a quadrant 
with the probe’s central position. A microneedle-loaded probe, see Figure 2-3 (b), was then attached 
to the TA. The following parameters were used for the TA program; 5kg Load Cell, Pre-Test Speed: 
0.5mm/sec, Test Speed: 0.5mm/sec, Post-Test Speed: 10mm/Sec, Trigger Force: 0.01N. The 
microneedles were inserted into the skin sample by the TA and the force-displacement profile 
recorded. Following their removal, the Gentian Violet dye was applied to the skin, Figure 2-3 (c) to 
visualise the number of microneedle channels generated.  The number of microchannels generated 
were counted to measure the percentage of successful microneedle insertion. The DermastampTM was 
housed in a custom mount that consist of a turned aluminium with a roll pin used to hold the 
microneedle array in place. An M6 grub screw was used in the rear of the mount as an attachment to 
the TA. For the Dermapen®, a 3D printed (Fused Deposition Modelling) jacket was designed to house 
the device within an aluminium tube and stub assembly via a tapered interference fit. The assembly 
was then attached to the TA again by an M6 grub screw. The Dermapen®’s adjustable needle length 




Figure 2-3 Schematic detailing the setup to investigate effect of biaxial strain on microneedle skin insertion. A 
40x40 mm grid of 5 mm squares ink was stamped onto the skin samples in Step (a) in order to measure the level 
of biaxial strain on the skin. Using a texture analyser (TA), respective microneedle systems were attached to the 
probe of the instrument to allow insertion into the skin as shown in Step (b). Visualisation of microneedle 
channels using Gentian Violet dye as depicted in Step (c) 
2.4.3 In vitro skin simulant insertion study  
As an alternative method to determine the microneedle penetration depth, a polymeric film  
(Parafilm M®,) was used as a skin simulant. This insertion study was adopted from Larrañeta et al.  248. 
In brief, eight layers of Parafilm M® were stacked onto each other on a cork layer. Both microneedle 
systems were applied onto the Parafilm M® stacks. Six replicates were performed, and the pores 
generated were investigated under an optical microscope. The percentage of holes created per layer 
for respective microneedle length was calculated using following Equation 2-2: 
% hole generated =  
𝑁 microneedle channels observed
𝑁 microneedles per array
 × 100 
Equation 2-2 Equation to establish the percentage of holes produced by the microneedle devices. Where N 
represents ‘number of’ 
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2.4.4 Ex vivo skin insertion study 
In order to evaluate the penetration depth of the Dermapen® and DermastampTM needles into the skin, 
an ex vivo penetration study using porcine skin was conducted. The porcine flank skin was defrosted 
at room temperature for an hour prior to the experiment. Using scissors, excess hair was carefully 
trimmed from the skin.  A 36-microneedle array tip was used, and the vibration speed was set to level 
1 (412 cycles/min) 249. The microneedle skin pre-treatment was applied by gently stretching the skin 
and placing the Dermapen® vertically upon the skin for 10 seconds. A microneedle length of 1000 μm 
was used in this study. After treating the skin with the microneedle pen, 10 μl of 1 % Gentian Violet 
Dye was applied to the surface of the skin and left at room temperature for 60 minutes. Excess dye 
was removed and the skin was then visually inspected to identify microneedle pores. The skin samples 
were then cryo-sectioned (Leica CM3050 S Research Cryostat, UK) and the depth of microneedle 
penetration was measured under an optical microscope (Zeta Profilometer, KLA-Tencor, US). The 
same procedure was repeated to evaluate the depth of DermastampTM penetration into the skin.  
2.4.5 Skin permeation study 
In order to investigate the influence of the different microneedle system on skin permeation, an ex 
vivo skin permeation study using a Franz-type diffusion cell was conducted using a model compound, 
imiquimod. Imiquimod was selected as a model compound as the molecule displayed poor 
permeation across the skin 68. The application of microneedle system to skin is hypothesised to 
improve the permeation of imiquimod into the skin.  Prior to the permeation study, skin samples were 
defrosted for at least an hour at room temperature. The skin was trimmed into small pieces according 
to the surface area of the donor chamber of the Franz diffusion cell (Soham Scientific, Cambridgeshire, 
UK). The trimmed skin samples were equilibrated by placing them above the receptor compartment 
for 15 minutes prior to skin treatment. The porcine skins were subjected to the following treatment 
modalities: i) application of 5% w/w of imiquimod cream alone as a control ii) application of 1000 µm 
microneedles to the skin as a pre-treatment using Dermapen® followed by 5% w/w of imiquimod 
cream iii) application of 1000 µm microneedles to the skin as a pre-treatment using DermastampTM 
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followed by 5% w/w of imiquimod cream. Next, the porcine skins were placed on top of the receptor 
compartment filled with 3 ml of degassed 100 mM acetate buffer pH 3.7. This buffer was selected as 
the receptor phase in order to maintain a sink condition throughout the permeation study. This is due 
to the insolubility of imiquimod at neutral or basic pH values. Various groups have reported the use of 
acetate buffer pH 3.7 as the receptor phase in imiquimod permeation studies as this ensure imiquimod 
is soluble at this pH while maintaining a sink condition in the receptor chamber 53–55. The skin was then 
secured between the donor and receptor compartment of the diffusion cell using a metal clamp, with 
the stratum corneum side facing the donor compartment. Upon assembling the Franz diffusion cell, 
the permeation experiment was conducted over a period of 24 hours in a thermostatically controlled 
water bath set at 36.5 oC. 
After a 24-hour permeation experiment, the excess cream was removed and collected from the skin 
surface by careful application of sponges soaked with 3% v/v Teepol® solution. The sponges were 
pooled for imiquimod HPLC analysis as a total skin wash. Any formulation which might have spread to 
the donor chamber was collected by the sponges and stored for imiquimod analysis by HPLC as a 
donor chamber wash. Upon removing excess formulation from the skin surface, 15 sequential tape 
strips were collected from the skin. The amount of imiquimod from the different Franz cell elements 
(skin wash, donor chamber wash, pooled tape strips and remaining skin after tape stripping) were 
extracted by the addition of 5, 5, 10 and 5 mL of methanol extraction mixture (methanol 70%: acetate 
buffer pH 3.7 100 mM 30%) respectively using a previously reported method 52. Samples were then 
vortexed for 1 minute and sonicated for 30 minutes before being left overnight. Subsequently, 
samples were vortexed again and sonicated for a further 30 minutes. 1000 µl of the extracts were 
collected and spiked with 100 µl of 100 µg/ml propranolol as an internal standard. The samples were 
then filtered through 0.22 µm membrane. For the receptor fluid, 1000 µl of the solution from each 
Franz cells were collected and spiked with 100 µl of 100 µg/ml propranolol as an internal standard 
before being filtered through 0.22 µm membrane. HPLC analysis was carried out using an Agilent 1100 
series instrument (Agilent Technologies, Germany) equipped with degasser, quaternary pump, column 
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thermostat, autosampler and UV detector. System control and data acquisition were performed using 
Chemostation software. The details of the HPLC chromatographic conditions are as follow: column 
C18 (150 × 4.6 mm) ACE3/ACE-HPLC with a particle size of 5 µm, pore size of 100 Å, pore volume of 
1.0 ml/g and a surface area of 300 m2/g, Hichrom Limited, UK. The mobile phase composition for 
analysis of extracts from skin wash, donor chamber wash, pooled tape strips and remaining skin 
consists of 10 mM acetate buffer: acetonitrile (79:21). Whilst, the mobile phase composition for 
analysis of receptor fluid consists of 10 mM acetate buffer: acetonitrile (70:30). The system operated 
at a flow rate of 1.0 mL/minute, UV detection at λmax= 226 nm, injection volume of 40 µL and column 
temperature of  
25 °C. 
2.4.6 Statistical analysis 
Results were reported as mean with standard deviation (SD) (n≥5). Statistical calculations were 
performed in Prism (IBM, USA), a software package. The Student’s t-test and One-Way ANOVA 
followed by a Tukey post-hoc test was applied to compare the results of different groups. Statistically, 
a significant difference was denoted by p value < 0.05. 
2.5 Results and Discussion 
2.5.1 Influence of biaxial strain on commercial microneedle perforation.  
A biaxial skin stretching experiment was conducted in order to investigate the effect of skin strain on 
the insertion of two commercial microneedle systems. From Figure 2-4 it can be seen that the force 
needed by the Dermapen® to perforate the skin was significantly lower than the Dermastamp™ for 
the range of strain rates investigated.  It was also found that an increase in force was needed for the 
Dermastamp™ to puncture the skin as the strain increased, however this force plateaued at a biaxial 
strain of circa 1.1. In contrast, a linear relationship is presented for the Dermapen® suggesting that 




Figure 2-4 Biaxial skin strain and insertion force relationship for commercial microneedle systems Dermapen® 
and DermastampTM. Data expressed as means ± SD, n=5. 
The relationships shown in Figure 2-4, an increase in force with increases in biaxial strain, align with 
Lanir & Fung’s work that showed skin as a non-linear material that exponentially stiffens when biaxially 
stretched 244. As stiffness is defined as the resistance to bending or deformation, it is proposed that as 
skin exponentially stiffens with an increase in strain. This results in the force needed to deform the 
skin and insert the needles will increase significantly with biaxial stretching.  
Following microneedle insertion, the formed puncture sites were visualised by application of Gentian 
Violet Dye. The percentage of successful microneedle insertions is shown in Figure 2-5 for the two 
microneedle systems. It is evident that as the biaxial strain of the skin sample increases, an increase 
in the number of successful microneedle insertions was observed for the Dermapen®, which then 
plateaus as the skin was subjected to further biaxial strain. For the DermastampTM, as the biaxial strain 
of the skin increases, we observed a rise in the percentage of successful microneedle insertion. 
However, as biaxial strain of the skin was increased further, the percentage of successful microneedle 
insertion into the skin decreased.  
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Figure 2-5 Averaged percentage of maximum number of dyed microneedle insertion holes generated for each 
level of stretch. Data expressed as means ± SD, n=5. 
Previous work by Maiti et al. has shown that subjecting the skin to strain may help smooth its  
surface  250. Such topographical change in skin structure may help mitigate the presence of micro-
furrows on the skin which fold around the microneedles and can present resistance to microneedle 
insertion 157. One of the ways to achieve skin smoothening is via subjecting the skin to strain or 
stretching 251. However, the current work suggests that smoothening the skin by subjecting the skin 
to biaxial strain may help improve microneedle insertion up to an optimum strain (1.0625 and 1.125) 
as shown with the DermastampTM in Figure 2-5. Beyond this optimum strain, the percentage of 
successful microneedle penetration decreases due to increased skin stiffness with increasing strain as 
shown by previous investigators 244. 
For the Dermapen®, the increase in the percentage of successful microneedle insertions with 
increasing strain is attributed to the observation that the skin smooths upon stretching 251. Subjecting 
the skin to biaxial strain results in flattening of the micro-furrows and permits an increased probability 
of the needles puncturing through the stratum corneum. This is due to the linear motor, that oscillates 
the microneedle array, providing a secondary force to assist with insertion into the skin, irrespective 
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of the rise in skin stiffness with the increasing strain. These results demonstrate that the Dermapen® 
is more effective than the DermastampTM in generating microneedle channels across the skin. 
Unlike the DermastampTM, the presence of plastic shoulders at the tip of microneedle cartridge of the 
Dermapen® imposes an additional surface tension to the skin during microneedle application. This 
helps to further mitigate the propensity of the skin to fold around the needles while mitigating the 
variability in puncture force. This is evidenced by the smaller standard deviation error bar for 
Dermapen® relative to DermastampTM for the level of skin strain investigated shown in Figure 2-4. The 
combination of these physical factors mimics the insertion mechanism of a mosquito’s proboscis. The 
shoulder of the cartridge of the Dermapen® plays a similar role to that of the mosquito labium which 
applies lateral strain to the skin prior to puncture. This ultimately focusses the force at the tip of the 
Dermapen® permitting a more effective insertion 122.  The microneedles in this case are equivalent to 
the mosquito’s labrum which insert itself at defined frequency in a stamping manner allowing deeper 
insertion with repeated insertion. 
2.5.2 In vitro skin simulant insertion depth study of commercial microneedle 
An in-vitro skin simulant study, using Parafilm M®, was performed to compare the percentage of 
successful microneedle channels against depth for the two commercial microneedle systems being 
considered; the Dermapen® and DermastampTM. The insertion profiles of the commercial microneedle 
systems were established using a methodology developed and validated by Larraneta et al. 248. The 
experiment involves the insertion of the microneedle devices into a stack of eight Parafilm M® layers, 
followed by the separation of the layers and their visualisation under an optical microscope to 




Figure 2-6 Microscopic images of first layer of Parafilm M® stack punctured by stainless steel microneedles by (a) 
Dermapen®, (b) DermastampTM Scale bar:300 µm (c) Insertion profile of different commercial microneedle 
systems, Dermapen® and DermastampTM into Parafilm M® layers, data expressed as means ± SD, n=6. 
The two microneedle systems typically pierce the first five layers, with approximately 100% of the 
needles piercing the first three layers before the percentage of microchannels generated begins to 
decrease. The generated channels displayed uniform geometry as shown in Figure 2-6 (a) and (b). 
However, less than 50% of the microneedles successfully pierced the fifth and sixth layer.  
Hutton et al. showed that microneedle patches fabricated from a copolymer of methyl vinyl ether and 
maleic acid were capable of penetrating the Parafilm M®  layers to a depth of approximately 60% of 
the microneedle height 252. Vora et al. also showed that microneedles fabricated from poly(vinyl 
pyrrolidone) (PVP) loaded with nano- and microparticles  were capable of penetrating the Parafilm 
layers up to 60% of the microneedle length 151. This work aligns with our findings that the commercial 
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microneedle systems were capable of penetrating Parafilm M® layers up to circa 60% of the 
microneedle length. Furthermore, the results in Figure 2-6 (c) suggest that for an in vitro skin simulant 
model, the insertion profiles are similar for both microneedle systems. In a follow up study,  
Larraneta et al. discovered that the insertion profile of microneedle arrays was more dependent on 
needle density and design rather than the material used 131. Such observations may explain the similar 
insertion profiles of the two commercial microneedles systems, as both microneedles are made from 
the same material; stainless steel.   
2.5.3 Ex vivo skin insertion study 
An ex vivo penetration study was conducted to ascertain the microneedle penetration depth of the 
two different commercially available microneedle systems in actual skin tissue. Figure 2-7 shows that 
successful penetration of microneedles into ex vivo porcine flank skin evidenced from the visualisation 
of microneedle channels from cryo-sectioned skin samples. From Figure 2-7 it was apparent that the 
region surrounding the microneedle pore retained a normal structure with intact stratum corneum. 




Figure 2-7 Visual image of porcine flank skin surface after gentian staining following (a) Dermapen® and (b) 
DermastampTM application. Optical microscopy images of porcine flank skin cross sections after application of 
(c) Dermapen and (d) Dermastamp. The skin was stained with 1% gentian violet solution to allow visualisation of 
microneedle channels formed after microneedle treatment. n=10, data is expressed as mean ± SD. Differences 




In the context of drug delivery, it has been shown by Andrews et al. that drug entry into and across 
the skin is not just limited by the outermost layer of the skin, the stratum corneum, but the penetration 
of molecules is limited by the overall epidermis itself 253. This would suggest that both microneedle 
systems were capable of perforating the skin to generate microneedle channels which could be used 
by drug molecules to enter deeper layers of the skin.  
It was evident that the microneedle penetration depth by the Dermapen® was significantly deeper in 
comparison to the DermastampTM. Such observation may be attributed to the oscillating motion of the 
device during skin application which has been suggested to improve skin penetration 254. Previous 
work by Izumi et al. investigated the influence of vibration on the penetration of microneedles into an 
in vitro silicone skin model. The group observed that the application of vibrating microneedles at  
30 Hz during skin application resulted in a reduction in the force needed to penetrate the skin 255. This 
reduction in puncture force is attributed to the reduction in effective frictional forces experienced by 
microneedles under vibration 256.  The rapid vibration of the microneedles also mitigates the likelihood 
of viscoelastic materials such as skin from attaching to the microneedle during the insertion step. This 
reduction of effective frictional forces experienced by oscillating microneedles may also serve as an 
explanation as to why the Dermapen® displayed lower peak insertion force in comparison to the 
DermastampTM, shown in Figure 2-4.  
Another factor that may influence microneedle insertion into the skin is the different organization of 
the microneedles on the Dermastamp and Dermapen systems. From Figure 2-7 (a) and (b) along with 
microscopy image from Figure 2-6 (a) and (b) it is evident that the 36 microneedles on the Dermapen® 
are organised in rows whereas the 42 microneedles on the DermastampTM are organised in concentric 
circles. The needles on Dermapen® are closely distributed to one another in comparison to the needles 
on the DermastampTM. Previous work by Olatunji et al. highlighted that insertion force increases when 
microneedle interspacing decreases 257. In contrast to the finding by Olatunji et al., we observed that 
although the needle interspacing on the Dermapen® are closer than the DermastampTM, the 
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Dermapen® still required less insertion than the DermastampTM. By comparing our findings to that of 
Olatunji et al., it can be postulated that the method (oscillating vs non-oscillating) in which the 
microneedle is applied to the skin overrides the influence of microneedle interspacing on insertion 
force and penetration depth.  
By comparing the penetration data for both microneedle systems from Figure 2-6 and Figure 2-7, it is 
evident that the insertion of microneedles into in vitro skin simulant, Parafilm M® stacks, were 
significantly deeper than that of ex vivo skin tissue. Such disparity in results suggest that the in vitro 
test developed by Larraneta et al. may have some limitations when the insertion data is translated to 
ex vivo tissues and potentially in vivo. Both Parafilm M® and skin are inherently viscoelastic materials 
which display both elastic and viscous properties under deformation. Unlike skin, which is an elastic 
biological tissue that  returns to its normal state after mild stretching or compression 258, Parafilm M® 
exhibits irreversible plastic deformation when stretched or compressed 259.  
2.5.4 Skin permeation study  
A permeation study was conducted to investigate the effect of different commercial microneedle 
systems on the permeation of imiquimod, a drug used in the management of BCC, that displayed poor 
cutaneous permeation 68. One of the strategies to overcome the limited permeation of imiquimod is 
to employ permeation enhancing strategy such as microneedle. Upon microneedle application, 
transient microchannels are generated within the skin that promote the delivery of the drug across 
the skin. The amount of imiquimod (µg) recovered from the various Franz cell components following 




Figure 2-8 HPLC analysis of the mean amount of imiquimod recovered from the different Franz cell components 
(donor chamber wash, skin wash, tape strips, remaining skin and receptor fluid) post-permeation study. Data is 
presented as the mean ± SD (n = 6). Differences were calculated using one-way ANOVA, followed by Tukey’s post 
hoc test, and deemed significant at p<0.05. n.s = not statistically significant at p>0.05. 
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For all treatment modalities, we observed no statistical difference (p>0.05) in the amount of 
imiquimod recovered from different Franz cell components (donor wash, skin wash, tape strips and 
remaining skin) except for the receptor fluid. With regards to receptor fluid, it was seen that when the 
skin was pre-treated with either microneedle systems, a strategy known as poke-and-patch, we 
observed enhanced delivery of imiquimod across the skin relative to the cream only control.  However, 
it was worth noting we observed no statistical difference in the permeation of imiquimod into the 
receptor fluid between Dermapen® and DermastampTM. In addition, it is also observed that the 
amount of imiquimod that was delivered into the remaining skin using the poke-and-patch strategy 
were statistically similar between all three treatment strategies. This highlights that using a poke-and-
patch strategy with these commercial microneedle systems only enhanced the amount of drug 
delivered across the skin but not into the skin. As the intended target site for imiquimod is the dermis 
where nodular BCC resides, this suggest that the poke-and-patch strategy with these commercial 
microneedle systems may not be a suitable strategy for managing this type of skin tumour as we did 
not observe any enhancement in intradermal delivery of imiquimod into the skin relative to the 
commercial cream AldaraTM.  
One possibility for the similarity in permeation profiles for the two microneedle systems is attributed 
the fact that both systems successfully breached the stratum corneum, epidermis and down to 
superficial dermis as highlighted in Figure 2-7 (c) and (d). It has been reported that the thickness of 
porcine epidermal layer varies between 30-140 µm 260 and it was shown that both microneedle system 
penetrated into the porcine skin to a depth of at least 200 µm, reaching the superficial dermal layer 
of the skin. This layer of the skin is viscoelastic due to the presence of a dense network of collagen and 
elastin 105,133,261. Although the Dermapen® may puncture the skin deeper than the DermastampTM, 
immediately upon microneedle removal the channels generated in the dermal layer of the skin 
immediately recoils and reseals conferring similar resistance in permeation for imiquimod across the 
dermis for both microneedle systems. A limitation which is frequently highlighted when a poke-and-




In conclusion, this work expands our knowledge on the mechanical insertion of microneedles into the 
skin. Applying biaxial strain on the skin indeed influences the penetration of microneedles into the 
skin. It was apparent that the two commercially available microneedle systems, Dermapen® and 
DermastampTM have very different insertion force profiles with increasing strain. For all the skin strain 
levels investigated, it was evident that the Dermapen® required less insertion force than the 
DermastampTM. Interestingly, the percentage of successful insertion continues to increase before 
plateauing with increasing skin strain for the oscillating Dermapen®. In contrast for the Dermastamp™, 
the percentage of successful microneedle insertions increases with strain before decreasing at higher 
strain rate. In terms of insertion depth, it was apparent that the penetration of the Dermapen® was 
much deeper than that of the DermastampTM. Such a difference was not detected when the 
microneedle systems were evaluated using the commonly used Parafilm M® stack insertion study but 
only became apparent when the devices were evaluated ex vivo. The lower insertion force and deeper 
penetration provided by the Dermapen® was attributed to the oscillating feature of the microneedle 
system which mitigates the effective frictional force experienced by the needle during skin insertion. 
Lastly, although the Dermapen® may puncture the skin deeper than the DermastampTM, such 
difference in penetration did not affect the permeation profile of imiquimod into and across the skin 
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3.1 Abstract  
Basal cell carcinoma (BCC) is the most common cutaneous malignancy in humans. One of the most 
efficacious drugs used in the management of basal cell carcinoma BCC is the immunomodulator, 
imiquimod. However, imiquimod has physiochemical properties that limit its permeation to reach 
deeper, nodular tumour lesions. The use of microneedles may overcome such limitations and promote 
intradermal drug delivery. The current work evaluates the effectiveness of using an oscillating 
microneedle device Dermapen® either as a pre or post-treatment with 5% w/w imiquimod cream 
application to deliver the drug into the dermis. The effectiveness of microneedles to enhance the 
permeation of imiquimod was evaluated ex vivo using a Franz cell set up. After a 24-hour permeation 
experiment, sequential tape strips and vertical cross-sections of the porcine skin were collected and 
analysed using time-of-flight secondary ion mass spectrometry (ToF-SIMS). In addition, respective 
Franz cell components were analysed using high performance liquid chromatography (HPLC). Analysis 
of porcine skin cross-sections demonstrated limited dermal permeation of 5% w/w imiquimod cream. 
Similarly, limited dermal permeation was also seen when 5% w/w imiquimod cream was applied to 
the skin that was pre-treated with the Dermapen®, this is known as poke-and-patch. In contrast, when 
the formulation was applied first to the skin prior to Dermapen® application, this is known as patch-
and-poke, we observed a significant increase in intradermal permeation of imiquimod. Such 
enhancement occurs immediately upon microneedle application, generating an intradermal depot 
that persists for up to 24 hours. Intradermal colocalization of isostearic acid, an excipient in the cream, 
with imiquimod within microneedle channels was also demonstrated. However, such enhancement in 
intradermal delivery of imiquimod was not observed when the patch-and-poke strategy used a non-
oscillating microneedle applicator, the DermastampTM. The current work highlights that using the 
patch-and-poke approach with an oscillating microneedle pen may be a viable approach to improve 





Basal cell carcinoma (BCC) is the most common skin cancer in humans 263.  Despite having a low 
tendency to metastasize, BCC may result in substantial peripheral tissue destruction if left untreated 
264. The two most common BCC subtypes are superficial and nodular 31.  Superficial BCC generally 
manifests and proliferates parallel to the epidermis 32,33. On the other hand, nodular BCC typically 
resides deep within the papillary and reticular dermis 36. Despite the effectiveness of surgical 
interventions which display a 95% cure rate 43, accurate detection of tumour margins prior to surgery 
is pivotal in ensuring complete tumour resection. Such prerequisites are both time-consuming and 
technical, which limits the use of such treatments 61. In addition, not all BCC patients are suitable for 
surgical intervention and some may opt for non-surgical treatment due to lower overall cost and 
better cosmetic outcomes 63-64. This is further corroborated by the findings of Tinelli et al. who 
reported that patients generally preferred topical therapy over surgical intervention 265. One of the 
most efficacious drugs used in topical therapy for BCC is the immunomodulator, imiquimod 59.  
Recently, William et al. reported that topical imiquimod therapy for nodular BCC resulted in a cure 
rate significantly less than surgical intervention 34. The lower cure rate of imiquimod in treating BCC, 
particularly the nodular variant is due to the location of the tumour that resides deeper within the 
dermis 266. This tumour location provides an anatomical barrier for imiquimod to permeate in 
sufficient quantity to eradicate the tumour 267.  
One of the methods to improve the delivery of therapeutics for the treatment of BCC is via the use of 
microneedles. Microneedles are biomedical devices that consist of arrays of fine needles with lengths 
ranging between 250 and 1000 µm. Upon application to the skin, these devices generate transient 
channels that provide a route across the stratum corneum into the deeper layers of the skin 262. The 
application of microneedle-based drug delivery for the management of BCC was pioneered by 
Donnelly et al. 169. Donnelly et al. demonstrated that microneedles enhanced the localised delivery of 
aminolaevulinic acid into the skin for BCC treatment. Further to this Naguib et al. demonstrated, via a 
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murine model, the feasibility of using solid microneedles to enhance the intradermal delivery of  
5-fluorouracil to treat skin tumours. Following these studies, various groups have explored different 
microneedle designs to deliver a range of anticancer agents such as methyl aminolevulinic acid  170, 
meso-tetra(N-methyl-4-pyridyl)orphinetetratosylate 171,  and itraconazole 172.   
Detailed analysis of the dermal distribution of pharmaceuticals within the skin strata is paramount in 
order to evaluate the permeation enhancement effect conferred by microneedles for targeted skin 
delivery. Traditionally, chromatographic analysis (e.g. high-performance liquid chromatography, 
HPLC) is frequently implemented in microneedle permeation studies in order to evaluate the delivery 
of drugs into and across the skin. However, this analytical method is dependent on efficient drug 
extraction and effective column separation from co-extracted endogenous components of the skin. 
Furthermore, the tissue manipulation steps and extraction procedures lead to the loss of valuable 
spatial information regarding drug localisation within the skin tissue 197. In order to overcome this 
limitation, microneedle permeation studies frequently utilise fluorescently-tagged molecules in order 
to track their distribution within the skin 104. This method of tracking dermal distribution can be 
achieved via the use of confocal laser scanning microscopy (CLSM). CLSM utilises point illumination 
via the use of focused laser beam that is rastered across the sample of interest. The emitted 
fluorescence from the in-focus plane is passed through a pinhole onto a detector, which measures the 
fluorescence from the site of analysis. Any out-of-focus fluorescence is blocked by the pinhole, which 
is said to be confocal with the focal point of the objective lens. CLSM has been used to tracked the 
permeation of compounds delivered using microneedle-based delivery systems 129,132,144. Although this 
approach allows the experimenters to track drug localisation within the skin, the use of fluorescent 
tagging with this method alters the physiochemical properties of molecules leading to erroneous 
estimation of drug distribution in biological tissues 198. In addition, the need for different fluorescent 
tagging to track the dermal distribution of multiple molecules complicates the method even further. 
Hence, there is a clear need for advanced analytical techniques to be utilised in the field of 
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microneedle research to allow researchers to track drug distribution within skin tissues in a label-free 
manner. 
Some of the techniques that offer label-free imaging of dermal drug distribution include confocal 
Raman microscopy and stimulated Raman scattering microscopy. These techniques has been used to 
visualise the dermal distribution of several pharmaceuticals such as 5-fluorouracil 199, ketoprofen 200, 
and terbinafine 200. Although these methods offer experimenters the ability to visualise dermal drug 
distribution in a label-free manner, the Raman signal is normally a weak. This necessitates that the 
molecule of interest should be present at sufficient concentration to allow detection. In addition, the 
drug molecules also need to possess Raman active chemical groups that are different from native skin 
biomolecules to permit differentiation and detection. Another issue associated with Raman-based 
imaging is the high level of autofluorescence from biological tissue which can mask the weak Raman 
signal thus limiting the utility of these techniques to map dermal drug distribution 202. 
Time-of-flight secondary ion mass spectrometry (ToF-SIMS) on the other hand is a powerful surface 
analytical technique that confers excellent mass and spatial resolution along with chemical  
sensitivity 203,204. Analysis of samples using ToF-SIMS allows chemical mapping of the distribution of a 
compound of interest by tracking the mass-to-charge ratio (m/z) of specific molecular ions from the 
mass spectra. This analytical approach allows us to track the distribution of compounds, both 
exogenous and endogenous, within a biological milieu in a label-free manner. Such analytical power 
conferred by ToF-SIMS has led to the use of the technique to analyse a range of biological materials 
such as insulin and even cancerous tissue  216–221. In addition, the ability of the instrument to track the 
topical permeation of pharmaceuticals and cosmeceuticals such as chlorhexidine 227,268, ascorbic acid 
197, dihydroquercetin 230, fatty acids 235,  carvacrol 231 and roflumilast 224 highlights the value of the 
technique in skin research. Despite the powerful analytical capability offered by this form of mass 
spectrometry imaging, the utility of ToF-SIMS in evaluating the effectiveness of microneedle-based 
drug delivery system has yet to be fully demonstrated. 
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A previous study demonstrated the limited permeation of imiquimod into the skin when the drug is 
administered as a topical cream 68. This work also demonstrated that solid microneedles provided a 
solution to deliver imiquimod beyond the stratum corneum and into the viable epidermis. However, 
such delivery depth was not sufficient to reach the dermal depth in which nodular BCC typically 
resides. In the present work, we explore further the application of solid microneedles as a physical 
permeation enhancement strategy to deliver imiquimod deeper into the dermis for BCC treatment. In 
addition, the microneedle system should deliver imiquimod to a depth of approximately 400 µm below 
the skin surface which is the target region in which nodular BCC typically manifests 34. The current 
study highlights that the approach in which microneedles are used in combination with an imiquimod 
cream, can lead to the successful intradermal delivery of imiquimod. The concept of using a patch-
and-poke strategy with solid microneedles was initially conceptualized in a review published by 
McCaffrey et al. as a method to deliver genes into the skin 269. Patch-and-poke is defined at the 
application of formulations onto the skin prior to solid microneedle application. However, research on 
the effectiveness of the patch-and-poke approach using solid microneedle is limited. This is because 
research on solid microneedles focuses mostly on a poke-and-patch strategy to deliver drug into or 
across the skin. Furthermore, using the poke-and-patch strategy results in the generation of 
hydrophilic/aqueous microneedle channels post application that act as a barrier to the permeation of 
hydrophobic drugs into the skin 247,270. Therefore, there is a lacuna in the knowledge about the 
effectiveness of using the patch-and-poke approach with solid microneedles.  
In this work, it is demonstrated that a patch-and-poke strategy is more effective in delivering 
imiquimod intradermally than the conventional poke-and-patch approach. This work also 
demonstrated that microneedle oscillation during application plays an important role in the effective 
intradermal delivery of imiquimod using the patch-and-poke strategy.   
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3.3 Materials  
Imiquimod was purchased from Cayman Chemicals, USA. Aldara™ topical cream (5% w/w imiquimiod), 
MEDA Company, Sweden was purchased from Manor Pharmacy, UK. Dermapen®, which is a 
microneedling pen, was purchased from ZJChao, China. The microneedles on the Dermapen® had a 
tapered conical structure. The microneedle had a base diameter of 370 µm with a tip radius of 53.4o. 
The distance between microneedles (pitch) was 620 µm. Microneedles were arranged in rows which 
formed an overall circular area. The Dermapen® has five different oscillation speeds- 8000, 10000, 
12000, 14000 and 16000 RPM. In addition, the needle length could be adjusted between  
250-1500 µm. For the purpose of the permeation study, we selected a microneedle length 1000 µm 
and an oscillation speed of 8000 RPM. During application, the pen was held by one hand with gentle 
pressure while the hand was used to hold the skin in place. The DermastampTM which was a 
microneedle stamp, was purchased from Teoxy Beauty, Wuhan, China. The microneedles on the 
DermastampTM also had a tapered conical structure. The microneedle had a base diameter of 210 µm 
with a tip radius of 22.8o. The distance between microneedles (pitch) was 1050 µm. Microneedles were 
arranged in an annular fashion which formed an overall circular area. The DermastampTM had no 
oscillating function and the needle length of the Dermastamp used was fixed to 1000 µm. During 
application, the DermastampTM was held by one hand with and applied by one swift stamping motion 
with gentle pressure. Sodium acetate was purchased from Sigma-Aldrich, UK. Acetonitrile (HPLC 
grade) and glacial acetic acid were obtained from Fisher Scientific, UK. Teepol solution (multipurpose 
detergent) was ordered from Scientific Laboratory Supplies, UK. D-Squame standard sampling discs 
(adhesive discs) were ordered from Cuderm corporation, USA. OCT media was obtained from VWR 
International Ltd. Belgium. Deionised water was obtained from an ELGA reservoir, PURELAB® Ultra, 
ELGA, UK. All reagents were of analytical grade, unless otherwise stated. Ex vivo porcine skin was used 
to investigate the permeation of imiquimod due to the similarities in histology, thickness and 
permeability to human skin 246. Skin samples were prepared from ears of six-month-old pigs obtained 
from a local abattoir prior to steam cleaning. Full skin thickness was used to prevent altering the skin 
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biomechanical properties which may lead to over-penetration of the microneedles into the skin 66. 
The porcine skin samples were stored at -20 °C until analysis. The integrity of the skin samples 
prepared via this method was assessed by electrical resistance, using the method and guidelines 
described by Davies et al. using EVOM2 Voltohmmeter (World Precision Instruments, U.S.A). Only skin 
that produced an electrical resistance reading of greater than 10 kΩ was used. 271. 
3.4 Methods 
3.4.1 Permeation study of 5% w/w imiquimod cream through porcine skin 
Imiquimod dermal permeation with and without microneedle treatment was evaluated ex vivo using 
a Franz-type diffusion cell. Prior to the permeation study, skin samples were defrosted for at least an 
hour at room temperature. The skin was trimmed into small pieces according to the surface area of 
the donor chamber of the Franz diffusion cell (Soham Scientific, Cambridgeshire, UK). The trimmed 
skin samples were equilibrated by placing them above the receptor compartment for 15 minutes prior 
to skin treatment. The Franz cells used in this study had a receptor compartment volume of 3 ml. 
The porcine skins were subjected to the following treatment modalities: i) application of 20 mg Aldara™ 
cream alone ii) application of 1000 µm microneedles to the skin as a pre-treatment using Dermapen® 
followed by 20 mg Aldara™ cream. 1000 µm refers to the length of the microneedles. This is known as 
the poke-and-patch approach. 12-microneedle array cartridges were used for this treatment. iii)  
Application of 20 mg Aldara™ cream followed by 1000 µm microneedle treatment using Dermapen®. 
This is known as the patch-and-poke approach. Either a 12-microneedle or a 36-microneedle array 
cartridge were used for this treatment. All the arrays used in the microneedle treatment groups have 
similar surface area of application which is 0.64 cm2. 
The choice of microneedles selected for this permeation were based on several reasons. Firstly, the 
microneedle selected were manufactured from stainless steel which displayed good biocompatibility 
with biological tissues such as skin 272,273. In addition, the high mechanical strength of stainless-steel 
microneedles overcome the issues of microneedle tip breakage and deposition within the skin upon 
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application. Such problems are frequently encountered with microneedles fabricated from brittle 
materials such as ceramics and silica 74. Furthermore, the higher mechanical strength of stainless-steel 
microneedles ensure relative to polymeric microneedles ensures that these microneedles would have 
higher insertion efficiency into the skin while thus generating more microneedle channels for drug 
permeation into the skin 274. The microneedle length selected was 1000 µm as this microneedle length 
gave an insertion depth of 600 µm as shown in Figure S3 1. This depth at which nodular BCC typically 
grows within the skin 34,35. Guided by these information and insertion data, stainless-steel 
microneedles with lengths of 1000 µm (Dermapen®) were selected for the skin permeation study. 
Next, the porcine skins were placed on top of the receptor compartment filled with 3 ml of degassed  
100 mM acetate buffer pH 3.7. This buffer was selected as the receptor phase in order to maintain a 
sink condition throughout the permeation study. This is due to the insolubility of imiquimod at neutral 
or basic pH values. Various groups have reported the use of acetate buffer pH 3.7 as the receptor 
phase in imiquimod permeation studies 53–55. The skin was then secured between the donor and 
receptor compartment of the diffusion cell using a metal clamp, with the stratum corneum side facing 
the donor compartment. Upon assembling the Franz diffusion cell, the permeation experiment was 
conducted over a period of 24 hours in a thermostatically controlled water bath set at 36.5 oC. 
3.4.2 Quantification of imiquimod post-permeation study 
After a 24-hour permeation experiment, the excess cream was removed and collected from the skin 
surface by careful application of sponges soaked with 3% v/v Teepol® solution. The sponges were 
pooled for imiquimod HPLC analysis as a total skin wash. Any formulation which might have spread to 
the donor chamber was collected by the sponges and stored for imiquimod analysis by HPLC as a 
donor chamber wash. Upon removing excess formulation from the skin surface, 15 sequential tape 
strips were collected from the skin as detailed in Section 3.4.3.  
The amount of imiquimod from the different Franz cell elements (skin wash, donor chamber wash, 
pooled tape strips and remaining skin after tape stripping) were extracted by the addition of 5, 5, 10 
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and 5 mL of methanol extraction mixture (methanol 70%: acetate buffer pH 3.7 100 mM 30%) 
respectively using a previously reported method 52. Samples were then vortexed for 1 minute and 
sonicated for 30 minutes before being left overnight. Subsequently, samples were vortexed again and 
sonicated for a further 30 minutes. 1 ml of the extracts were collected and spiked with 100 µl of  
100 µg/ml propranolol as an internal standard. The samples were then filtered through 0.22 µm 
membrane. For the receptor fluid, 1 ml of the solution from each Franz cells were collected and spiked 
with 100 µl of 100 µg/ml propranolol as an internal standard before being filtered through 0.22 µm 
membrane. HPLC analysis was carried out using an Agilent 1100 series instrument (Agilent 
Technologies, Germany) equipped with degasser, quaternary pump, column thermostat, autosampler 
and UV detector. System control and data acquisition were performed using Chemostation software. 
The details of the HPLC chromatographic conditions are as follow: column C18 (150 × 4.6 mm) 
ACE3/ACE-HPLC with a particle size of 5 µm, pore size of 100 Å, pore volume of 1.0 ml/g and a surface 
area of 300 m2/g, Hichrom Limited, UK. The mobile phase composition for analysis of extracts from 
skin wash, donor chamber wash, pooled tape strips and remaining skin consists of 10 mM acetate 
buffer: acetonitrile (79:21). Whilst, the mobile phase composition for analysis of receptor fluid consists 
of 10 mM aqueous acetate buffer: acetonitrile (70:30). The system operated at a flow rate of 1.0 
mL/minute, UV detection at λmax=226 nm, injection volume of 40 µL and column temperature of  
25 °C.   
3.4.3 Tape stripping and cryo-sectioning of porcine skin post-permeation experiment for 
ToF-SIMS analysis. 
After 24 hours, the skins were detached from the Franz diffusion cells. Excess AldaraTM cream was 
removed. 15 sequential tape strips were collected for each skin samples. Sequential removal of 
corneocytes was judged by the resistance felt during the stripping step and the change in opacity of 
the tape post stripping.  The skin was rotated 180° for each tape strip. This ensures that the tape 
stripping would not result in premature removal of the whole stratum corneum during tape stripping. 
All tape strips collected were stored in a freezer at -20 °C until analysis. 
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In order to measure the depth of imiquimod permeation into the skin, the permeation experiments 
were repeated as described above in Section 3.4.1. After the permeation study, excess formulation 
was removed and a 1 cm x 1 cm of each microneedle application site was fresh frozen with liquid 
nitrogen. Skin cross-sectioning was performed using a cryostat (Leica CM3050 S Research Cryostat, 
UK). The skin slices were then thaw mounted on a glass slides and stored at -20 oC prior to ToF-SIMS 
analysis. 
3.4.4 ToF-SIMS analysis 
ToF-SIMS was used to analyse individual tape strips and cryo-sectioned porcine skin samples. ToF-
SIMS analysis was performed using a ToF-SIMS IV instrument (IONTOF, GmbH) with a Bi3+ cluster 
source. A primary ion energy of 25 KeV was used, the primary ion dose was preserved below 1 × 1012 
per cm2 to ensure static conditions. Pulsed target current of approximately 0.3 pA, and post-
acceleration energy of 10 keV were employed throughout the sample analysis. The mass resolution 
for the instrument was 7000 at m/z 28. The scanned area of the tape strips samples was 
(4 mm × 4 mm) encompassing the skin area exposed to Aldara™ cream during Franz cell diffusion 
experiments. On the other hand, an analysis area of (1.5 mm x 3 mm) was employed for the skin cross-
sections. Both sample types were analysed at a resolution of 100 pixels/mm. An ion representing 
biological material and therefore indicative of skin (skin marker) was identified as CH4N+ and was used 
to threshold the data sets from tape strips. CH4N+ is a common fragment observed in organic materials 
such as biological specimens. Therefore, this secondary ion was used to track the presence of 
corneocyte extracted on the tape strips. The data was reconstructed to remove the data from the 
adhesive tape material found between the fissures in the stripped skin and therefore the data was 
only analysed from the skin material. Following this, each image of the individual tape strip 
(4 mm × 4 mm) was divided into four smaller data sets of (2 mm × 2 mm) which results in four repeats 
(n = 4) for each sample and their intensities were normalised to the total ion intensity. All ToF-SIMS 
data were acquired in positive ionisation mode as this gave the best ionization intensity for imiquimod 
based on our previous work 68. In addition, pure imiquimod, pure isostearic acid and Aldara™ cream 
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reference spectra were obtained by analysing the pure drug, pure fatty acid and the cream on silicon 
wafers using ToF-SIMS. 
3.4.5 Understanding the effect of vibration of Dermapen® on the intradermal permeation 
of imiquimod 
One of the features of the Dermapen® is the ability of the device to vibrate the microneedles at the tip 
of the device. In order to understand the role of oscillation on the intradermal delivery of imiquimod 
into the skin, the permeation study was repeated as detailed in Section 3.4.1. However, porcine skins 
were subjected to the following treatment modalities: i) Application of 20 mg AldaraTM cream followed 
by 1000 µm microneedle treatment using Dermapen®. A 36-microneedle array cartridge was used for 
this treatment ii) Application of 20 mg AldaraTM cream followed by 1000 µm microneedle treatment 
using a non-vibrating DermastampTM. The DermastampTM consists of 40-microneedle array per stamp. 
The DermastampTM was similar to the Dermapen® in terms of microneedle length used (which is  
1000 µm) and the material used to manufacture the needle, which was stainless steel. The only main 
difference was that the DermastampTM did not have any vibration function. After a 24-hour 
permeation study, the skin samples were cryo-sectioned and analysed by ToF-SIMS using the same 
conditions outlined in Section 3.4.4. In addition, a time point study (0, 1, 6, 12 and 24 hours) was 
conducted to evaluate how the dermal distribution of imiquimod changes over the course of 24 hours 
with the patch-and-poke approach using the Dermapen®. 
3.5 Results and discussion 
3.5.1 Skin insertion and dye binding study 
An ex vivo skin insertion study was conducted to establish the microneedle length needed to reach 
the skin strata where nodular BCC typically resides. From the supplementary data, Figure S3 1, it can 
be seen that when the length of Dermapen was adjusted to 1000 µm, an insertion depth of 
approximately 600 µm was observed. Such penetration depth is sufficient to reach beyond the 
epidermis layer and into the dermis layers. As nodular BCC typically manifests from the stratum basale 
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at the dermoepidermal junction and grows deeper into the dermis, this suggests that adjusting the 
Dermapen® to 1000 µm would provide sufficient penetration to reach nodular BCC tumours 4. 
Therefore, guided by the skin insertion study data, we selected the 1000 µm length microneedles 
(Dermapen®) for the skin permeation study.  
3.5.2 HPLC analysis of imiquimod from Franz cell components post-permeation study. 
HPLC analysis was performed in order to quantify the amount of imiquimod that has remained or 
permeated into respective Franz cell compartments over the course of the permeation study. The 
mean amount of imiquimod (µg) recovered from the various Franz cell components following the 24-
hour permeation study is shown in Figure 3-1. The amount of imiquimod extracted from the applied 
dose from cream alone was highest in the skin wash relative to other Franz cell components. This 
suggests that when imiquimod is delivered as a topical cream, the drug displayed limited permeation 
into the skin. Such findings agree with previous work that showed that application of imiquimod as a 
topical cream resulted in the majority of the dose being recovered from the skin surface 68. However, 
the amount of imiquimod recovered contradicts the finding by Stein et al., who found that only 19% 
of the applied AldaraTM cream remained on the skin surface highlighting sufficient dermal permeation 
of imiquimod 275. Such enhanced permeation reported by Stein and co-worker is likely due to the use 




Figure 3-1 HPLC analysis of the mean amount of imiquimod recovered from the different Franz cell components 
(donor chamber wash, skin wash, tape strips, remaining skin and receptor fluid) post-permeation study. Data is 
presented as the mean ± SD (n = 6). The inset details the amount of imiquimod that has permeated into (b) tape 
strips (c) remaining skin and (d) receptor fluid. Differences were calculated using one-way ANOVA, followed by 
Tukey’s post hoc test, and deemed significant at p<0.05. n.s = not statistically significant at p>0.05. MN refers to 
microneedles. 
One of the ways to circumvent the limited dermal permeation of imiquimod is to utilise a physical 
permeation enhancer such as microneedles to promote the delivery of the drug into the skin. Thus, in 
this study, we utilised a microneedling device, Dermapen® in order to enhanced imiquimod delivery 
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into the skin. One of the earliest and simplest microneedle-based approaches to promote intradermal 
drug delivery is via the poke-and-patch method 247. However, when we conducted an ex vivo skin 
permeation study, we observed that the delivery profile of imiquimod with the poke-and-patch 
approach was similar to topical cream application as shown in Figure 3-1.  
One of the possible explanations for the similar permeation profile of imiquimod into and across ex 
vivo skin between these two strategies (cream alone vs poke-and-patch) is due to the formation of 
hydrophilic microneedle channels from the outflow of dermal interstitial fluid upon microneedle 
application 247,270. Such channels may act as a barrier for the effective permeation of a hydrophobic 
drug such as imiquimod 277. Therefore, we also investigated if the application of topical AldaraTM cream 
(5% w/w imiquimod) followed by microneedling, a patch-and-poke approach, as an alternative 
strategy to improve the delivery of imiquimod into the skin. When the ex vivo skin permeation study 
was carried out using the patch-and-poke strategy, we observed a decrease in the amount of 
imiquimod recovered from the skin wash. This was statistically significant when the patch-and-poke 
approach used a 36-needle cartridge. 
Although not statistically significant, the HPLC analysis of imiquimod extracted from remaining skin 
showed an increasing trend in the amount of imiquimod delivered into the skin with the patch-and-
poke approach in comparison to the poke-and-patch approach. However, the difference in the 
amount delivered across the skin was most prominent from the analysis of receptor fluid. Analysis of 
receptor fluid indicates an increase in the amount of imiquimod delivered into and across the skin. 
However, such differences were only statistically significant when the patch-and-poke approach was 
adopted using the 36-microneedle array Dermapen®.  
In addition, we have established that sink condition was maintained throughout our study as will be 
described. The saturation solubility of imiquimod, which is a weak base, in the receptor compartment, 
acetate buffer 100 mM, has been reported by De Paula et al. is 1360.2 (μg/mL) at pH 4.0 52. Therefore, 
as we used a lower pH acetate buffer, pH 3.7, which has been used in by other investigators 53–55, we 
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predicted that the solubility of the drug at pH 3.7 would be comparable if not higher than that reported 
by De Paula et al.  Data for the receptor fluid that has been converted into μg/mL in the Supplementary 
Information (Figure S3 2) indicates that the highest concentration detected was on average  
48.7 µg/ml. This indicates that after 24 hours, the highest average concentration imiquimod within 
the receptor fluid was 3% of its saturation solubility concentration reported. Ng et al. have indicated 
that in order for sink conditions to be maintained, the penetrant concentrations in the receptor 
solution should not be more than 10% of their saturation solubility concentration 278. Based on this 
information, we can confirm that sink conditions were indeed maintained throughout the permeation 
study. 
The increase in amount of imiquimod delivered across into the receptor fluid may be attributed to the 
enhanced amount of imiquimod delivered into the dermis using the patch and poke approach. 
Imiquimod is known to have low aqueous solubility such as in the interstitial fluid within the dermal 
microenvironment, but displays higher solubility in acidic pH due the molecule being a weak base 52. 
Based on the physiochemical property of the drug, it is likely that imiquimod delivered into the dermis 
may have partitioned into the acidic acetate buffer within the receptor solution over time as the drug 
has higher solubility in the acidic buffer. In addition, it is worth noting that the dermis receives a rich 
blood supply that is derived from the hypodermis. Therefore, it is postulated that any drug that 
reaches this layer of the skin, after traversing the tortuous epidermal layers, has the potential to be 
rapidly absorbed into the systemic circulation 4. Based on Figure 3-1 (c) and (d), it can be inferred that 
the patch-and-poke strategy may result in improved delivery into the dermis which is target region for 
nodular BCC. The partitioning of the drug into the receptor fluid may provide some indication of 
potential systemic exposure. Based on Figure 3-1 it can be inferred that although the patch-and-poke 
strategy may result in improved delivery into the dermis, such mode of delivery may lead to increased 
systemic exposure of imiquimod which could result is side effects such as flu-like symptoms 279. 
Therefore, in order to limit the likelihood of such side effects arising, it could be suggested that 
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reducing dosing frequency for the patch-and-poke strategy relative to the dosing frequency of 
AldaraTM cream application may mitigate the likelihood of such side effects arising. 
3.5.3 ToF-SIMS analysis of tape strips post-permeation study 
Despite the quantitative results provided by HPLC analysis, the method does not confer any 
information detailing imiquimod distribution within individual layers of skin. Therefore, an additional 
analytical technique was used to provide spatial information regarding imiquimod permeation. 
Analysis of samples using ToF-SIMS allows a chemical map of the distribution of a compound of 
interest to be acquired as well as providing information on how such distribution changes with depth. 
It has been mentioned in Section 3.4.3 that the skin was washed 3 % Teepol solutions followed by 
subsequent wash with deionised water to remove excess AldaraTM cream from the skin surface. Where 
sensitive analyses are done on these samples by ToF-SIMS, concerns may arise of potential interfering 
chemicals from the Teepol solutions on the samples. Additional validation has been done to show that 
the main surfactants present in Teepol which are sodium dodecylbenzene sulphonate, sodium lauryl 
sulfate and Pareth-10 (polyethylene glycol ether) are not present in detectable amount via ToF-SIMS 
analysis following subsequent wash with deionised water. This can be seen in the supplementary data, 
Figure S3 3 
In previous work, it has been found that the permeation of the imiquimod across the skin could be 
tracked by monitoring the molecular ion C14H17N4+ 68. ToF-SIMS secondary ion images of the analysed 
tape stripped area, which represents the exposed area of the skin to Aldara™ cream during Franz cell 
diffusion experiment, are illustrated in Figure 3-2. An ion representative of skin tissue (CH4N+) and a 
diagnostic imiquimod ion (C14H17N4+) ion image for tape strips no. 6 is shown in Figure 3-2 (a). It was 
apparent that the signal from the skin marker (CH4N+) was much lower in the two top ion images. 
However, should there be a reduction or increase in the ions collected, each ToF-SIMS image collected 
is normalised to the total ion collected. As all the ion images collected have been scaled to the same 
value as shown with scale bars, we attributed the signal reduction from the skin marker (CH4N+) for 
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the two top ion images is due to biological variation as the porcine skin used is from different pigs’ 
ears. 
 
Figure 3-2 (a) ToF-SIMS 4 mm × 4 mm secondary ion distribution maps on tape strip surfaces. The scale bar 
represents 1 mm, and the images have been normalized to the total ion image. The distribution maps are from 
tape strip no. 6, showing the distribution of the imiquimod molecular ion (C14H17N4+), and biological marker for 
corneocytes (CH4N+) (b) ToF-SIMS exported peak intensities (normalized to total ion intensity) for imiquimod 
molecular ion peak as a function of increasing tape strip number from porcine skin. The skin was either treated 
with AldaraTM cream only, pre-treated with microneedles (1000 µm) before AldaraTM cream application or 
treated with microneedles (1000 µm) of different array size after cream application. Data are expressed as  
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mean ± SEM for n=12 analytical repeats. MN-refers to microneedles, Differences were calculated using one-way 
ANOVA, followed by Tukey’s post hoc test, and deemed significant at p<0.05.  
Figure 3-2 (b) highlights how imiquimod ion intensity changes with stratum corneum depth as a function of tape 
strip number. The decrease in permeation of imiquimod from tape strips no. 2 to  
no. 12 is due to an increase in water content with stratum corneum depth which limits the permeation of 
imiquimod 280. The poor water solubility and lipophilicity of imiquimod resulted in limited dermal permeation 
when the drug is applied to the skin as a topical cream. Specifically, as imiquimod is a lipophilic molecule, when 
the drug is only applied as a topical cream it is likely that the molecule mostly permeates from the cream and 
into the superficial layer of the stratum corneum. As the superficial layer of the stratum corneum are known to 
be lipid rich, imiquimod would partition into this lipid matrix and remain there relative to permeating deeper into 
the skin. This may serve as an explanation for the higher imiquimod ion intensity observed from tape strips 
obtained from skin samples treated with AldaraTM cream alone relative to skin subjected to microneedle 
application. 
In contrast, it can be seen from Figure 3-2 (b) that perforating the skin with microneedles either before 
or after cream application results in a decrease in the measured imiquimod ion intensity from ToF-
SIMS analysed tape strips in comparison to tape strips from skin samples treated with AldaraTM cream 
alone. This finding agrees with the trend observed from the HPLC results in Figure 3-1 (b) that showed 
lower imiquimod concentration in the pooled tape strips from skin samples subjected to microneedle 
perforation relative to AldaraTM cream only treated skins. This observation may be attributed to the 
generation of microneedle channels within the stratum corneum with microneedle application. When 
the microneedle was applied as a pre-treatment using the 12 arrays via the poke-and-patch strategy, 
the stratum corneum is now perforated with aqueous microneedle channels. As the drug is poorly 
water soluble these aqueous channels may hinder the permeation of the drug into the stratum 
corneum resulting in lower imiquimod ion intensity relative to AldaraTM cream. Without any aqueous 
microneedle channels in the cream only treated group, the drug will be able to partition and remain 
in the lipid rich matrix of the stratum corneum. However, when the microneedle was applied after 
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cream application using either the 12 or 36 arrays, via the patch-and-poke strategy we also observed 
lower imiquimod ion intensity relative to AldaraTM cream. In this instance, the microneedle application 
is now mechanically inserting the drug across the stratum corneum and directly into the epidermis 
and dermis. Therefore, there will be less cream available on the skin surface as evidenced from the 
HPLC data in Figure 3-1 (a) for skin wash. As there is less cream on the skin surface, there will now be 
less drug to partition from the skin surface and into the stratum corneum resulting in lower imiquimod 
ion intensity relative to AldaraTM cream. 
On the other hand, the current finding contradicts our previous report that showed higher imiquimod 
ion intensity from ToF-SIMS analysed tape strips obtained from the poke-and-patch approach relative 
to topical cream application alone 68. In the previous work, a shorter microneedle length (250 µm) was 
employed while 1000 µm was used in this study. The shorter needles used in the previous work may 
generate shallower microneedle channels that remained mostly within the viable epidermis layer. 
These shallower microneedle pores are more likely to promote the permeation of imiquimod into the 
superficial layer of the skin rather than flowing deeper into the dermis. These shallower drug-filled 
microneedle channels may act as focal points for the drug to radiate out to surrounding corneocytes, 
resulting in higher imiquimod intensity when a shorter microneedle length is used with the poke-and-
patch approach relative to topical cream alone. 
3.5.4 ToF-SIMS Analysis of Skin Cross-sections 
3.5.4.1 Effect of microneedle pre-treatment “poke-and-patch” versus post-treatment “patch-
and-poke” on the delivery of imiquimod. 
It was apparent from ToF-SIMS analysis of tape strips as shown in Figure 3-2 (b), that using either the 
poke-and-patch or patch-and-poke approach, we observed a similar trend in the permeation of 
imiquimod through the stratum corneum. This suggests that both microneedle application strategies, 
either before or after cream application may not influence the permeation of imiquimod through the 
stratum corneum. In order to investigate if the two solid microneedle application strategies may 
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influence the intradermal delivery of imiquimod deeper into the skin, we employed ToF-SIMS analysis 
of skin cross-sections in addition to tape strip analysis. Understanding the spatial distribution of 
molecular species is paramount in elucidating the effectiveness of drug delivery systems within a 
biological tissue. Conventional liquid chromatography mass spectrometry (LC-MS) is traditionally 
employed to understand the effectiveness of a drug delivery strategy, however the extraction process 
employed leads to loss in spatial information 281. ToF-SIMS has the capability to simultaneously map 
molecular ion of the dosed compound in tandem with the native fragment ions from skin tissue 268. 
Examples of ion signals used to distinguish respective skin strata are C5H15NPO4+ (a fragment ion for 
phosphatidylcholine) and C17H32N+ (a fragment ion for ceramide) 224. The stratum corneum displays 
high levels of ceramide whilst being devoid of phospholipids 282. Therefore, phosphatidylcholine ion 
fragments were used to map the viable epidermis and dermis while ceramide fragment ions were used 
to identify the stratum corneum.  
From Figure 3-3, it is evident that there is limited availability of imiquimod within deeper skin layers 
when applied either through topical cream alone (i) or via the poke-and-patch (ii) approach. However, 
when Aldara™ is applied via the patch-and-poke approach in Figure 3-3 (iii) and (iv), we observed 
enhanced imiquimod delivery into the dermis. This observation agrees with the trend observed from 
the HPLC analysis from Figure 3-1 (c) that shows an increase in imiquimod concentration in the skin 
with the patch-and-poke approach using 36-needle array Dermapen®. In addition, the delivered drug 
is localised within microchannels formed during microneedle insertion. Typically nodular BCC presents 
400 µm below the skin surface 34. The ToF-SIMS analysis of skin cross-sections from Figure 3-3 suggest 
that the patch-and-poke approach may be a suitable strategy to enable enhanced imiquimod delivery 




Figure 3-3 ToF-SIMS secondary ion distribution map of skin cross sections from porcine skin that were treated 
with (i) AldaraTM cream (5% w/w imiquimod) alone (ii) in combination with Dermapen (1000 µm) using the ‘poke-
and-patch’ approach (iii)-(iv) in combination with Dermapen (1000 µm) using the ‘patch-and-poke’ approach 
with different needle arrays. This resulted in improved drug delivery into the lower layer of the skin (dermis) with 
the ‘patch and poke’ strategy. 
It has been demonstrated previously that ToF-SIMS can chemically image drug permeation through 
microneedle channels in the stratum corneum and upper epidermis 68 . However, these studies 
adopted a poke-and-patch approach that showed localisation of imiquimod within the stratum 
corneum which agrees with the current findings 68. One of the possible explanations for the limited 
drug permeation with the poke-and-patch approach is the viscoelastic property of the skin that causes 
some regions of the skin to recoil and close over time after microneedle application. In some instances, 
the closure can be as rapid as 5 minutes 95,97.  This rapid closure of microneedle pores may limit dermal 
permeation of imiquimod via the poke and patch approach. Additionally, perforating the skin with 
microneedles prior to cream application promotes the flow of more interstitial fluid into the 
microneedle channels.  This results in the formation of hydrophilic pores that act as a barrier to the 
entry of hydrophobic drugs, such as imiquimod, deeper into the dermis 247,270.  This phenomenon does 
not affect the intradermal delivery of imiquimod using the patch-and-poke approach, as the drug is 
mechanically driven into the skin during repeated microneedle insertion circumventing the effect of 
microneedle pore closure. 
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Another possible limitation of the poke and patch approach with solid microneedles is limited drug 
flux from highly viscous formulations through microneedle perforated skin. This hypothesis was 
evaluated by Milewski et al. The group observed that as the viscosity of a formulation increases, the 
flux of naltrexone hydrochloride decreased across microneedle pre-treated ex vivo mini-pig skin 283. 
Pharmaceutical creams, such as AldaraTM (5%  w/w imiquimod) are inherently viscous formulations 
relative to gels and lotions 284. The rapid closure of microneedle channels coupled with slow 
permeation of the drug from the highly viscous AldaraTM cream into the skin may only limit the drug 
distribution into the stratum corneum with the poke-and-patch approach. 
Owing to the parallel detection capability, ToF-SIMS analysis can simultaneously map the presence of 
excipients within biological tissues as well as the drug. One example of an excipient that is present in 
AldaraTM cream is isostearic acid. Conventionally, isostearic acid has been incorporated in various 
topical and cosmetic products as a permeation enhancer 285. However, Walter et al. have shown that 
isostearic acid also displayed active pharmacological properties which are independent of the immune 
mediated response induced by imiquimod 286. Isostearic acid plays a critical role in inflammasome 
activation, which is pertinent for the overall efficacy of AldaraTM cream. It is also therefore of interest 
to chemically map the presence of isostearic acid in the microneedle channels. Through monitoring 
the molecular ion peak at m/z 285.3 indicated in Figure 3-4 (a), we were able to detect the co-
localisation of the excipient within the microneedle channels as shown in Figure 3-4 (b) and (c). The 
peak assignment for isostearic acid was validated by referring to fragmentation pattern at m/z 285 





Figure 3-4 (a) Positive polarity ToF-SIMS spectra of ex vivo porcine skin treated with 5% w/w imiquimod topical 
cream using patch and poke approach, where the inset spectrum shows the peak of the [M+H]+ of imiquimod at 
m/z=241 and [M+H]+ of isostearic acid at m/z=285.3 (b) ToF-SIMS 2D chemical ion maps of phosphatidylcholine 
(biological tissue), imiquimod (active) and isostearic acid (excipient) acquired from cross section analysis of ex 
vivo porcine skin tissue after a 24 hour permeation experiment. Chemical ion map shows location of skin tissue 
along with the biodistribution of active and excipient. (c) an overlay image of the excipient isostearic acid marker 
(C18H37O2+) in red, imiquimod (C14H17N4+) in green and the skin marker (C5H15NPO4+) in blue. The overlay indicates 
the ability ToF-SIMS to detect the colocalisation of imiquimod (active) and isostearic acid (excipient) within the 
microneedle channel within the ex vivo skin tissue. 
Traditional methods to study microneedle-enhanced permeation require the use of fluorescently-
labelled drug molecules to track the intradermal localisation of pharmaceuticals within the skin. This 
approach may alter the physiochemical properties of the drug leading to erroneous estimation of drug 
permeation into the skin 198. In addition, such methods only allow the tracking of the active drug 
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molecule which limits our understanding of the dermal distribution of the other components in the 
formulation such as polymers and fatty acid-based surfactants.  The current work, highlights that the 
patch-and-poke strategy using oscillating solid microneedles may be a simple strategy to enable  
co-localised intradermal delivery of a poorly water soluble active and an excipient as evidenced by 
ToF-SIMS analysis. Similar to imiquimod, isostearic acid also has low water solubility which limits the 
penetration of the fatty acid into the more aqueous dermis 287. The co-delivery of these compounds 
into the dermis ensures that isostearic acid may execute a synergistic action along with imiquimod in 
stimulating an effective inflammatory response for the treatment of nodular BCC. 
3.5.4.2 Effect of vibration on the delivery of imiquimod into the dermis using patch-and-poke 
approach with Dermapen 
One of the features of the Dermapen® is the vibration of microneedles at the tip of the device. This 
generates a stamp-like motion overcoming the issue of varying pressure of application by  
end-users 288. Hence, we attempted to understand if vibration plays a functional role in the 
intradermal delivery of imiquimod using the patch and poke approach. We repeated the experiment 
using an ex vivo porcine skin permeation study followed by ToF-SIMS analysis of skin cross-section. As 
a comparator to the vibrating Dermapen®, we treated the skin with a DermastampTM. The 
DermastampTM perforates the skin in a single stamp motion without the assistance of a vibrating 
electric motor. Both microneedle devices used were 1000 µm in length. It can be seen from  
Figure 3-5 that generation of imiquimod filled microneedle channels within the dermis with the patch-
and-poke strategy only occurred when the skin was treated with the oscillating Dermapen® following 




Figure 3-5 ToF-SIMS secondary ion distribution map of skin cross sections for ex vivo porcine skins that were 
treated with (i) Aldara cream (5% w/w imiquimod) followed by Dermapen® (1000 µm) application and (ii) Aldara 
cream (5% w/w imiquimod) application followed by 1000 µm DermastampTM 
The ability of the Dermapen® to efficiently penetrate the skin relative to other microneedle systems is 
attributed to the vibrating-stamping motion of the device during device application 254,289. Izumi et al. 
explored the effect of vibration on the penetration of microneedles into artificial silicone rubber skin. 
The group found that applying a vibration of 30 Hz to a microneedle array during skin insertion 
resulted in a reduction in the force needed to penetrate the skin 255. The reduction in puncture force 
is attributed to the reduction in frictional forces experienced by microneedles under vibration 256. The 
rapid vibration of the microneedles also mitigates the likelihood of viscoelastic materials such as skin 
and topical cream from attaching to the microneedle during the insertion step. This phenomenon 
provides an explanation as to why the patch-and-poke motion using DermastampTM was unsuccessful 
in delivering imiquimod into the dermis. The topical cream along with superficial skin tissues (i.e., 
stratum corneum) may attach to the tip of the needles during microneedle application resulting in 
poor penetration profile. Aoyagi et al. also showed that that vibration indeed plays a critical role in 
microneedle insertion. However, Aoyagi and co-workers also demonstrated that a reduction in 
puncture force is also achievable when the skin is stretched prior to microneedle application 122. Unlike 
the DermastampTM, the presence of shoulders at the tip of microneedle cartridge of the Dermapen® 
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generates tension on the skin during microneedle application. This helps to reduce the propensity of 
the skin to fold around the needles while decreasing the puncture force needed to perforate the skin. 
As it was apparent that the patch and poke approach using the Dermapen® provided the most effective 
intradermal delivery of imiquimod into skin, we then attempt to understand how imiquimod dermal 
distribution changes over 24 hours with this strategy. Subsequently, we repeated the ex vivo Franz cell 
permeation experiment using the patch-and-poke approach and performed ToF-SIMS analysis on the 
skin at five different time points. From Figure 3-6, we can see that using the patch-and-poke approach, 
the generation of imiquimod filled channels took place immediately (0 hours) post microneedle 
application on the skin after cream application. It is well known that the conventional poke-and-patch 
strategy is reliant on passive diffusion for the entry of drug molecules across aqueous microneedle 
channel to achieve intradermal delivery 283. Such a process is both slow and ineffective for the delivery 
of hydrophobic molecules due to their poor solubility in the aqueous channels. Coupled with the rapid 
closure of microneedle channels, this renders the poke-and-patch approach a poor strategy for the 
delivery of hydrophobic drugs. On the other hand, the patch-and-poke approach is dependent on the 
mechanical insertion of drug directly into the skin during microneedle application which overcomes 




Figure 3-6 ToF-SIMS secondary ion distribution map of porcine skin cross sections from different time points. 
These images highlight improved drug delivery into the lower layer of the skin (dermis) that persisted in the skin 
up to 24 hours. In addition, the formulation was immediately present in the deeper layers of the skin upon 
microneedle application. Phosphatidylcholine highlights the viable epidermis and dermis while ceramide 
highlights the top layer of the skin. Black circles indicate areas filled by hair follicles. 
The presence of imiquimod loaded channels within the dermis that persisted for 24 hours was 
attributed to the poor water solubility of the drug 290. The limited water solubility of imiquimod 
coupled with the fact that the water composition increases with dermal depth serves as possible 
explanation as to why imiquimod channels remained in the ex vivo skin tissues up to 24 hours 291. The 
application of imiquimod cream followed by Dermapen® application generates localised regions of 
imiquimod within the skin which resemble the structure of the microneedle channels. This shows that 
using a patch-and-poke strategy with oscillating microneedles provide an elegant synergy of existing 
products to enhance localisation of imiquimod intradermally. Such a drug delivery strategy may help 





This work expands current understanding on the application of solid microneedles as a physical 
permeation enhancement strategy to promote the delivery of imiquimod into the skin for the 
treatment for BCC. The approach in which microneedles are used in combination with Aldara™ cream 
plays a critical role for the successful intradermal delivery of imiquimod into the skin. It has been 
demonstrated that in order to successfully deliver a hydrophobic molecule such as imiquimod into the 
dermis, a patch-and-poke approach is superior to the conventional poke-and-patch approach. 
Furthermore, it has also been demonstrated that an oscillating microneedle system, such as the 
Dermapen® for the patch-and-poke strategy, is a critical factor in providing successful intradermal 
delivery of imiquimod into the skin. Using this novel patch-and-poke approach hydrophobic drugs are 
mechanically inserted into the microneedle channels within the dermis upon microneedle application. 
This avoids the generation of hydrophilic/aqueous microneedle channels formed using the traditional 
poke-and-patch which can pose as a barrier to drug permeation. In summary, this work suggests that 
the combination of AldaraTM cream in combination with the oscillating Dermapen® provides an elegant 
synergy to enhance localised intradermal delivery of imiquimod. Such a strategy may provide a less 
invasive intervention to patients who would prefer an alternative treatment to surgery for the 




3.7 Supplementary Figures 
 
Figure S3 1 (a) Gentian violet staining of microneedle channels formed after microneedle application of different 
length followed by gentian violet staining (b) Optical microscopy images of porcine skin histological cross sections 
after application of microneedle pens of differing lengths. Microneedle channels were visualised and tracked by 
monitoring region of the skin stained by gentian violet solution. (c) Microneedle penetration depth measured 
from the length of microneedle channels from skin cross-sections. Data are expressed as mean ± SD, n=8. 
Differences were calculated using one-way ANOVA, followed by Tukey’s post hoc test, and deemed significant at 
p<0.05. n.s = not statistically significant at p>0.05. 
 
Figure S3 2 HPLC analysis of imiquimod concentration in receptor fluid post-permeation study. Data is presented 
as the mean ± SD (n = 6). Differences were calculated using one-way ANOVA, followed by Tukey’s post hoc test, 



































































































































Figure S3 3 ToF-SIMS spectra of pure concentrated Teepol solution, blank untreated skin and skin that has been 
washed with Teepol followed by subsequent wash with deionised (similar to how skin samples were treated in 
the experimental chapter post permeation). The control spectra highlight the absence of (a) sodium lauryl sulfate 
(b) sodium dodecylbenzene sulphonate and (c) Pareth-10 (polyethylene glycol ether) from the Teepol washed 
skin following subsequent wash with deionised water. In addition, Figure (d) showed that the phosphatidylcholine 
fragment ion C5H15NPO4+ which is used as a marker to identify the skin was absent from the Teepol solution. 
Collectively this control spectra showed that there was minimal chemical interference from the washing step post 









Figure S3 4 Overlaid ToF-SIMS spectra of (a) blank untreated skin (b) skin treated with Aldara™ cream using the 
patch and poke approach (c) pure isostearic acid reference, showing the peak of the [M+H]  + of isostearic acid 
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Despite being one of the most efficacious drugs used in the treatment of basal cell carcinoma (BCC), 
imiquimod has limited cutaneous permeation. The current work presents the development of 
polyvinylpyrrolidone-co-vinyl acetate (PVPVA) microneedles loaded with imiquimod for improving 
intradermal delivery of imiquimod for the treatment of nodular BCC.  In vitro permeation studies, 
using full thickness ex vivo porcine skin were used to evaluate the effectiveness of these imiquimod 
loaded polymeric microneedles in comparison to the topical application of commercial AldaraTM 
cream. HPLC analysis demonstrated similar intradermal permeation of imiquimod from AldaraTM 
cream and imiquimod-loaded microneedles despite the microneedle having a six-fold lower drug 
loading than the clinical dose of AldaraTM used for BCC management. In addition, ToF-SIMS analysis of 
skin cross sections demonstrated intradermal localisation of imiquimod following microneedle-based 
delivery while the AldaraTM treated skin showed the drug localised predominantly within the stratum 
corneum. ToF-SIMS analysis also demonstrated intradermal co-localisation of the PVPVA polymer, 
used in fabricating the microneedle, with imiquimod within the microneedle channels in a label-free 
manner. This study demonstrates that a polymeric microneedle system with a lower drug loading may 











Basal cell carcinoma (BCC) is the most prevalent type of skin cancer, with the number of 
individuals affected by the disease escalating worldwide. For instance, a large US sex-
stratified cohort study by Wu et al. highlighted that the incidence rate of BCC in both men 
and women have doubled over the past 20 years 27. In addition, similar trends have been 
reported in Canada, Asia, Australia and Europe 28. Furthermore, it is anticipated that the 
incident rate will continue to escalate due to the rise in an aging population coupled with 
historical UV exposure  29. Given that UV exposure is a risk factor in developing BCC, it 
therefore quite common that BCC typically manifests on sun exposed regions of the body such 
as the face, arms and necks 30. The two most common BCC subtypes are superficial and 
nodular 31.  Superficial BCC generally manifests as flat red patches on the skin on the skin 
surface and proliferates parallel to the epidermis 32,33. On the other hand, nodular BCC 
manifests as a translucent pearly nodule that resides within dermis at approximately 400 µm 
below the skin surface 34,35. In addition, it has been reported that at least one-third of nodular 
BCC coexists with superficial BCC 36 
Despite displaying low metastasis rates of 0.0028 %, this form of skin cancer can lead to 
considerable local tissue destruction (nose, ears and eyelids) leading to poor cosmetic 
outcomes and disfigurement at the disease site 37,38. The high incidence rate of the disease 
also forms a considerable proportion of a dermatologist’s workload 39. Therefore, there is a 
need to develop a simple and efficacious treatment strategy, which patients could simply 
administer by themselves in the management of BCC. Although surgical intervention is 
effective in treating BCC, such treatment is both time-consuming and  
technical 61. In addition, some patients may opt for non-surgical alternatives that offer lower 
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overall treatment costs and improved cosmetic outcomes 64,265. One of the most effective 
non-surgical interventions is the topical application of the immunomodulator, imiquimod 59.  
Imiquimod is a potent immune response modifier that induces its immunomodulation 
through Toll-like receptors (TLR) located on antigen presenting cells. Upon binding to these 
receptors, imiquimod induces the release of  pro-inflammatory cytokines which culminate in 
its antitumoral activity 58. Imiquimod is marketed as Aldara™ cream (5% w/w) by 3M 
Pharmaceuticals for the treatment of anogenital warts, actinic keratosis and superficial BCC. 
Despite its potency, the drug has limited dermal permeation thus reducing its therapeutic 
value to superficial BCC 67. However, in the case of nodular BCC, it has been found that topical 
therapy with imiquimod typically has a lower cure rate than surgical intervention 34. Such a 
finding is attributed to the efficient barrier function of the stratum corneum which limits the 
permeation of imiquimod into the skin 68. In addition, the location of nodular BCC that resides 
deep within the aqueous dermis presents another barrier for imiquimod delivery. This is 
because imiquimod is poorly water soluble and thereby has limited permeation into the 
dermis 267,292. The poor permeation properties of imiquimod deeper into the skin is attributed 
to the various physiochemical properties of the drug. It is suggested some of the ideal 
characteristics for a drug to permeate deeper into the skin include a Mw < 600 Da, a Log P 1.0 
to 3.0, a low melting point, and ≤2 hydrogen bonding groups 237. Although imiquimod meets 
some of these criteria, the drug has a high melting point of 292 °C and a total of 4 hydrogen 
bonding groups. The presence of such hydrogen bonding groups, especially the primary amine 
that may interact with the anionic components of the stratum corneum, contribute to the 
poor permeation profile of imiquimod deeper into the skin 68. Furthermore, the drug has poor 
aqueous solubility which precludes the drug from permeating deeper into the aqueous and 
water rich dermal layers 35 .The combination of these factors presents a challenge in 
117 
 
delivering imiquimod in a concentrated and localised fashion into the dermis for the 
treatment of nodular BCC.  
It has been reported by patients that topical treatment such as creams are often 
unfavorable as this drug delivery vehicle typically has poor cosmetic feel upon administration 
as well as exuding an unpleasant scent once applied. In addition, the restriction in daily 
activities post application may result in poor compliance 69. Also, the likelihood of the cream 
spreading onto clothes and healthy skin also raises the issue of unwanted side effects.  
One of the drug delivery platforms that could be utilised to improve the delivery of 
imiquimod into the dermis for the management of basal cell carcinoma are microneedles. 
Microneedles consist of arrays of fine micro-projections that generate transient channels 
when applied to the skin. The accepted view is that microneedles breach the outermost layer 
of the skin, stratum corneum, generating channels which promote the entry of molecules into 
and across the skin 293. Microneedles have been widely investigated as a drug delivery 
platform for skin cancer therapy, as such systems provide more localised delivery of 
therapeutics. In the context of skin tumours, microneedle-based drug delivery systems can 
locally mediate the release of drugs and increase their permeation into deeper tumour 
regions within the skin 237. Several researchers have investigated the utility of using solid 
microneedles, as a skin pre-treatment via the poke-and-patch strategy, to improve the utility 
of delivering anticancer compounds into the skin for the treatment of skin cancer. Naguib et 
al. demonstrated, via a murine model, the feasibility of using solid stainless-steel 
microneedles to enhance the intradermal delivery of 5-fluorouracil, 5-FU to treat skin 
tumours. In their in vitro work, the group demonstrated that 5-FU flux increased by 4.5-fold 
when 5-FU cream was applied on microneedle perforated murine skin compared to cream 
application on intact skin 66. More recently, Al-Mayahy et al. showed that using a two-step 
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application process involving pre-treating the skin with solid stainless-steel microneedles 
followed by AldaraTM cream application, they were able to enhance the permeation of 
imiquimod deeper into the skin 68.  
However, the utility of using solid stainless-steel microneedles is limited by the short 
duration  
(< 15 min) than the channels remain open, due to the regeneration of skin, ultimately 
reducing the amount of drug delivered 95. Given these limitations of topical cream application, 
there is an impetus to reformulate imiquimod into a dissolving microneedle system which 
could offer a more effective and patient friendly treatment strategy for the management of 
nodular BCC. The simple and straightforward one-step application using dissolving polymeric 
microneedle patch loaded with imiquimod relative to the two-step application process via the 
poke-and-patch strategy using solid microneedles and AldaraTM may be a more preferred 
treatment option for patients. However, there are no studies to date that have evaluated 
improving the delivery of imiquimod into the dermis via the use of dissolving polymeric 
microneedles for the management of nodular BCC.  
The aim of this study is to fabricate and characterize polymeric microneedles as a drug 
delivery system to achieve the localised intradermal delivery of imiquimod for nodular BCC 
treatment. Polyvinylpyrollidone-co-vinyl acetate (PVPVA) microneedles loaded with 
imiquimod were developed through a microfabrication and micromoulding technique. PVPVA 
is a biocompatible polymer that is widely used in the pharmaceutical industry as a dry binder 
in tableting, as a film-forming agent in tablet coating, as well as a film-forming agent in topical 
drug delivery systems 294,295. Besides that, being a derivative of PVP, PVPVA is a chemically 
and biologically inert polymer which obviates the issues of polymer-drug compatibility along 
with biological toxicities 296,297. A series of experiments were performed to characterise the 
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PVPVA microneedle formulation. In addition, an in vitro permeation study, using full thickness 
ex vivo porcine skin was used to evaluate imiquimod delivery into and across the skin. HPLC 
and ToF-SIMS analysis were utilised to illustrate the permeation and dermal distribution of 
imiquimod into skin following the application of imiquimod loaded microneedles versus 
Aldara™ cream. This study can serve as a basis for future in vivo and clinical studies with 
imiquimod loaded PVPVA microneedles for nodular BCC treatment. 
4.3 Materials 
Imiquimod was purchased from Cayman Chemicals, USA. Aldara™ topical cream (5% w/w imiquimod), 
MEDA Company, Sweden was purchased from Manor Pharmacy, UK. Polyvinylpyrollidone-co-vinyl 
acetate, PVPVA (Kollidon® VA 64 Mw 15-20 kDa), was kindly provided by BASF (Ludwigshafen, 
Germany). Polyethylene glycol, PEG 400 was purchased from Sigma Aldrich, Belgium. Sodium 
carboxymethyl cellulose, Mw 90,000 was purchased from Sigma Aldrich, USA. Glycerol was purchased 
from Sigma Aldrich, USA. Sodium acetate was purchased from Sigma-Aldrich, UK. Acetonitrile (HPLC 
grade) and glacial acetic acid were obtained from Fisher Scientific, UK. Teepol solution (Multipurpose 
detergent) was ordered from Scientific Laboratory Supplies, UK. D-Squame standard sampling discs 
(adhesive discs) were purchased from Cuderm corporation, USA. OCT media was obtained from VWR 
International Ltd. Belgium. Deionised water was obtained from an ELGA reservoir, PURELAB® Ultra, 
ELGA, UK. All reagents were of analytical grade, unless otherwise stated. Ex vivo porcine skin was used 
in imiquimod permeation studies due to the similarities in histology, thickness and permeability to 
human skin 246. Skin samples were prepared from ears of six-month-old pigs obtained from a local 
abattoir prior to steam cleaning. The skins were of full skin thickness to prevent altering the 
biomechanical properties of the tissue that may lead to over-penetration of the microneedles into the 




4.4.1 Design and production of microneedle master structure and microneedle PDMS 
moulds 
To produce the custom PDMS moulds, a stainless-steel microneedle master structure was designed in 
SolidWorks 2018 (Dassault Systèmes), consisting of a 10 x 10 array of 300 µm x 300 µm x 1000 µm  
(W x L x H) pyramidal microneedles with tip-to-tip spacing of 800 µm. This master structure, and a 
corresponding mould housing, Figure S4- 1, were then produced from stainless-steel using a Kern Evo 
CNC Micro Milling Machine at the University of Nottingham Institute for Advanced Manufacturing. A 
polydimethylsiloxane (PDMS) (Sylgard 184®, Dow Corning, Midland, MI) mould was then created from 
the stainless-steel microneedle master structure. A mixture of elastomer and curing agent, Sylgard 
184®, were prepared at a ratio of 10:1 (elastomer: curing agent). The mixture was then degassed for 
45 minutes to remove any trapped air in the mixture. After degassing the PDMS mixture was poured 
into the stainless-steel master mould structure and placed in an 80 oC oven for one hour to cure the 
PDMS. After curing, the mould along with the cured PDMS was plunged into an ice bath to allow ease 
of removal of the cured PDMS mould. The stainless-steel master structure was then cleaned with 
propan-2-ol before being reused to make further PDMS moulds. 
4.4.2 Fabrication of blank and drug loaded polyvinylpyrrolidone-co-vinyl acetate (PVPVA) 
microneedles 
Polymeric microneedles were prepared using a micromolding technique. The PDMS moulds produced 
as described in Section 4.4.1 were used to fabricate the blank microneedles. The microneedle matrix 
was prepared using 16.2 % w/v PVPVA (in water) by dissolving the polymer at room temperature and 
pressure for one hour. Then, 2% v/v of PEG 400 was added to the polymer solution. The polymer 
solution was then degassed for 30 minutes and 150 µl of the PVPVA solution was then pipetted using 
a positive displacement pipette into the PDMS mould and centrifuged at 4000 RPM for 15 min at room 
temperature to fill the needle cavities. Then, excess polymer was removed before leaving the needle 
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layer to dry overnight in a desiccator. The backing layer of the microneedle patch were prepared using 
5.2 % w/w of carboxymethylcellulose, CMC (in water). The backing solution was made by dissolving 
CMC under stirring at 75 oC for 2 hours. In addition, 0.66 % v/w of glycerol was added to the backing 
solution as a plasticiser.  Using a positive displacement pipette, 200 µl of the CMC solution was then 
pipetted on top of the needle layers and centrifuged at 3500 RPM for 10 minutes. The mould was 
dried at room temperature for 48 hours in a desiccator. The polymeric microneedles were then 
demoulded and stored in a desiccator until further use. For imiquimod loaded microneedles the 
fabrication process was repeated in a similar fashion and composition, however the drug, PEG 400 
and PVPVA were dissolved in 0.05 M of hydrochloric acid under stirring for 1 hour. 
4.4.3 Characterisation of PVPVA microneedles (SEM, tensile strength, skin insertion 
properties) 
4.4.3.1 Microscopy 
Polymeric microneedle images were captured using an optical microscope (Zeiss Axioplan, Germany) 
and an environmental scanning electron microscopy (ESEM) (FEI Quanta 650) in low vacuum mode to 
visualize the shape and dimensions of the microneedles. For ESEM imaging, the microneedles were 
mounted on a metal stub using double-sided carbon tape prior to imaging. 
4.4.3.2 Measurement of needle fracture force 
The needle fracture force of the polymeric microneedles was determined using a texture analyser 
(Stable Microsystems, UK) following a previously reported method 137. This is to investigate the effect 
of applying an axial force parallel to the microneedle vertical axis, similar to the force encountered by 
the needles during application to the skin.  The polymeric microneedles were visually inspected before 
and after application of the compression force. For this, the force required for compression of the 
polymeric microneedle to a specified distance was measured. The polymeric microneedles were 
attached to a 10 mm cylindrical Delrin probe (part code P/ 10) using double-sided adhesive tape. The 
probe is connected to a 50-kg load cell and was set at the same distance from the platform for all the 
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test measurements. The TA XT Plus Texture Analyser was set to compression, the pre-test speed was 
set at 2 mm/s and post-test speed at 10 mm/s. The trigger type was set to auto (force) with a trigger 
force of 0.009 N. The test station compresses the polymeric microneedle against a flat block of 
aluminium of dimensions 10.0 × 9.0 cm. Compression force versus displacement curves were plotted 
to calculate the fracture force. A total of five microneedle patches were used to evaluate the fracture 
force of the microneedles. 
4.4.3.3 In vitro skin simulant insertion 
As an alternative method to determine the microneedle penetration depth as a function of length, a 
polymeric film (Parafilm M®, a blend of a hydrocarbon wax and a polyolefin) was utilised as a skin 
model. This insertion study was adapted from Larrañeta et al.  248. In brief, 8 layers of Parafilm M® were 
stacked onto each other on a cork mat that mimics underlying muscles. The PVPVA microneedle patch 
was applied under thumb pressure for 10 seconds. Six replicates were generated and observed under 
the Zeta Profilometer (KLA-Tencor, US) for the number of micropores created.  
4.4.3.4 Dye binding study 
In order to evaluate if the microneedle patch is capable of penetrating the skin and to visualise the 
depth of microneedle penetration into the skin, a dye binding study using ex vivo porcine skin was 
conducted. The porcine ear skin was defrosted at room temperature for an hour prior to the 
experiment. Using clippers, excess hair was carefully trimmed from the skin.   Regions of the skin were 
then selected for microneedle treatment. The skin was treated with PVPVA microneedles loaded with 
methylene blue dye (1% w/v), which is a hydrophilic dye. The microneedle was left in the skin for one 
hour before removing the microneedle patch. Upon removing the patch, the skin was visually 
inspected to see if any microneedle channels have been generated in the skin. In order to gauge the 
depth of microneedle penetration into the skin, skin cross-sectioning was performed. In brief, each 
microneedle application site was cut into 1 cm × 1 cm and fresh frozen on a metal block that was 
cooled with liquid nitrogen. Skin cross-sections were performed using a cryostat (Leica CM3050 S 
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Research Cryostat, UK). The depth of microneedle penetration as visualised by methylene blue 
permeation was measured using an optical microscope (Zeta Profilometer, KLA-Tencor, US). 
4.4.4 Measurement of imiquimod permeation from PVPVA microneedles 
Imiquimod skin permeation was evaluated ex vivo using a Franz-type diffusion cell. Prior to the 
permeation study, skin samples were defrosted and carefully trimmed into small pieces according to 
the area of the donor chamber of the Franz diffusion cell (Soham Scientific, Cambridgeshire, UK). The 
ex vivo porcine skins were subjected to the following treatments: i) application of 20 mg Aldara™ 
cream. This is in accordance with clinical dose approved by the FDA for the treatment of BCC. ii) 
imiquimod loaded PVPVA microneedles. Next, the treated porcine skins were placed on top of the 
receptor compartment filled with 3 ml of degassed 100 mM acetate buffer pH 3.7. This buffer was 
chosen as the receptor phase in order to maintain sink conditions throughout the permeation study. 
This is due to the insolubility of imiquimod at neutral or basic pH values. Various researchers have 
reported using acetate buffer pH 3.7 as the receptor phase in imiquimod permeation studies 53–55. The 
skin was then secured between the donor and receptor compartment of the diffusion cell using a 
metal clamp, with the stratum corneum side facing the donor compartment. Upon assembling the 
Franz diffusion cell, the permeation experiment was conducted over a period of 24 hours in a 
thermostatically controlled water bath set at 36.5 oC. 1000 µl of the receptor fluid at designated time 
points (0.5, 1, 3, 6, 12 and 24 hours) was sampled and then replaced with equal volume of fresh 100 
mM acetate buffer pH 3.7.  Upon sampling, 1000 µl of the solution from each Franz cell after collection 
was then spiked with 100 µl of 100 µg/ml propranolol as an internal standard before being filtered 
through 0.22 µm membrane prior to HPLC analysis. 
After the 24-hour permeation experiment, the excess cream was removed from the AldaraTM cream 
treated skin surface by careful application of sponges soaked with 3% v/v Teepol® solution. For the 
microneedle patch treated skin, the remaining microneedle patch was removed from the skin. Upon 
removing excess formulation from the skin surface, 15 sequential tape strips were collected from the 
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skin. The amount of imiquimod from the pooled tape strips and remaining skin after tape stripping 
were extracted by the addition of 10 and 5 mL of methanol extraction mixture (Methanol 70%: Acetate 
Buffer pH 3.7 100 mM 30%) respectively using a previously reported method 52. Samples were then 
vortexed for 1 minute and sonicated for 30 minutes before being left overnight. Subsequently, 
samples were vortexed again and sonicated for a further 30 minutes. After sonication, 1000 µl of the 
extracts were collected and spiked with 100 µl of 100 µg/ml propranolol as an internal standard. The 
samples were then filtered through 0.22 µm membrane prior to HPLC analysis. 
4.4.5 High performance liquid chromatography (HPLC) analysis 
HPLC analysis was carried out using an Agilent 1100 series instrument (Agilent Technologies, Germany) 
equipped with degasser, quaternary pump, column thermostat, autosampler and UV detector. System 
control and data acquisition were performed using Chemostation software. The details of the HPLC 
chromatographic conditions are as follow: column C18 (150 × 4.6 mm) ACE3/ACE-HPLC with a particle 
size of 5 µm, pore size of 100 Å, pore volume of 1.0 ml/g and a surface area of 300 m2/g, Hichrom 
Limited, UK. The mobile phase composition for analysis of extracts from skin wash, donor chamber 
wash, pooled tape strips and remaining skin consists of 10 mM acetate buffer: acetonitrile (79:21). 
Whilst, the mobile phase composition for analysis of receptor fluid consists of 10 mM acetate buffer: 
acetonitrile (70:30). The HPLC was operated at a flow rate of 1.0 mL/minute, UV detection at  
λmax=226 nm, an injection volume of 40 µL and a column temperature of 25 °C.   
4.4.6 ToF-SIMS analysis of skin cross-sections 
In order to evaluate the depth of imiquimod permeation into the skin, the permeation experiments 
were repeated as described above Section 4.4.4. After the permeation study, excess formulation was 
removed from skin samples treated with cream and microneedles. Then, 1 cm × 1 cm of each 
application site was fresh frozen with liquid nitrogen. Skin cross-sectioning was performed using a 
cryostat (Leica CM3050 S Research Cryostat, UK). The skin slices were then thaw mounted on a glass 
slides and stored at -20 oC prior to ToF-SIMS analysis. ToF-SIMS was used to analyse the cryo-sectioned 
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porcine skin samples. ToF-SIMS analysis was performed using a ToF-SIMS IV instrument (IONTOF, 
GmbH) with a Bi3+ cluster source. A primary ion energy of 25 KeV was used, the primary ion dose was 
preserved below 1 × 1012 per cm2 to ensure static conditions. Pulsed target current of approximately 
0.3 pA, and post-acceleration energy of 10 keV were employed throughout the sample analysis. The 
mass resolution for the instrument was 7000 at m/z 28.  
4.4.7 Statistical analysis 
Statistical analysis was conducted using GraphPad Prism 7.02 software. Data are shown as 
mean ± standard error of mean. When comparing two groups an unpaired t-test analysis was used, 
while one-way analysis of variance (ANOVA) with Tukey's multiple comparisons tests was used to 
compare multiple groups. p values < 0.05 were considered statistically significant. 
4.5 Results and Discussion 
4.5.1 Microneedle fabrication 
In this work, polymeric PVPVA microneedles of pyramidal geometry were fabricated through four 
manufacturing stages; structure design via CAD, micromachining, PDMS mould production and casting 
as shown in the schematic of Figure S4- 1. Micro-milling was used to fabricate the designed stainless-
steel master structures with minimal surface imperfections as evidenced in Figure S4- 1. Micro-milling 
was used as the technique enables simplicity in the design process while offering low manufacturing 
cost in generating complex geometry with high accuracy and repeatability 298.  
Next, the PDMS moulds were produced by micromoulding followed by microneedle patch fabrication 
via casting, centrifugation and drying. The resulting polymeric microneedle patch is shown in  
Figure 4-1. Upon visual inspection as shown in Figure 4-1 (a), we found that the microneedle array 
consists of 100 uniformly distributed pyramidal microneedles. Each microneedle array had a slightly 
opaque and off-white appearance. The microneedle patch displays micro projections, pyramidal in 
structure with a length of 992.3 ± 45.3 µm (mean ± SD, n=10) and a tip diameter of 32.3 ± 3.1 µm 
(mean ± SD, n=4) as visualised by optical microscopy images shown in Figure 4-1 (b) and (c). With 
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regards to the production method used in this study, which involved centrifugation and 
micromoulding, such methodology is most suited for lab-based research. However, this method of 
microneedle fabrication would not be ideal for the manufacture of patches at a commercial scale. 
However, the use of aqueous drug-polymer blend casting could be potentially be translated into the 
scalable roller system manufacturing method developed by Lutton et al.  299. The use of the roller 
system manufacturing method would provide a potential scale-up manufacturing method at a 
commercial scale, enabling the transition from laboratory to industry and subsequent clinical practice.  
 
Figure 4-1a) Photograph image of PVPVA microneedles post-fabrication (b) Optical microscopy image of PVPVA 
microneedles at 12.5x magnification (c) close up microscopy image - of a single PVPVA polymeric microneedle at 
50x magnification (d) SEM images of PVPVA microneedles at 39x magnification 
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An analysis by SEM, as shown in Figure 4-1 (d), revealed equally spaced, sharp pyramidal 
microneedles, on a clean and smooth base. This clearly indicates that the copolymer PVPVA was a 
suitable material for fabricating polymeric microneedles. Although, PVPVA has not been used 
previously for microneedle fabrication, the homopolymer PVP has been widely used. In addition, the 
hydrophilic nature of both of these polymers makes it easy to use them for fabricating microneedles 
via casting and micromoulding aqueous solutions of the polymers into the PDMS moulds. This 
overcomes the need for organic solvents which could damage the PDMS moulds with repeated  
use 300. Previous work has shown that PVP microneedles are capable of delivering a range of 
therapeutics such as sumatriptan, polymyxin B, atorvastatin, aspirin, and lisinopril  301–303. In addition, 
although PVPVA has never been used previously in microneedle fabrication, the extensive 
biocompatible and cytocompatible data on the polymer strongly suggest that the PVPVA microneedles 
are safe for this biomedical application 304. 
Preliminary microneedle fabrication without the use of PEG 400 as a plasticiser resulted in 
microneedles with fractured tips as shown in Figure S4- 2. A lack of consistency in microneedle length 
and tip formation may result in complications such as failure to penetrate the skin as well as 
inconsistent drug release from the individual microneedles within the same patch. The presence of 
fractured tips is attributed to the formation of brittle polymeric microneedles post-drying. The 
brittleness of the preliminary PVPVA microneedles was due to the high Tg of the polymer at 107 oC as 
shown in Figure S4- 3.  Since the microneedles were demoulded at room temperature, the polymer is 
well below its Tg and is in a glassy and brittle state making it prone to fracture 12. In order to overcome 
this issue, PEG 400 was introduced into the needle matrix as a plasticiser. The use of PEG 400 falls 
under the category of an external plasticiser which has been used in several other microneedle 
formulations 302,303,305.  
Due to the rigid but brittle nature of PVPVA, we discovered that using the same PVPVA and PEG 400 
polymer solution as a backing layer resulted in microneedle patches that fractured during the 
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demoulding stage as shown in Figure S4- 4. A microneedle backing layer ought to be flexible to enable 
easy demoulding while allowing the microneedle patch to adapt to the skin curvature during 
administration 306. In order to meet these criteria, we used a different polymer blend consisting of 
CMC and glycerol to fabricate the backing. CMC is one of the most commonly used polymer solutions 
in fabricating the backing layer of microneedle patches 307,308.  
4.5.2 Microneedle characterisation 
The mechanical properties of the needles were determined using a texture analyser. The polymeric 
microneedle arrays were subjected to an axial compression test to measure the fracture force of the 
polymeric microneedles. Profiles of force versus displacement (analogous to stress-strain curves), 
based on average force values (n = 5), were generated for the PVPVA polymeric microneedle patch. 
This force versus displacement curve was then used to determine the average fracture force per 
needle.  From the microneedle fracture test, the PVPVA microneedles displayed a fracture force of 
0.106 ± 0.003 N/needle (mean ± SD, n=5). The required fracture force that microneedles need to 
possess in order to puncture the skin without fracturing is 0.098 N/needle 129,130. In addition, Donnelley 
et al. has even reported successful skin insertion with microneedles that possess a fracture force as 
low as 0.03 N/needle 115. Therefore, it can be inferred that the fabricated microneedles displayed 
sufficient mechanical strength above the reported threshold needed to puncture the skin without 
fracturing. 
It is of great importance that fracture test is coupled to insertion studies in order to evaluate the 
penetration capability of the fabricated microneedles. The insertion of PVPVA microneedle patch into 
a stack of Parafilm® layers was used as an in vitro skin model. This was performed by applying the 
patches onto the Parafilm® stacks under thumb pressure. Upon application, each Parafilm layer was 
separated and visualised using an optical microscope to evaluate the pore uniformity as a function of 
penetration depth. Figure 4-2 (a) shows that square shaped pores, which follows the shape of the 
square pyramidal PVPVA microneedle, were created on the Parafilm layers upon microneedle patch 
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application. In addition, it can be seen that the number of microneedle channels generated decreased 
as a function of Parafilm layer number with the deepest layer penetrated by the microneedle patch 
being the fourth layer as shown in in the insertion profile of Figure 4-2 (b). In addition, it was apparent 
that all replicates resulted in complete microneedle insertion in the first parafilm layer as shown in 
Figure 4-2 (b). The Parafilm® insertion test was developed by Larrañeta et al. as an in vitro test to 
predict the insertion capabilities of microneedles in actual skin tissues 248. Collectively, Figure 4-2 (a) 
along with the insertion profile from Figure 4-2 (b), suggests that fabricated PVPVA microneedle patch 
is capable breaching the stratum corneum permitting microneedle insertion into the skin. 
 
Figure 4-2 (a) Microscopic images of first Parafilm® treated by PVPVA microneedles (b) Insertion profile of PVPVA 
microneedle into Parafilm® layers, data is expressed as mean± SD for n=6 (c) Microchannels created in ex vivo 
porcine skin visualised via the release of methylene blue from PVPVA microneedles (d) Optical microscopy image 
of microneedle channels created when the skin is treated with PVPVA microneedles 
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A dye release study was then performed to evaluate the ability of the microneedle patches to puncture 
the skin. Methylene blue loaded microneedle patch was applied onto porcine cadaver skin, which 
upon application resulted in the release of the hydrophilic dye to the surrounding skin tissue upon 
PVPVA dissolution. This results in the formation of blue microneedle channels within the porcine skin 
that follows the distribution of PVPVA microneedles on the patch as shown in Figure 4-2 (c). The 
histological image of the vertical section of microneedle treated skin, shown in Figure 4-2 (d) provides 
an estimate into the depth of microneedle penetration into the skin. The application of PVPVA 
microneedles loaded with methylene blue breached the stratum corneum and epidermis layers as 
shown in Figure 4-2 (d). The average depth of microneedle penetration was 426 ± 72 µm (mean ± SD, 
n=10). The penetration depth of the microneedles is of approximately the same depth as that 
observed with the Parafilm insertion study. With regards to clinical translation of the technology, 
reproducible insertion of microneedles by patients and carers is an important factor to consider. 
Various strategies have emerged over the years to ensure effective and reproducible insertion of 
microneedle patches into the skin. One of the strategies could be the use of microneedle applicators. 
Some examples of the microneedle applicator that could be used include MicroCorTM and Macroflux® 
289. Alternatively, the use of pressure-indicating sensor film such as Pressurex-micro® Green may be 
an alternative, might be an option in providing feedback to patient and carers that they had pressed 
the microneedle with sufficient force into the skin 309 
It was apparent that the microneedle penetration depth into ex vivo skin was shorter than the length 
of the microneedle. This observation agrees with earlier findings by Martanto et al. who reported 
partial microneedle insertion into the skin 105. Such an observation is attributed to the inherent elastic 
nature of the skin which resists microneedle penetration. However, since it has been reported that 
the thickness of the porcine epidermal layer varies between 30-140 µm 260 it can be seen that from 
the vertical cross-sectional data Figure 4-2 (a) the microneedle application in this case has reached 
the dermis. In comparison, the human skin is reported to have an epidermal thickness of  
800-1500 µm for thick skin (palm of the hands and sole of the feet) and 70-150 µm for thin skin (face, 
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eye lids, neck and arm) 310.  Importantly in this instance, as BCC mainly manifests on thin skin surfaces 
such as the face, neck and eyelid 311, it can be postulated that application of the PVPVA microneedle 
patch would bypass the epidermis and reach the dermis which is the target site for the treatment of 
nodular BCC. Besides that, in regions where there are curvatures such as the facial cheeks, nose and 
eyelids the application of microneedle would still be viable. However, in this instance, the use of a 
very flexible backing layer such as those fabricated from polyethylene glycol diacrylate (PEGDA) would 
allow the microneedle patch to adapt to skin curvature whilst permeating effective skin insertion 306. 
The hygroscopic nature of PVPVA could have an adverse effect on the needle architecture along with 
its insertion capabilities on long term storage. Hence in order for this technology to be translated into 
clinical practice stability studies will need to be carried out to verify the needle structure. With respect 
to the hygroscopicity of PVPVA, relative to PVP which is widely used in microneedle research, PVPVA 
is less hygroscopic that PVP. The work by Shamblin and Zografi showed that the amount of water 
absorbed by PVPVA was one-third of that absorbed by PVP when stored at humidity levels similar to 
that of ambient room conditions. Such an observation is attributed to the carbonyl group of the vinyl 
acetate moiety which is less basic and hence less prone to hydrogen bonding than the carbonyl group 
in the pyrrolidone ring 312. Therefore, the use PVPVA which is a less hygroscopic polymer than the 
widely used PVP, may produce microneedles which are less susceptible to moisture than the 
commonly fabricated PVP microneedles. Nevertheless, one of the manufacturing and distribution 
challenges will be the need to manufacture, distribute and store the microneedles in a low humidity 
environment to reduce the exposure to moisture that may affect the architecture of the needle and 
ultimately the insertion of the needle into the skin. One possible suggestion to overcome this is to 
pack the microneedle patches in nitrogen flushed sterile packets that demonstrate protection against 
water ingress.   
Considering the fact that microneedle dosage forms penetrate the stratum corneum rather than 
adhere to the surface of the skin as in a conventional transdermal patch, sterility will potentially be a 
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key requirement by regulatory bodies. Previous work by Mccrudden et al. 2014 have shown that 
endotoxin levels in dissolving microneedles can achieve levels below set by the Food and Drug 
Administration (FDA) guidelines for medical devices that are in direct contact with lymphatic tissue 
(20 units/device) using the appropriate sterilisation techniques 313.   As PVPVA microneedles may be 
susceptible to moisture due to the hygroscopic nature of polymeric microneedle, the use of 
heat/steam sterilisation may damage this type of microneedle necessitating microneedle production 
under aseptic conditions. The use of gamma irradiation may be an alternative, however previous work 
has shown that this method of terminal sterilisation alters the release profile of dissolving 
microneedles 313. 
4.5.3 Drug release study from PVPVA microneedles 
4.5.3.1 HPLC analysis  
In vitro permeation studies utilising Franz diffusion cells are widely used to study the intradermal and 
transdermal delivery of drugs across the skin. In this work, we investigated the delivery of imiquimod 
from drug loaded microneedle patches into and across the skin in comparison to the commercial 
imiquimod cream, AldaraTM. Imiquimod was loaded into the microneedles by dissolving both the 
polymer (PVPVA) and the drug into a polymer blend, casting the solution into the PDMS micromoulds, 
centrifugation and finally drying. Imiquimod-loaded polymeric PVPVA microneedles dissolved 
gradually in a limited volume of the skin’s interstitial fluid to release drug into and across the skin 
layer. It was apparent that both drug delivery systems were capable of delivering imiquimod into the 
stratum corneum, remaining skin and into the receptor fluid as shown in Figure 4-3. 
From Figure 4-3 (a) we observed that the mean amount of imiquimod delivered into the stratum 
corneum as evidenced from HPLC analysis of tape strips are 23.2 µg for microneedle treated and  
8.6 µg for AldaraTM cream treated skins. The differences in amount of imiquimod delivered into the 
stratum corneum was of statistical significance (p<0.05). Such enhanced permeation into the stratum 
corneum with imiquimod loaded microneedles may be attributed to the generation of microneedle 
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channels within the skin. These channels act as focal points for imiquimod to permeate laterally and 
localise to the surrounding corneocytes, thus enhancing delivery to the upper layer of the skin.  
 
Figure 4-3 Amount of drug extracted from skin (a) tape strips and (b) remaining skin after 24 hours in the 
permeation study. (c) Drug concentration within receptor fluid as a function of time during permeation study 
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from AldaraTM and imiquimod microneedles. Data are expressed as mean± SEM for n=6. Differences were 
determined using a two-tailed Student’s t test, and deemed significant at p<0.05. n.s = not statistically significant 
at p>0.05 
However, in the case of nodular BCC the drug delivery system must be capable of delivering the drug 
beyond the stratum corneum and deeper into the skin 34. Therefore, in order to gauge the amount of 
drug delivered deeper into the skin, HPLC analysis was conducted on remaining skin after tape 
stripping. Figure 4-3 (a) also shows that the mean amount of imiquimod delivered into the remaining 
skin from both treatment groups. It was observed that the amount drug extracted from the remaining 
skin treated with the microneedles was lower than the amount of drug delivered by the commercial 
cream, AldaraTM although such differences were not statically significant (p>0.05). This would suggest 
that the overall amount delivered per application of both delivery system are similar. From a dose 
delivered perspective, it may appear that the microneedle patch does not offer any additional 
benefits. However, when the two systems are viewed in terms of ease of application, the microneedle 
patch offers a simple one-step application to insert the microneedles into the skin under thumb 
pressure. This avoids the issues of dosing accuracy with the amount of cream applied and problems 
associated with the cream spreading to non-diseased skin which are associated with AldaraTM cream. 
With regards to the amount of imiquimod delivered for the management of BCC, it would be more 
preferable to use the AldaraTM cream in the management of superficial BCC as we would mitigate the 
unnecessary exposure of underlying healthy skin tissue to imiquimod.  However, given the fact that at 
least one-third of nodular BCC coexist with superficial BCC 36, the use of imiquimod loaded 
microneedles in such instances would be useful as the drug could deliver equal amounts of imiquimod 
to tumour located at the skin surface and underlying skin tissues. 
In addition, Figure 4-3 (b) shows the amount of imiquimod delivered into the stratum corneum and 
remaining skin when calculated as a percentage of the applied dose. In this instance the percentage 
of the drug successfully delivered into the stratum corneum and remaining skin is significantly higher 
with imiquimod microneedles than that of AldaraTM cream. The drug loading in the microneedle patch 
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was 165.6 ± 21.4 µg (mean ± SD, n=8). Whilst, ≈20 mg of Aldara cream (1000 µg of imiquimod) was 
applied to the skin area of 3.8 cm2, in the Franz cell, which is based on clinical dose for AldaraTM cream 
for the treatment of BCC 314.  Figure 4-3 (b) highlights that we are able to deliver similar amounts of 
imiquimod into the remaining skin using a different delivery system despite a 6-fold lower drug loading 
with the microneedle patch. 
Figure 4-3 (c) shows the concentration of imiquimod detected in the receptor fluid over time. It can 
be seen that the concentration of imiquimod in the receptor fluid overtime, was similar between 
AldaraTM cream and imiquimod microneedle treated skin for up to 12 hours. However, at 24 hours, the 
concentration of imiquimod within the receptor fluid is less for skin treated with imiquimod 
microneedles relative to AldaraTM cream. This highlights that over the course of 24 hours, the 
microneedle patch resulted in less imiquimod delivery across the skin while delivering similar quantity 
of the drug into the remaining skin.  It is understood the amount of drug detected in receptor fluid 
following an in vitro Franz cell permeation study  provide a an indicator on the likelihood of systemic 
exposure  1.  Hence, it could be postulated that the likelihood for systemic exposure to imiquimod 
following microneedle treatment is lower in comparison to AldaraTM application. This may limit the 
likelihood of influenza-like symptoms, an undesirable side effect associated with imiquimod systemic 
exposure 315.  Based on the current work, it is suggested that the microneedle is left in the skin for 24 
hours to allow comparative application and delivery of imiquimod into the skin as to that of AldaraTM 
cream. In terms of practical delivery of imiquimod using microneedle relative to other routes of 
administrations such as oral delivery, a microneedle based intradermal delivery would be more 
practical as it enables more targeted delivery and avoids the likelihood of systemic side effects arising 
from oral delivery of imiquimod which could give rise to flu-like symptoms and result in a poor overall 
quality of life for the patient. 
In terms of enhancing imiquimod permeation, several groups have considered alternative drug 
delivery systems such as the use of an emulsion gel 275, transethosomes 67 and a hydrogel/oleogel 
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colloidal mixture 316.  However, these types of formulations are typically associated with poor sensory 
and cosmetic issues (e.g., tackiness and stickiness) upon application. In addition, these semisolid 
dosage forms could potentially stain patients’ clothes as well as spread to healthy skin regions leading 
to unwanted side effects 69,317. This may ultimately limit patient compliance to the overall treatment.  
These limitations are not encountered with microneedle formulations as the patches are anchored in 
place by the micro-projections ensuring precise localised delivery at the site of application. In addition, 
with regards to disposal of the patch upon skin insertion, as the PVPVA microneedles are dissolving 
microneedles, the microneedles will dissolve in the skin leaving behind the backing layer. Therefore 
the microneedle patch is self-disabling post-insertion overcoming the issues of dangerous sharp waste 
disposal in resource-poor settings 318. 
4.5.3.2 ToF-SIMS analysis 
 It was apparent that HPLC analysis provided quantitative results that permit us to compare the 
delivery efficiency of both formulations. However, HPLC does not provide any spatial information 
pertaining to the dermal distribution of imiquimod. In order to complement the HPLC data, ToF-SIMS 
was utilised to provide insight into the dermal distribution of imiquimod.  
Figure 4-4 shows ToF-SIMS secondary ion images from skin cross-sections analysed after a 24-hour 
permeation study. Due to the parallel detection capabilities of the ToF-SIMS, secondary ions 
originating from both the skin tissue, polymer and drug were detected and analysed. By carefully 
monitoring the ion peaks from the ToF-SIMS spectra (Figure S4- 5), we are able to visualise the 
localisation and distribution of these secondary ions. The fragment ion for phosphatidylcholine, 
C5H15NPO4+ was used to identify the dermis and viable epidermis. Additionally, the fragment ion for 
ceramide, C17H32N+ is utilised to distinguish the stratum corneum from the viable epidermis and  
dermis  224.  This is because, the stratum corneum displays high levels of ceramide whilst being devoid 
of phospholipids which makes C17H32N+ a good marker for the stratum corneum  197,282. In a previous 
work, it has been found that the permeation of the imiquimod across the skin could be tracked by 
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monitoring the molecular ion C14H17N4+ 68. Through monitoring the fragment ion peak C6H10NO+ we 
were able to detect the localisation of the PVPVA polymer within the microneedle channels as shown 
in Figure 4-4. The peak assignment for PVPVA was validated by referring to fragmentation pattern at 
m/z 112 with the reference spectra of pure PVPVA on silicon wafer as shown in the supplementary 
data (Figure S4- 6). It is worth noting that, that the parallel detection capability of the ToF-SIMS also 
enabled the detection of Si+ marker -an inorganic ion of silicon -indicated in yellow in Figure S4- 7 and 
Figure S4- 8 used to identify the glass slide (the substrate used to mount the cross-sections) as silicon 
is a common fundamental constituent of glass. Figures Figure S4- 7 and Figure S4- 8 also shows the 







Figure 4-4 ToF-SIMS image of skin cross sections from ex vivo porcine skin that were treated with (a) AldaraTM 
cream (5% w/w imiquimod) alone (b) PVPVA microneedles loaded with imiquimod after a 24-hour permeation 
study. Figure (b) shows localisation of semi-dissolved polymeric microneedles within the dermis with skin treated 
imiquimod loaded microneedles. C14H17N4+inidicated in green is the molecular ion for imiquimod, C5H15NPO4+ 
indicated in blue is the fragment ion for phosphatidylcholine used to identify the viable epidermis and dermis. 
C17H32N+ indicated in red is the fragment ion for ceramide used to identify the stratum corneum. C6H10NO+ 
indicated in pink is the fragment ion for PVPVA polymer. Scale bar: 500 µm 
It is apparent from Figure 4-4 (a) that there is limited availability of imiquimod within deeper skin 
strata when the molecule was delivered as a topical cream, AldaraTM. When the drug is applied as a 
topical cream, imiquimod is localised in the stratum corneum as evidenced from overlay of imiquimod 
molecular ion, C14H17N4+ with the fragment ion for ceramide, C17H32N+. However, when imiquimod is 
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delivered as a polymeric microneedle patch, we observed delivery of imiquimod into the dermis within 
microchannels as shown in Figure 4-4 (b). It is clear from the ceramide fragment ion, C17H32N+ in  
Figure 4-4 (a) that the stratum corneum looks intact when the drug is administered as a topical cream.  
In contrast, when the drug is delivered as a polymeric microneedle patch, we observed disruption in 
the ceramide fragment ion, C17H32N+ distribution within top layer of the skin as shown in Figure 4-4 (b) 
that suggest that the microneedles have disrupted the stratum corneum permitting the insertion of 
the drug loaded polymeric microneedles into the skin. Typically, nodular BCCs are much harder to 
treat effectively as the tumour typically manifests 400 µm below the skin surface 34. The ToF-SIMS 
analysis of skin cross-sections from Figure 4-4 suggests that the microneedle patch penetrated the 
skin to a depth of approximately 450 µm resulting in imiquimod delivery into the dermis. With regards 
to penetrating the BCC tumours with microneedles, concerns may be raised on the likelihood of 
aggravating the tumour which may lead to unintended side effects. However, there is little to no 
clinical concerns with regards to penetrating BCC tumour as the tumours are routinely penetrated via 
punch biopsy and intraoperative incisional biopsy. Such surgical procedures do not lead to any 
localised or distant spread of the BCC tumour. In fact, microneedle insertions are minimally invasive, 
therefore the damage inflicted from penetrating the BCC tumour with microneedles is less relative to 
these routine surgical procedures. In addition, many BCC lesions are also frequently traumatised 
accidentally by the patients themselves which causes localised bleeding but again no serious 
consequences 319,320.  
With regards to the dermal distribution of the various components of a microneedle system, several 
research groups have employed techniques such as fluorescently tagging the molecule of interest in 
order to visually track the delivery of compound into the skin 129,321. This method results in modification 
of the physiochemical properties of the drug leading to potentially inaccurate estimation of drug 
permeation into the skin 198. However, there is no work in the field that has demonstrated the 
capability to simultaneously detect the deposition of both drug and polymer from a dissolving 
microneedle patch in a label free manner. ToF-SIMS analysis also provides the capability to perform 
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parallel detection of both endogenous and exogenous chemistry present in the analysed samples, thus 
permitting simultaneous mapping the presence of polymer within biological tissues as well as the 
drug. The polymer that is used in fabricating the microneedle patch is PVPVA. Through monitoring the 
fragment ion peak at m/z 112 we were able to detect the co-localisation of the polymer and imiquimod 
within the microneedle channels as shown in Figure 4-4.  
By comparing this finding with the ToF-SIMS analysis of skin cross-section from samples treated 
imiquimod loaded microneedles in Figure 4-4 (b), it was observed that imiquimod was colocalised in 
the presence of PVPVA polymer within the dermis following skin application. This leaves imiquimod 
which is embedded in a polymer matrix within skin. It has been previously postulated that embedded 
drug-polymer matrix slowly undergoes dissolution; generating localised regions of enhanced viscosity 
within the skin that slows the rate of drug release to surrounding tissues 72,73. However, in the current 
work we are able to demonstrate via ToF-SIMS analysis the existence of such semi-dissolved polymeric 
regions within the dermis that retains drug from permeating across the skin and into the receptor 
fluid. From a clinical perspective, the reduction in imiquimod permeation across the skin may limit the 
likelihood of systemic side-effects.   The ability of a microneedle patch to deliver the drug to a desired 
location despite having lower drug loading may serve as a possible explanation for the dose sparing 
advantage conferred by dissolving polymeric microneedles. To the best of our knowledge, this is the 
first report of the dose sparing advantage conferred by microneedles for small molecule therapeutics.  
Although a PVPVA polymer depot was observed, there is evidence based on this commercial polymer’s 
Mw i.e 15-20 kDa that it would be eventually excreted. Indeed, based on the findings from  
Kagan et al. on the elimination of macromolecules from the skin, it is estimated that a majority of the 
polymer will be drained into the dermal blood capillaries with some drainage into the dermal 
lymphatics before reaching the systemic circulation 322. Furthermore, as the PVPVA has a Mw less than 




The HPLC analysis data for AldaraTM cream treated skin shown in Figure 4-3 (a) appears to contradict 
the ToF-SIMS analysis of skin cross-section with regards to amount drug delivered into the superficial 
layer of the skin, i.e., the stratum corneum. In order to elucidate this discrepancy, we performed a 
closer analysis of skin cross-sections of AldaraTM cream treated skin as shown in Figure 4-5. As 
discussed earlier, the fragment ion for phosphatidylcholine (C5H15NPO4+) was used to identify the 
dermis and viable epidermis while the fragment ion for ceramide, C17H32N+ is now utilised to 
distinguish the stratum corneum from the viable epidermis and dermis. Closer analysis of the AldaraTM 
cream treated skin showed that the majority of the molecule of interest, imiquimod resides within the 
stratum corneum. 
 
Figure 4-5 ToF-SIMS image of skin cross sections from porcine skin that were treated with AldaraTM cream  
(5% w/w imiquimod) alone. This analysis was conducted at a higher resolution closer to the skin surface to image 
the localisation of imiquimod  near the stratum corneum and epidermis junction. C14H17N4+ the molecular ion for 
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imiquimod indicated in green is, C5H15NPO4+ the fragment ion for phosphatidylcholine used to identify the viable 
epidermis and dermis indicated in blue. C17H32N+ is the fragment ion for ceramide used to identify the stratum 
corneum indicated in red. The overlays highlights imiquimod localisation within the stratum corneum and some 
near the epidermis just below the stratum corneum. Scale bar: 100 µm 
With regards to tape stripping as a method to quantify drug permeation into the superficial layer of 
the skin, various groups have observed a reduction in corneocytes removed with tape strip number. 
Such reduction in corneocyte extraction is attributed to the increase in corneocyte cohesion with 
stratum corneum depth 325–327. In addition, the increase in skin hydration with skin depth also reduces 
the ability of the tape adhesive to remove the corneocyte during the stripping process 291. When 
analysing the distribution of imiquimod on the AldaraTM treated skin from Figure 4-4, it may appear 
that most imiquimod is with the top layer of the skin. However, upon closer cross-sectional analysis 
of Figure 4-5 the majority of the molecule of interest, imiquimod resides within the deeper layer of 
the stratum corneum. These layers are not so easily removed by tape stripping and thus are extracted 
with the remaining skin.  
4.6 Conclusions 
In conclusion, the current work highlights the design, fabrication, evaluation and application of drug 
loaded polymeric microneedles as a drug delivery platform for the intradermal delivery of imiquimod 
for the treatment of nodular BCC. Permeation studies utilising Franz diffusion cells demonstrated that 
the imiquimod loaded polymeric microneedles were capable of delivering similar quantities of 
imiquimod to the region of tumours, despite a 6-fold lower drug loading, relative to the current clinical 
dose of AldaraTM cream used in BCC treatment. This ability of the polymeric microneedle to deliver the 
drug to the right target site despite lower drug loading may be of economic benefit while also limiting 
the likelihood of side effects. Using a microneedle patch, imiquimod loaded polymeric microneedles 
are mechanically inserted and embedded within the dermis upon application which is the target site 
for the treatment of nodular BCC. ToF-SIMS analysis of skin cross-sections highlighted the presence of 
the embedded drug-polymer matrix within the skin, which retains the drug in the dermis while 
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reducing the permeation of the drug across the skin. This provides evidence to support the 
mechanistic understanding of how the embedded drug-polymer matrix following polymeric 
microneedles administration controls the release of drugs. In summary, this work suggests that 
imiquimod loaded polymeric microneedles may be of clinical utility for localised intradermal delivery 
of imiquimod. Such formulations may provide a less invasive intervention to patients who would 






4.7 Supplementary Figures 
 
Figure S4- 1 Representation schematics of PVPVA microneedle production process. (a) Microneedle structure was 
first engineered using computer aided design (CAD).  (b) Micromachining technique is utilized to produce the 
master structure. (c) microscopy image of a machined pyramidal microneedle from the stainless-steel master 
structure. (d) PDMS mould were then producted via micromoulding. (e) Afterwards, PVPVA microneedles were 







Figure S4- 2 Pyramidal PVPVA microneedle fabricated without using the plasticiser PEG 400 resulting in 

















Figure S4- 3 Differential scanning calorimetry thermogram of pure PVPVA showing the glass transition 
temperature (Tg) at approximately 107 oC.  
 
Figure S4- 4 Pyramidal PVPVA microneedle patches fabricated with PVPVA and PEG 400 for both the needle and 



























Figure S4- 5 ToF-SIMS spectra of (a) skin treated with AldaraTM cream (5% w/w imiquimod) (b) skin treated with 






Figure S4- 6 Overlaid ToF-SIMS spectra of (c) blank untreated skin (b) skin treated with PVPVA polymeric 
microneedles (c) pure PVPVA reference, showing the fragment peak of PVPVA  













Figure S4- 7 ToF-SIMS secondary ion image of skin cross sections from ex vivo porcine skin that were treated with 
(i) AldaraTM cream (5% w/w imiquimod) alone (ii) PVPVA microneedles loaded with imiquimod after a 24-hour 
permeation study. Localisation of semi-dissolved polymeric microneedles within the dermis with skin treated 
imiquimod loaded microneedles. C14H17N4+inidicated in green is the molecular ion for imiquimod, C5H15NPO4+ 
indicated in blue is the fragment ion for phosphatidylcholine used to identify the viable epidermis and dermis. 
C17H32N+ indicated in red is the fragment ion for ceramide used to identify the stratum corneum. C6H10NO+ 
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indicated in pink is the fragment ion for PVPVA polymer. Si+ is an inorganic ion marker indicated in yellow is used 
to identify the glass slide. Scale bar: 500 µm. 
 
 
Figure S4- 8 ToF-SIMS analysis of skin cross sections from porcine skin that were treated with AldaraTM cream 
(5% w/w imiquimod) alone. This analysis was conducted at a higher resolution closer to the skin surface to image 
the localisation of imiquimod  near the stratum corneum and epidermis junction. C14H17N4+ the molecular ion for 
imiquimod indicated in green is, C5H15NPO4+ the fragment ion for phosphatidylcholine used to identify the viable 
epidermis and dermis indicated in blue. C17H32N+ is the fragment ion for ceramide used to identify the stratum 
corneum indicated in red. Si+ is an inorganic ion marker used to identify the glass slide. The overlays highlights 
imiquimod localisation within the stratum corneum and some near the epidermis just below the stratum 
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Imiquimod is one of the most efficacious drugs used in the treatment of superficial basal cell 
carcinoma (BCC). Nevertheless, imiquimod possesses physicochemical properties that limit its 
permeation to deeper tumour lesions such as those seen in nodular BCC. The current work presents 
the development, characterisation and evaluation of a series polymeric microneedles of different 
designs and polymeric chemistries as a drug delivery platform for nodular BCC. The polymeric 
microneedles were manufactured from the commercial PVPVA polymer, Kollidon® VA 64 as well as 
pAMPS, pNAM and pHEAM that were synthesised via free radical polymerisation reactions. The 
microneedles fabricated from pAMPS, pNAM and pHEAM displayed superior mechanical strength 
relative to the commercial PVPVA polymer. In addition, microneedle insertion studies highlighted that 
microneedles formulated out of pHEAM and pNAM displayed the highest insertion efficiency and 
penetration profile out of all the microneedle formulations evaluated. However, drug release studies 
into ex vivo skin tissues demonstrated that only the pNAM obelisk microneedle patch was capable of 
achieving higher intradermal delivery of imiquimod relative to the commercial cream, AldaraTM, and 
the PVPVA microneedles that was manufactured in our previous study. This was further corroborated 
by ToF-SIMS analysis of ex vivo patient BCC tumours treated with imiquimod loaded microneedle 
patches that demonstrated significant intradermal delivery of imiquimod within the tumour relative 
to the commercial cream AldaraTM. In addition, an in vivo tumour mouse efficacy study for skin 
tumours highlighted that the pNAM microneedles were capable of delivering the drug into the skin 
tumour which ultimately slowed down tumour growth. This study demonstrates that the pNAM 
obelisk microneedle system developed may be a viable approach in improving the intradermal 
delivery of imiquimod for the treatment of nodular BCC for patients who would prefer a less invasive 
treatment relative to surgical interventions. Furthermore, the pNAM microneedle system may be 





Basal cell carcinoma (BCC) is the most common cutaneous malignancy that accounts for 
approximately 70-80 % of all skin cancers 328. Data from epidemiology studies indicate that the overall 
incidence of BCC is growing at steady rate of 1-3 % annually and it is predicted that this incidence will 
continue to rise globally due to the rise in the aging patient population coupled with an increase in UV 
exposure 25,29. Nevertheless, this cancer is not regarded as life threatening as BCC typically have a very 
low metastasis rate of 0.0028 % resulting an overall mortality rate of less than 0.1 % 28,329. However, 
should BCC be left untreated the tumour can cause considerable local tissue damage (nose, ears and 
eyelids), leading to poor cosmetic outcomes and skin site disfigurement 37,38. The high incidence rate 
of the disease forms a considerable burden to the healthcare system. In the US, direct treatment costs 
for the management of BCC are estimated to amount to US$1.8–3.4 billion annually 39. Such high 
treatment costs are attributed to the use of Mohs micrographic surgery in the management of BCC, 
which imposes a financial burden of over US$2.0 billion annually as well as being a considerable 
burden to the workload of dermatologists 39,330. Therefore, the development of a simple and effective 
treatment that patients could self-administer themselves for the treatment of BCC is needed. 
Furthermore, some patients may prefer a non-surgical intervention that offers lower overall 
treatment costs with improved cosmetic outcomes 64,265.  
One of the most effective non-surgical interventions used in the management of BCC is the topical 
application of the immunomodulator, imiquimod 59. The drug is marketed as AldaraTM cream  
(5% w/w imiquimod) by 3M Pharmaceuticals and was initially approved by the FDA for the 
management of external genital and perianal warts in 1997. However, in 2004 AldaraTM was approved 
for the management of actinic keratosis and superficial BCC. Imiquimod belongs to a class of drugs 
known as imidazoquinoline which is an immunomodulator that stimulates toll-like receptors 7 (TLR-7) 
on dendritic cells, macrophages and monocytes when applied topically. Upon binding to the TLR-7 
receptor on these immune cells, imiquimod stimulates downstream processes which leads to the 
production of  pro-inflammatory cytokines culminating in its antitumoral activity 58. However, topical 
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therapy with AldaraTM has been met with low cure rates when the formulation was administered to 
patients presenting with cases of nodular BCC 34. This finding is attributed to  efficient barrier of 
function of the stratum corneum as well as the location of nodular BCC that resides deep within the 
aqueous dermis, thus presenting a formidable challenge for the delivery of imiquimod in a 
concentrated and localised fashion into the dermis for the treatment of nodular BCC 68.  
One of the drug delivery strategies that could be used to improve the delivery of imiquimod into 
the dermis for the treatment of nodular basal cell carcinoma are microneedles. Microneedles consist 
of arrays of fine micro-projections that upon application the skin produce micron size channels within 
the skin. The general consensus is that these microneedles channels can then be utilised to promote 
the delivery of therapeutics into and across the skin 293. As microneedles provide direct application 
and administration of drug into the skin, this drug delivery platform has gained interest as a strategy 
to provide more localised delivery of therapeutics in the treatment of skin cancer 237.  
Several researchers have investigated the utility of using solid microneedles, as a skin pre-treatment 
strategy prior to formulation administration, to improve the utility of delivering anticancer 
compounds into the skin for the treatment of skin cancer. For instance, Al-Mayahy et al. showed that 
using a two-step application process involving pre-treating the skin with solid stainless-steel 
microneedles followed by AldaraTM cream application, they were able to provide some degree 
permeation enhancement of imiquimod into the skin although 68. However, it was apparent from the 
imaging mass spectrometry data, that the permeation of imiquimod into skin pre-treated with solid 
stainless-steel microneedles was mainly localised in the epidermis and did not reach the deeper 
dermal layer where some skin cancers such as nodular BCC resides. Furthering this, we have explored 
and demonstrated that by switching the application step of the oscillating solid microneedle, using 
the Dermapen® device, from pre-treatment to post-treatment, we were able to enhance the delivery 
of imiquimod deep into the dermal layers to the depth where nodular BCC resides 35.  
Nevertheless, the utility of using solid stainless-steel microneedles with either pre-treatment of 
post-treatment strategies are limited by the two step application process which may not be favourable 
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by some patients as they would prefer formulations that they can administer in a single step with  
ease 331. Given these limitations, we have recently explored the strategy of reformulating imiquimod 
into dissolvable polymeric microneedles for the treatment of nodular BCC. We have shown that by 
reformulating imiquimod into dissolving pyramidal polymeric microneedles using poly 
(vinylpyrrolidone/vinyl acetate) PVPVA, we were able to deliver the drug deeper into the skin relative 
to Aldara cream. Nevertheless, quantitative analysis using HPLC highlights that the amount delivered 
into the remaining skin layers were similar between the imiquimod loaded PVPVA microneedles and 
Aldara cream, indicating that there is still room to improve the delivery strategy even further 332. 
The current work highlights the fabrication and evaluation of a series of polymeric microneedles 
patches of different geometries and polymeric chemistries as a drug delivery system to achieve the 
localised intradermal delivery of imiquimod for the management of nodular BCC. Microneedle moulds 
of different microneedle architectures were produced using micromachining. The moulds were then 
used to manufacture dissolving microneedles from the commercial PVPVA polymer, Kollidon® VA 64 
as well as poly N-acryloylmorpholine (pNAM), poly N-hydroxyethyl acrylamide (pHEAM) and poly 2-
acrylamido-2-methyl-1-propanesulfonic acid (pAMPS) that were synthesised via free radical 
polymerisation reactions. pNAM, pHEAM and pAMPS are biocompatible polymers that have been 
utilised to some degree, although their use is not as widespread as other pharmaceutical polymers, 
for various applications either as a hydrogel for wound healing 333,  drug delivery 334, or as a system to 
control cellular adhesion335. Nevertheless, the utility of these polymers in fabricating polymeric 
microneedle systems have yet to be explored. Using polymer casting and micromoulding, polymeric 
microneedles of pyramidal and obelisk architecture with different polymer chemistries were 
manufactured. A series of experiments were performed to characterise the range of polymeric 
microneedle formulations developed. In addition, in vitro permeation studies utilising using full 
thickness ex vivo porcine skin was performed to evaluate imiquimod delivery from these polymeric 
microneedle patches into and across the skin. Subsequently, the formulation that provides the 
greatest enhancement in intradermal delivery of imiquimod with minimal transdermal release was 
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then evaluated in an ex vivo human BCC tumour in order to gauge if the polymeric microneedle 
formulation was capable delivering imiquimod into the tumour. Lastly, the efficacy of the formulation 
was also evaluated in vivo using a rodent model for skin tumours in order to determine if the delivered 
imiquimod was capable of slowing down tumour growth.  This study can serve as a basis for the future 
development of polymeric microneedles therapies for the management of nodular BCC as well as 
other skin cancers alike. 
5.3 Materials 
Imiquimod was purchased from Cayman Chemicals, USA. Aldara™ topical cream (5% w/w imiquimod), 
MEDA Company, Sweden was purchased from Manor Pharmacy, UK. Polyvinylpyrollidone-co-vinyl 
acetate (PVPVA), was kindly provided by BASF (Ludwigshafen, Germany). Polyethylene glycol, PEG 400 
was purchased from Sigma Aldrich, Belgium. Sodium carboxymethyl cellulose, Mw 90,000 was 
purchased from Sigma Aldrich, USA. N-acryloylmorpholine (97%), N-hydroxyethyl acrylamide (97%) 
and 2-acrylamido-2-methyl-1-propanesulfonic acid (99%) were purchased from Sigma Aldrich, USA 
and the inhibitor removed by passing the monomers through a column of aluminium oxide. Thermal 
initiators 4,4′-azobis(4-cyanovalericacid) (ACVA, > 98%) was purchased from Sigma-Aldrich while 2,2'-
azobis[2-(2-imidazolin-2-yl) propane] dihydrochloride (VA-044, > 98%) was purchased from Wako 
Pure Chemical Industries Ltd. Glycerol was purchased from Sigma Aldrich, USA. Dimethyl sulfoxide 
(DMSO), tetrahydrofuran (THF) and diethyl ether were of reagent grade and were purchased from 
Fisher Chemical, UK. Deuterium oxide (99.9% D atom), DMSO-d6 (99.5% D atom), and Chloroform-d 
(99.8% D atom) were obtained from Sigma-Aldrich and used for 1H NMR spectroscopy. Sodium acetate 
was purchased from Sigma-Aldrich, UK. Acetonitrile (HPLC grade) and glacial acetic acid were obtained 
from Fisher Scientific, UK. Teepol solution (multipurpose detergent) was ordered from Scientific 
Laboratory Supplies, UK. D-Squame standard sampling discs (adhesive discs) were purchased from 
Cuderm corporation, USA. OCT media was obtained from VWR International Ltd. Belgium. Deionised 
water was obtained from an ELGA reservoir, PURELAB® Ultra, ELGA, UK. All reagents were of analytical 
grade, unless otherwise stated. Ex vivo porcine skin was used in imiquimod permeation studies due to 
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the similarities in histology, thickness and permeability to human skin 246. Skin samples were prepared 
from ears of six-month-old pigs obtained from a local abattoir prior to steam cleaning. The skins were 
of full skin thickness to prevent altering the biomechanical properties of the tissue that may lead to  
excessive penetration of the microneedles into the skin 66. The porcine skin samples were stored at -
20 °C until analysis. 
5.4 Methods 
5.4.1 Design and production of microneedle master structure and microneedle PDMS 
moulds 
To produce the custom polydimethylsiloxane (PDMS) moulds, a stainless-steel microneedle master 
structure was designed in SolidWorks 2018 (Dassault Systèmes), consisting of a 10 x 10 array of  
300 µm x 300 µm x 1000 µm (W x L x H) of either pyramidal or obelisk microneedles with tip-to-tip 
spacing of 800 µm. This master structure, and a corresponding mould housing were then produced 
from stainless-steel using a Kern Evo CNC Micro Milling Machine at the University of Nottingham 
Institute for Advanced Manufacturing. PDMS (Sylgard 184®, Dow Corning, Midland, MI) moulds were 
then created from the stainless-steel microneedle master structure. A mixture of elastomer and curing 
agent, Sylgard 184®, were prepared at a ratio of 10:1 (elastomer: curing agent). The mixture was then 
degassed for 45 minutes to remove any trapped air in the mixture. After degassing the PDMS mixture 
was poured into the stainless-steel master mould structure and placed in an 80 oC oven for one hour 
to cure the PDMS. After curing, the mould along with the cured PDMS was plunged into an ice bath to 
allow ease of removal of the cured PDMS mould. The stainless-steel master structure was then 
cleaned with propan-2-ol before being reused to make further PDMS moulds. 
5.4.2 Polymer synthesis 
Polymers were synthesized using the following general procedure from the conditions described in 
Table 5-1. Monomer, initiator and solvents were added to a 50 mL round bottomed flask equipped 
with a magnetic stirrer. The flask was sealed, the solution purged with argon gas for 10 min and then 
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immersed in an oil bath at 70 oC for two hours. Polymerisations were monitored by 1H NMR 
spectroscopy and quenched by removing from the reaction mixture from heat and exposing it to air. 
Polymers were purified and isolated either by precipitation or dialysis in water followed by 
lyophilisation. 
Table 5-1 Concentration and monomer and initiator used for polymer synthesis along with purification method 
post-synthesis. [M] refer to molar concentration, [mM] refer to millimolar concentration, MWCO refer to 
molecular weight cut-off.  







pHEAM DMSO 1.0 ACVA 1.0 Dialysis against water  
(25 kDA MWCO) 
 
pNAM H2O 1.0 VA-044 1.0 Polymer was dissolved 
in THF and precipitated 
in diethyl ether 
 
pAMPS H2O 0.5 VA-044 1.0 Dialysis against water  
(25 kDA MWCO) 
 
 
5.4.3 Polymer characterisation by gel permeation chromatography (GPC)/size exclusion 
chromatography (SEC) 
SEC analysis for PVPVA and pHEAM were determined was performed using a Polymer Laboratories PL-
50 instrument fitted with a differential refractive index detector. The system was equipped with 2× 
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PLgel Mixed D columns (300 × 7.5 mm) and a PLgel 5 μm guard column. The eluent used was 0.1% LiBr 
in dimethylformamide (DMF). Samples were eluted at 1 mL min−1 with the column oven heating to 
50 °C. PMMA standards (Agilent EasyVials) were used for conventional calibration between 
500−955,550 g mol−1. Experimental molar mass (Mn,SEC) and dispersity (Đ) values of synthesized 
polymers were determined by using Cirrus GPC software. 
SEC analysis for pNAM was performed using a Shimadzu Prominence instrument fitted with a 
differential refractive index detector. The system was equipped with 2× PLgel Mixed D columns (300 
× 7.5 mm) and a PLgel 5 μm guard column. The eluent used was 2% (w/w) triethylamine and 0.01% 
butylated hydroxytoluene (w/w) in THF. Samples were eluted at 1 mL min−1 with the column oven 
heating to 50 °C. PMMA standards (Agilent EasyVials) were used for conventional calibration between 
500−955,550 g mol−1. Experimental molar mass (Mn,SEC) and dispersity (Đ) values of synthesized 
polymers were determined by using Shimadzu GPC software. 
SEC analysis for pAMPS was performed using an Agilent GPC instrument fitted with a differential 
refractive index detector and UV detector. The system was equipped with 2x PL Aquagel-OH columns 
(300 × 7.5 mm) and a PL Aquagel-OH guard column. The eluent used was an aqueous solution of 
NaNO3 (0.1 M). Samples were eluted at 1 mL min−1 . PEG standards (Agilent EasyVials) were used for 
conventional calibration between 500 − 955,550 g mol−1.  Experimental molar mass (Mn,SEC) and 
dispersity (Đ) values of synthesized polymers were determined by using ASTRA software 
5.4.4 Differential scanning calorimetry of polymers 
In order to understand the physical properties of PVPVA polymer, DSC measurements were 
conducted. Dry polymer samples (~10 mg) were assessed using a Mettler Toledo DSC1 using a scan 
rate of 10 K/min in a temperature range of -100 to 150 °C. The glass transition temperature (Tg) was 
recorded as the midpoint of the glass transition observed in the second heating run. 
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5.4.5 Fabrication of blank and drug loaded polymeric microneedles 
Polymeric microneedles were prepared using a micromolding technique. The PDMS moulds produced 
as described in Section 5.4.1 were used to fabricate the blank microneedles. The microneedle matrices 
of different polymers were prepared by dissolving respective polymer and additive in water under 
stirring for one hour. The optimised compositions of different microneedle formulations are shown in 
Table 5-2. 







PEG 400, % v/v PVA, % w/v 
pHEAM 
Pyramidal 
6.25 n/a 2.0 
pHEAM  
Obelisk 
6.25 n/a 2.0 
pNAM 
Pyramidal 
6.25 n/a 2.0 
pNAM  
Obelisk 
6.25 n/a 2.0 
pAMPS 
Pyramidal 
6.25 n/a 2.0 
pAMPS  
Obelisk 
5.42 n/a 2.9 
PVPVA 
Pyramidal 
16.2 2.0 n/a 
PVPVA  
Obelisk 
16.2 4.0 n/a 
 
The polymer solution was then degassed for 30 minutes before 150 µl of the polymer solution was 
pipetted into the PDMS mould and centrifuged at 4000 RPM for 15 min at room temperature, to fill 
the needle cavities. Then, excess polymer was removed before leaving the needle layer to dry 
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overnight in a desiccator. The backing layer of the microneedle patches were prepared using 5.2 % 
w/w of carboxymethylcellulose, CMC (in water). The backing solution was made by dissolving CMC 
under stirring at 75 oC for 2 hours. In addition, 0.66 % v/w of glycerol was added to the backing solution 
as a plasticiser.  Using a positive displacement pipette, 200 µl of the CMC solution was then pipetted 
on top of the needle layer and centrifuged at 3500 RPM for 10 minutes. The mould was dried at room 
temperature for 48 hours in a desiccator. The polymeric microneedles were then demoulded and 
stored in a desiccator until further use. For imiquimod loaded microneedles the fabrication process 
was repeated in a similar fashion with the addition of 1 % w/v of imiquimod for all formulation 
composition, however the drug and polymer were dissolved in 0.05 M of hydrochloric acid under 
stirring for 1 hour. 
5.4.6 Characterisation of polymeric microneedles (SEM, tensile strength, skin insertion 
properties) 
5.4.6.1 Microscopy 
Polymeric microneedle images were captured using an optical microscope (Zeiss Axioplan, Germany) 
and an environmental scanning electron microscopy (ESEM) (FEI Quanta 650) in low vacuum mode to 
visualize the shape and dimensions of the microneedles. For ESEM imaging, the microneedles were 
mounted on a metal stub using double-sided carbon tape prior to imaging. 
5.4.6.2 Measurement of needle fracture force 
The needle fracture force of the polymeric microneedles was determined using a texture analyser 
(Stable Microsystems, UK) following a previously reported method 137. Needle fracture force was 
measured to investigate the effect of applying an axial force parallel to the microneedle vertical axis, 
similar to the force encountered by the needles during application to the skin, on the mechanical 
properties of the needles.  The polymeric microneedles were visually inspected before and after 
application of the compression force. For this, the force required for compression of the polymeric 
microneedle to a specified distance was measured. The polymeric microneedles were attached to a 
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10 mm cylindrical Delrin probe (part code P/ 10) using double-sided adhesive tape. The probe was 
connected to a 50-kg load cell and was set at the same distance from the platform for all the test 
measurements. The TA XT Plus Texture Analyser was set to compression, the pre-test speed was set 
at 2 mm/s and post-test speed at 10 mm/s. The trigger type was set to auto (force) with a trigger force 
of 0.009 N. The test station compresses the polymeric microneedle against a flat block of aluminium 
of dimensions 10.0 × 9.0 cm. Compression force versus displacement curves were plotted to calculate 
the fracture force. A total of five microneedle patches were used to evaluate the fracture force of the 
microneedles. 
5.4.6.3 In vitro skin simulant insertion 
As an alternative method to determine the microneedle penetration depth as a function of length, a 
polymeric film (Parafilm M®, a blend of a hydrocarbon wax and a polyolefin) was utilised as a skin 
model. This insertion study was adapted from Larrañeta et al.  248. In brief, 8 layers of Parafilm M® were 
stacked onto each other on a cork mat that mimics underlying muscles. The polymeric microneedle 
patches were applied under thumb pressure for 10 seconds. Six replicates were generated and 
observed under the Zeta Profilometer (KLA-Tencor, US) for the number of micropores created.  
5.4.6.4 Dye binding study 
In order to evaluate if the microneedle patch was capable of penetrating the skin and to visualise the 
depth of microneedle penetration into the skin, a dye binding study using ex vivo porcine skin was 
conducted. The porcine ear skin was defrosted at room temperature for an hour prior to the 
experiment. Using clippers, excess hair was carefully trimmed from the skin.   Regions of the skin were 
then selected for microneedle treatment. The skin was treated with polymeric microneedles loaded 
with methylene blue dye (1% w/v), which is a hydrophilic dye. The microneedle was left in the skin for 
one hour before removing the microneedle patch. Upon removing the patch, the skin was visually 
inspected to see if any microneedle channels had been generated in the skin. In order to gauge the 
depth of microneedle penetration into the skin, skin cross-sectioning was performed. In brief, each 
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microneedle application site was cut into 1 cm × 1 cm and fresh frozen on a metal block that was 
cooled with liquid nitrogen. Skin cross-sections were performed using a cryostat (Leica CM3050 S 
Research Cryostat, UK). The depth of microneedle penetration, as visualised by methylene blue 
permeation, was measured using an optical microscope (Zeta Profilometer, KLA-Tencor, US). 
5.4.7 Measurement of imiquimod permeation from polymeric microneedles 
Imiquimod skin permeation was evaluated ex vivo using a Franz-type diffusion cell. Prior to the 
permeation study, skin samples were defrosted and carefully trimmed into small pieces according to 
the area of the donor chamber of the Franz diffusion cell (Soham Scientific, Cambridgeshire, UK). The 
ex vivo porcine skins were subjected to the following treatments: i) application of 20 mg Aldara™ 
cream, in accordance with clinical dose approved by the FDA for the treatment of BCC. ii) imiquimod 
loaded polymeric microneedles. Next, the treated porcine skins were placed on top of the receptor 
compartment filled with 3 ml of degassed 100 mM acetate buffer pH 3.7. The skin was then secured 
between the donor and receptor compartment of the diffusion cell using a metal clamp, with the 
stratum corneum side facing the donor compartment. Upon assembling the Franz diffusion cell, the 
permeation experiment was conducted over a period of 24 hours in a thermostatically controlled 
water bath set at 36.5 oC. 1000 µl of the receptor fluid at designated time points (0.5, 1, 3, 6, 12 and 
24 hours) was sampled and then replaced with equal volume of fresh 100 mM acetate buffer pH 3.7.  
Upon sampling, 1000 µl of the solution from each Franz cell after collection was then spiked with 
100 µl of 100 µg/ml propranolol as an internal standard before being filtered through 0.22 µm 
membrane prior to HPLC analysis. 
After the 24-hour permeation experiment, excess cream was removed from the AldaraTM treated skin 
surface by careful application of sponges soaked with 3% v/v Teepol® solution. For the microneedle 
patch treated skin, the remaining microneedle patch was removed from the skin. Upon removing 
excess formulation from the skin surface, 15 sequential tape strips were collected from the skin. The 
amount of imiquimod from the pooled tape strips and remaining skin after tape stripping were 
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extracted by the addition of 10 and 5 mL of methanol extraction mixture (Methanol 70%: Acetate 
Buffer pH 3.7 100 mM 30%) respectively using a previously reported method 52. Samples were then 
vortexed for 1 minute and sonicated for 30 minutes before being left overnight. Subsequently, 
samples were vortexed again and sonicated for a further 30 minutes. After sonication, 1000 µl of the 
extracts were collected and spiked with 100 µl of 100 µg/ml propranolol as an internal standard. The 
samples were then filtered through 0.22 µm membrane prior to HPLC analysis. 
5.4.8 High performance liquid chromatography (HPLC) analysis 
HPLC analysis was carried out using an Agilent 1100 series instrument (Agilent Technologies, Germany) 
equipped with degasser, quaternary pump, column thermostat, autosampler and UV detector. System 
control and data acquisition were performed using Chemostation software. The details of the HPLC 
chromatographic conditions are as follow: column C18 (150 × 4.6 mm) ACE3/ACE-HPLC with a particle 
size of 5 µm, pore size of 100 Å, pore volume of 1.0 ml/g and a surface area of 300 m2/g, Hichrom 
Limited, UK. The mobile phase composition for analysis of extracts from skin wash, donor chamber 
wash, pooled tape strips and remaining skin consists of 10 mM acetate buffer: acetonitrile (79:21). 
Whilst, the mobile phase composition for analysis of receptor fluid consists of 10 mM acetate buffer: 
acetonitrile (70:30). The HPLC was operated at a flow rate of 1.0 mL/minute, UV detection at  
λmax=226 nm, an injection volume of 40 µL and a column temperature of 25 °C.   
5.4.9 ToF-SIMS analysis of microneedles and human BCC skin cross-sections 
The chemical composition of the microneedles manufactured was established by ToF-SIMS analysis. 
Prior to the analysis, the microneedles were carefully removed from the backing layer using a pair of 
micro-scissors. Following the removal of the microneedles from the backing layer, the microneedles 
were adhered on a glass slide that was coated with 5% w/v poly (hydroxyethylmethacrylate) and left 
to dry overnight before analysis under room temperature and pressure. ToF-SIMS analysis was 
performed under delayed extraction mode which is set to 90 ns using the Hybrid-SIMS instrument 
(IONTOF, GmbH) with a Bi3+ cluster source. A primary ion energy of 30 keV was used, the primary ion 
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dose was preserved below 1 × 1012 per cm2 to ensure static conditions. A pulsed target current of 
approximately 0.12 pA, and post-acceleration energy of 10 keV were employed throughout the 
sample analysis. In order to visualise the sub-surface chemical composition of the microneedle glass 
cluster ion beam (GCIB) sputtering was conducted on the microneedles using a 20 keV GCIB (Ar1500+) 
with a target current of 3 nA. Non-interlaced sputtering was employed, whereby the sputter and 
analysis ion beams do not operate simultaneously but at regular alternating intervals, with a single 
cycle consisting of 10 s sputtering, a 1.0 s pause and 3.25 s of analysis. After sputtering, the 
microneedles were analysed using the same analysing parameter with Bi3+ cluster source. 
In order to evaluate the depth of imiquimod permeation into the skin, the permeation experiments 
were repeated as described above Section 5.4.7. However, in this instance ex vivo human BCC samples 
were utilised in the permeation experiment instead. Samples were obtained from patients attending 
Mohs micrographic surgery for the removal of nodular BCC at the dermatology clinic at Leicester Royal 
Infirmary. Patients’ informed consent were first sought before samples were collected for the 
investigation. The study protocol was approved by the East of Scotland Research Ethics Service 
(EoSRES) Board and the NHS Health Research Authority (NHS HRA approval ID: 130880). After the 
permeation study, excess formulation was removed from skin samples treated with cream and 
microneedles. Subsequently, 1 cm × 1 cm areas of each application site were fresh frozen with liquid 
nitrogen. Skin cross-sectioning was performed using a cryostat (Leica CM3050 S Research Cryostat, 
UK). The skin slices were then thaw mounted on a glass slides and stored at -20 oC prior to ToF-SIMS 
analysis. ToF-SIMS was used to analyse the cryo-sectioned porcine skin samples. ToF-SIMS analysis 
was performed using a ToF-SIMS IV instrument (IONTOF, GmbH) with a Bi3+ cluster source. A primary 
ion energy of 25 KeV was used, the primary ion dose was preserved below 1 × 1012 per cm2 to ensure 
static conditions. Pulsed target current of approximately 0.3 pA, and post-acceleration energy of 
10 keV were employed throughout the sample analysis.   
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5.4.10 In vivo tumour study 
Female HHDII/HLA- DP4 (DP*0401) mice (EM:02221, European Mouse Mutant Archive), aged between 
8 and 12 weeks old, were used. All work was carried out at Nottingham Trent University under a Home 
Office approved project license. For the tumour study mice were randomized into different groups 
and not blinded to the investigators. The three treatment groups were (i) mice that received 
imiquimod loaded polymeric microneedle patches, (ii) mice that received unloaded polymeric 
microneedle patches and (iii) mice that did not receive any treatment which was selected as a negative 
control (n=10 per cohort). In the tumour study mice were challenged with 4×105 B16 HHDII DP4 
melanoma cells on the right flank. The fur on the right flank was shaved prior to microneedle 
application. Microneedle patches were applied to the melanoma tumour site on the right flank and 
secured using a kinesiology tape to avoid the microneedle from being dislodged by the mice during 
the study. The patch was applied to the melanoma tumour site for 24 hours before removal. The 
imiquimod loaded microneedle patch were administered on days 4, 8, 11 and 15 post tumour 
implantations. Tumour growth was monitored at 3 to 4-day intervals and mice were humanely 
euthanized once the tumour reached 10 to 15 mm in diameter. Tumour volume was estimated using 
the following formula, volume = (π/6) x (L x W2), where L is length and W is width of the tumour. 
5.4.11 Statistical analysis 
Statistical analysis was conducted using GraphPad Prism 7.02 software. Data are shown as 
mean ± standard error of mean. When comparing two groups an unpaired t-test analysis was used, 
while one-way analysis of variance (ANOVA) with Tukey's multiple comparisons tests was used to 
compare multiple groups. p values < 0.05 were considered statistically significant. 
5.5 Results and Discussion 
5.5.1 Polymer synthesis 
Three hydrophilic polymers, polyNAM, polyHEAM and polyAMPS were synthesised via free radical 
polymerisation reaction followed by purification either through precipitation or dialysis to remove 
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impurities left from the polymerisation reaction, such as unreacted monomer and initiators. The 
successful conversion of monomer into polymer is evidenced by 1H-NMR shown in Figure S5- 1. The 
reaction scheme for respective polymers is shown in Figure 5-1.  These polymers were chosen as they 
have yet to be explored as a material for microneedle fabrication despite being used elsewhere the 
field of drug delivery and tissue engineering 333–335.  
Free radical polymerisation was chosen as the method for polymer synthesis due to the simplicity in 
the synthesis route, low cost and applicability to a wide range of monomer chemistries 336. In addition, 
this form of polymerisation reaction can be carried out in solution, emulsion, or suspension and bulk 
monomer, highlighting the versatility of this polymerisation reaction. Furthermore, as this form of 
polymerisation reaction is one of the most common methods employed in polymer synthesis in the 
industry, there is a possibility for the polymer synthesised in this work to be produced at commercial 
scale  337. Prior to polymer reaction, all the reaction medias were purged with Ar(g). The purpose of this 
step was to remove any oxygen molecules from the reaction vessel as oxygen molecules will scavenge 
the radicals produced from thermolysis of the thermoinitiators in addition to the propagating 
macroradicals. This could lead to the production of stable peroxyl radicals, which are less reactive, 




Figure 5-1 Reaction scheme for the synthesis of poly (N-acryloylmorpholine), poly (N-hydroxyethyl acrylamide) 
and poly (2-acrylamido-2-methyl-1-propanesulfonic acid) 
From Table 5-3 it is clear that all the polymers synthesised displayed a broad dispersity, Ð ranging from 
1.80 for pAMPS up to 3.10 for pNAM. Within polymer chemistry, polymers are consider to have broad 
dispersity when the molecular weight distribution displays a dispersity of Ð >1.4 339. Some of the 
hallmarks of the polymer synthesis by free radical polymerisation are high monomer to polymer 
conversion rate, as well as the presence of broad polymer dispersity. Such broad dispersity is 
attributed to the lack of control over chain propagation as well as premature and irreversible chain 
termination via recombination or disproportionation during the polymerisation reaction 340,341. It is 
also worth noting that the commercial polymer, PVPVA used in a previous study also displayed Ð of 
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2.23 suggesting that the commercial polymer was also synthesised by a free radical polymerisation 
reaction 332.    
Table 5-3 Summary of the characterisation and properties of the polymers synthesised via free radical 
polymerisation along with the commercial polymer PVPVA used in the study 
Polymers Conversion, 
% 







Dispersity, Ð Glass transition 
temperature, Tg, oC 
PVPVA n/a 16, 900 2.23 106 
pNAM 94 55, 800 3.10 117 
pHEAM >99 126, 900 2.72 127 






Despite similar reaction temperatures and times for all the polymers synthesised, it can be seen that 
there were differences in the molecular weight of the polymers synthesised, with pHEAM displaying 
the greatest molecular weight. This is attributed to the Trommsdorff–Norrish effect that took place 
during the synthesis of pHEAM, leading to enhanced localised viscosity of polymerisation media, which 
slows down the polymer termination step. In contrast, the propagation step in the free-radical 
polymerisation reaction is insensitive to the increase in viscosity. This ultimately causes the polymer 
chains to grow with minimal termination thus culminating in pHEAM exhibiting the highest molecular 
weight relative to the other polymers synthesised 342. Such observations in which polymers exhibit 
Trommsdorff–Norrish have been reported for the synthesis of methacrylate and styrene-based 
polymers 343,344 as well as acrylamide-based polymers345,346. However, such an effect has never been 
reported before for homopolymers of polyacrylamides. 
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It is worth noting that the synthesised polymers, pNAM, pHEAM and pAMPS displayed a higher glass 
transition temperature, Tg relative to the commercial polymer PVPVA. Such high glass transition 
temperatures are attributed to the greater molecular weight of the synthesised polymers relative to 
PVPVA. Such an observation is corroborated by the findings by other research groups that showed 
that the Tg of polymers increased with increasing polymer molecular weight 347–349.  This observation 
can be explained by the Flory-Fox theory that describes how the glass transition temperature, Tg of a 
polymer increases with an increase in molecular weight, Mn. With higher molecular weight polymers, 
there is a decrease in the concentration of the more molecularly mobile polymer end chains, but a rise 
in the concentration of the less molecularly mobile polymer middle chain. This results in a lower excess 
free volume and slower molecular mobility, resulting in greater intermolecular interaction between 
polymers that culminates in a rise in Tg  350. However, in the case of pAMPS the increase in Tg is not 
only attributed to a rise in the polymer molecular weight but also to the presence of the highly 
ionisable propanesulfonic acid side group. This can form strong intermolecular ionic interactions 
between polymer chains giving rise to higher Tg, relative to the other polymers. Such an observation is 
corroborated by the work by Shibata et al. in which they discovered that poly(4-vinylpyridine) 
polymers with a higher degree of ionic interactions, through the incorporation of disulfonic acid 
moiety into the polymer, exhibit a rise in  Tg. 351. Therefore, despite pAMPS having a lower molecular 
weight relative to pHEAM and pNAM, the presence of strong ionic interaction between polymer chains 
in pAMPS reduces the polymer molecular mobility resulting in the polymer with the highest Tg out of 
the four polymers evaluated. Following synthesis and purification, the polymers synthesised along 
with the commercial polymer PVPVA were then used to fabricated polymeric microneedles for the 
delivery of imiquimod. 
5.5.2 Microneedle fabrication 
In this work, eight different polymeric microneedles of varying geometries and chemistries were 
fabricated following polymer synthesis. First the dimensions of the master structures were designed 
via computer aided design (CAD), then manufactured by micromachining. Two different microneedle 
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geometries were chosen i.e., pyramidal and obelisk. The stainless-steel master structures were used 
to manufacture PDMS moulds which were subsequently used for microneedle production. Micro-
milling was used to fabricate the designed stainless-steel master structures as this method produced 
has been shown to produce minimal surface imperfections 332. In addition, it has been described that 
micro-milling offers low manufacturing cost in generating complex architecture at a micron scale with 
high accuracy and repeatability 298.  
The polymeric microneedles were fabricated via casting, centrifugation and drying. The resulting 
polymeric microneedle patch is shown in Figure 5-2. Upon inspection via microscopy as shown in 
Figure 5-2 (a)-(d), the microneedle patch displays visible micro projections, which were either 
pyramidal or obelisk depending on the mould which the polymer blend was casted into. All 
microneedle formulations gave a needle length of ≈ 980 µm as shown in Figure S5- 2. The pyramidal 
microneedle displayed a tip radius of 32.3 ± 3.1 µm (mean ± SD, n=4) while the obelisk microneedles 
showed a tip radius of 22.3 ± 2.5 µm (mean ± SD, n=4) as observed via optical microscopy  




Figure 5-2 Optical microscopy image of (a) obelisk pNAM microneedles and (b) pyramidal pNAM microneedles 
at 12.5× magnification. SEM images of (c) obelisk an (d) pyramidal pNAM microneedles at 39× magnification. (e) 
Measurement of microneedle tip radius for obelisk and pyramidal PVPVA microneedles data are expressed as 
mean ± SD, n=4 Inset within the bar charts highlights a closeup microscopy image - of a single pyramidal and 
obelisk polymeric microneedle at 50× magnification, scale bar: 250 µm. Differences were determined using a 
two-tailed Student’s t test, and deemed significant at p<0.05. (f) Measurement of microneedle fracture force for 
different microneedle formulations data are expressed as mean ± SD, n=6.  
174 
 
SEM analysis, as shown in Figure 5-2 (c)-(d), revealed that equally spaced, sharp pyramidal and obelisk 
microneedles, on a clean and smooth baseplate were formed when the polymer blends were casted, 
dried and demoulded from the respective PDMS moulds. This was true for all the polymers used in 
fabricating the microneedles as shown in Figure S5- 3. This clearly indicates that the copolymer PVPVA 
along with the homopolymers pNAM, pHEAM and pAMPS were suitable materials for fabricating 
polymeric microneedles. We have previously demonstrated for the first time that PVPVA was a 
suitable material for fabricating dissolvable microneedles for the delivery of imiquimod 332. However, 
the current work has explored and expanded the range of polymers that could be used as a material 
for microneedle fabrication by introducing the use of pNAM, pHEAM and pAMPS. Additionally, these 
polymers are hydrophilic which permitted formulation of these polymers into an aqueous blend for 
casting and micromoulding for microneedle production. The use of water as a solvent to dissolve these 
polymers is an advantage as this avoids the use of organic solvents. The use of organic solvents in 
formulation production may be an issue especially during commercial manufacture, due to an inability 
to completely remove the solvent from the formulation. This will ultimately lead to trace amounts of 
organic solvents in the formulation, which are sometimes known as residual solvent. Despite meeting 
the standards set out in pharmacopeias, these solvents may accumulate in patients’ body over time 
with repeated application, which may lead serious side effects over time 352.  Furthermore, the 
absence of organic solvents also mitigates the swelling the PDMS moulds used in microneedle 
production 300.. 
We have previously reported that in order to prepare microneedles using Kollidon® VA 64, the 
formulation necessitates the incorporation of PEG 400 as a plasticiser. PEG 400 in this case may act as 
a plasticiser which reduces the brittleness of the microneedle post manufacture by imparting some 
degree of flexibility to permit ease of handling during demoulding 332. Similarly, in the current work it 
was observed that microneedles prepared from the use of pure aqueous blend of pNAM, pHEAM and 
pAMPS (without the presence of any other additive) also resulted in microneedle formation with poor 
mechanical properties, such as fractured tips as shown in Figure S5- 3. Nevertheless, such a limitation 
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was ameliorated by the incorporation of PVA as an additive during the fabrication of the microneedle 
layer. PVA is a water-soluble, synthetic, semi-crystalline polymer has previously been used as an 
additive in the manufacture of microneedle fabrication 353. When incorporated into a microneedle 
formulation PVA does not act as a plasticiser directly with the polymer that it is mixed with but instead 
act as a carrier in which it retains some water molecules. Indeed, water was used as a solvent to 
dissolve the polymers during for the casting and micromoulding stage.  However, upon drying not all 
of these water molecules are completely removed as some are retained in the amorphous region of 
the PVA structure 354. These water molecules form hydrogen bonds with the hydroxyl group of PVA 
and the hydrogen bond forming groups of other incorporated hydrophilic polymers, forming a 
structural water layer. In this instance, the remaining water molecules, which are retained in the 
presence of PVA, behave as an internal plasticiser thus reducing the brittleness of the needle layer 
during the demoulding stage and handling post-manufacture.  
The mechanical properties of the fabricated microneedles formulation were determined using a 
texture analyser. The polymeric microneedle arrays were subjected to an axial compression test to 
measure the fracture force of the polymeric microneedles.  From the microneedle fracture test as 
shown in Figure 5-2, the PVPVA based microneedle formulations, which were manufactured from the 
commercial polymer Kollidon® VA 64, displayed the lowest fracture force out of all the eight 
formulations evaluated. Nevertheless it has been highlighted that on average, a microneedle ought to 
display  a fracture force of approximately 0.098 N/needle in order for the needle to display effective 
insertion into the skin without fracturing 129,130. The superior fracture force from the microneedle 
patches fabricated from pNAM, pHEAM and pAMPS may be attributed to the higher molecular weight 
of the polymer used in making the microneedle patches relative to the PVPVA microneedles as it has 
been shown that polymers with higher molecular weight display a greater tensile strength relative to 
lower molecular weight polymers 355. Secondly, such enhanced fracture force can be attributed to the 
additive added during the microneedle manufacturing stage. In the case of pNAM, pHEAM and pAMPS 
microneedles, PVA was added into the microneedle formulation to provide some degree of 
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plasticisation in order to mitigate microneedle fracture during the demoulding stage. However, there 
is a possibility for pNAM, pHEAM and pAMPS polymers to form polymer-polymer interactions with 
the high molecular weight PVA polymer (20kDa) via hydrogen bonding and chain entanglement within 
the microneedle. Such supramolecular interaction between polymers have been shown by Lamm et 
al. to significantly improve the tensile strength of polymers resulting in stronger microneedles 356,357. 
In the case of pAMPS, these interactions were further reinforced by the presence of ionic hydrogen 
bonding between the charged sulfonic acid group on the polymer pendant with the oxygen group on 
the PVA polymer which resulted in pAMPS formulation displaying the highest tensile strength. In 
contrast, the addition of PEG 400, which with a lower molecular weight, was insufficient to cause any 
polymer-polymer entanglement in the PVPVA microneedles. Instead, the PEG 400 molecule would 
embed itself as an external plasticiser between the PVPVA polymer chain giving enhanced free 
polymer volume and thus weakening the polymer-polymer interaction that ultimately results in a 
weaker overall microneedle fracture force 358. 
5.5.3 Microneedle insertion characterisation 
 It is of great importance that the microneedle fracture test is coupled with insertion studies to 
evaluate the penetration capability of the fabricated microneedle patches. The insertion of the 
microneedle patches into a stack of Parafilm® layers was used as an in vitro skin model. This was 
performed by applying the microneedle patches onto the Parafilm® stacks under thumb pressure. 
Upon application, respective Parafilm® layers were separated and observed using an optical 
microscope to evaluate the pore uniformity as a function of penetration depth. It can be seen from 
Figure 5-3 (a)-(b) that the number of microneedle channels generated decreased as a function of 
Parafilm® layer number with pyramidal microneedles displaying greater insertion relative to obelisk 
microneedles. This observation may be attributed to the surface area of different microneedle designs 
that are in contact with the Parafilm® layers during insertion, with the pyramidal design having a 
smaller surface area (0.6 mm2 per needle) of contact relative to the obelisk design (0.9 mm2 per 
needle). Therefore, the obelisk design will experience more effective frictional force relative to the 
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pyramidal design resulting in a lower insertion profile into the Parafilm® layers. In addition, it was clear 
that for all the formulation evaluated, complete microneedle insertion was observed in the first 
Parafilm® layer as shown in Figure 5-3 (a)-(b). Collectively, the fracture force data from  
Figure 5-2 (e) along with the insertion profile from Figure 5-3 (a)-(b) would suggest that all of the 
microneedle patches fabricated were capable breaching the stratum corneum permitting microneedle 




Figure 5-3  Insertion profile of different polymeric microneedle formulations into Parafilm® layers for 
microneedles with (a)obelisk design and (b) pyramidal design. (c) Percentage of successful microneedle insertion 
for different microneedle formulation into ex vivo porcine flank skin. Inset shows an example of an ex vivo porcine 
skin treated with methylene blue loaded polymeric microneedles (d) Microneedle penetration depth for different 
microneedle formulation into ex vivo porcine flank skin. Inset shows an example of an optical microscopy image 
of microneedle channels created when the skin is treated with polymeric microneedle patches. Data are 
expressed as mean ± SEM for n = 6.  
The Parafilm® insertion experiment was then complemented with dye release study in order to 
evaluate the ability of the microneedle patches to puncture actual skin tissue ex vivo. Methylene blue 
loaded microneedle patches were administered onto porcine cadaver skin, which upon application 
resulted in the release of the hydrophilic dye into the surrounding skin tissue upon polymer 
dissolution. This ultimately resulted in the formation of blue pores within the porcine skin that 
followed the distribution of microneedles on the patch as shown in Figure 5-3 (c).  
However, when the number of microneedles generated in the skin from the application of methylene 
blue loaded microneedles was evaluated, we observed that the number of channels in the skin was 
much lower than that observed from the Parafilm® insertion study. Such discrepancy in results 
suggests that the although the in vitro test developed by Larraneta et al. is useful in providing early 
estimation data of microneedle insertion, the test indeed has some limitations when the insertion 
data is translated into ex vivo skin tissues. This may be explained by the fact that Parafilm M® exhibits 
irreversible plastic deformation when stretched or compressed, thus providing a lower resistance to 
microneedle insertion 259. In contrast, the skin is an elastic biological tissue that returns to its normal 
state under mild stretching or compression thus conferring greater level of resistance to microneedle 
insertion relative to the Parafilm® layers.  
From Figure 5-3 (c) it was apparent that all microneedle formulations were unable to generate 100 % 
microneedle channels into the ex vivo porcine tissue. Such observations whereby incomplete insertion 
of all needles from microneedle patches has been observed previously by other researchers  359,360. 
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This observation can be attributed to the “bed of nail” effect, a situation where the force experienced 
by each microneedle is less than the overall force applied to the microneedle patch due to force 
redistribution between the needles 143. When the fracture force of the microneedles was evaluated 
using the texture analyser it was assumed that the fracture force recorded was evenly distributed 
between needles. This assumption may not be the case when the patch is applied to the skin ex vivo 
or in vivo under thumb pressure as it has been shown in the work by Vicente-pérez et al. that force 
distribution across a microneedle patch as visualised via pressure-indicating sensor film was not 
entirely uniform, giving rise to heterogenous force redistribution 309. This may lead to the situation 
where only some microneedles on the patch experience sufficient force to pierce the skin leading to 
poor insertion efficiency. In the case of PVPVA microneedles, the introduction of PEG 400 already 
resulted in mechanically weaker microneedles, which combined with the phenomenon of 
heterogenous force redistribution under manual application resulted in poor insertion efficiency 
especially with the obelisk design. In the case of pAMPS microneedles, although the polymer displayed 
a high fracture force, the poor insertion properties of this formulation was attributed to the brittleness 
of the pAMPS polymer. This is because the polymer is far below its Tg relative to the other polymers 
making it brittle and prone to fracture during needle insertion. In addition, the brittle nature of pAMPS 
have been reported by other researcher as well 361.  
Although the Parafilm® insertion study is a poor predictor of the number of microneedle channels in 
ex vivo skin tissues, comparison between the penetration depth from the Parafilm® insertion data and 
ex vivo porcine skin insertion data suggested that the penetration depths of the microneedles were of 
approximately the same depth. This does suggest that the skin simulant, Parafilm® may have some 
value as an in vitro surrogate in estimating the penetration depth of the microneedle when ex vivo 
skin tissues are scarce. It worth noting from Figure 5-3 (d) that microneedles fabricated from pNAM 
polymer with either pyramidal or obelisk design resulted in the deepest microneedle insertion into 
the ex vivo skin with an insertion depth of approximately ≈ 600 µm.  
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Branski et al.  have reported that the average thickness of the porcine epidermal layer varies between 
30-140 µm 260. It can be seen from Figure 5-3 (d) that all the microneedle formulations evaluated 
resulted in insertion depths that were greater than 200 µm, suggesting that all the formulations 
evaluated would reach the dermis. In comparison, the human skin is reported to have an epidermal 
thickness of around 70-150 µm for thin skin (face, eye lids, neck and arm); regions where BCC mainly 
manifests 310,311.  Therefore, it can be postulated that application of these microneedle patches would 
provide the insertion depth needed to bypass the epidermis and reach the dermis, the target site for 
the treatment of nodular BCC. 
5.5.4 Chemical imaging and characterisation of microneedle via ToF-SIMS 
ToF-SIMS analysis was conducted on the fabricated microneedles of different designs and chemistry 
in order visualise the chemical composition and distribution of imiquimod and the polymer used in 
fabricating the microneedles. It is apparent from Figure 5-4 that the micromoulding strategy using the 
drug polymer blend to fabricate the polymeric microneedles resulted in the formation of homogenous 
microneedles in terms of polymer and drug distribution. It can be observed that the choice of the 
polymers used, this case PVPVA, pNAM, pHEAM and pAMPS, did not result in any observable 
differences in the distribution of the drug or polymer along the microneedle length. Furthermore, this 
form of analysis provides a method of validating visually that both the drug and the polymer has been 





Figure 5-4 ToF-SIMS secondary ion image of imiquimod loaded microneedle of different polymeric chemistries 
showing the total ion images collected along with the respective ions used to track the presence of the drug, 
polymer and PDMS contaminant. C14H17N4+indicated in green is the molecular ion for imiquimod. Indicated in red 
are the respective fragment ion for the different polymers used to fabricate the microneedle. Si2C5H15O+ indicated 
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in blue is the fragment ion for PDMS. Overlay images highlight the homogenous distribution of drug and polymer 
along the microneedle length for respective formulation. 
Conventionally, dyes such as fluorescence isothiocyanate and Nile-red are frequently utilised either 
through conjugating with the payload or as a surrogate to the payload in order to gauge if the 
therapeutic has been successfully incorporated into microneedles 127,362. This provides some degree 
of information on the spatial localisation of the therapeutic along the microneedles, but this approach 
introduces an additional step of conjugating the delivered therapeutic with the dye prior to 
microneedle fabrication. The conjugation process in some respects also presents the need of purifying 
the conjugated payload post synthesis, which can be time consuming. Furthermore, the use of these 
dyes also introduces the requirement of conducting these experiments in the absence of light to avoid 
photobleaching of the incorporated dye 363.  In addition, this approach only provides detail on the 
spatial localisation of the therapeutic along the needle but does not provide any visual information 
regarding the distribution of the other components of the microneedles, such as the polymer used, as 
well as the presence of potential contaminants arising from the fabrication process. 
In order to obviate the limitation of this conventional approach, it has been demonstrated that mass 
spectrometry imaging using ToF-SIMS may serve as an alternative method to visualise the distribution 
of both drugs and polymer along the microneedle in a label free fashion. It was demonstrated for the 
first time as seen in Figure 5-4 that the conventional process of producing microneedles using PDMS 
moulds resulted in the deposition of PDMS on the microneedle itself. This was achieved by tracking 
the fragment ion, Si2C5H15O+ which is specific to PDMS.  Nevertheless, such contamination is only 
superficial and is limited to the surface of the microneedle because it was shown that upon sputtering 
the microneedles with Ar1500 gas cluster ion beam to remove the first few nanometers of the 
microneedle surface of the microneedle there was no longer any PDMS signals observed within the 
microneedle as seen in Figure S5- 4.  
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This observation may be attributed to the leaching of the PDMS oligomers from the mould into the 
microneedle formulation when the drug polymer blends were casted into the moulds during 
production. PDMS is one of the most widely used synthetic polymers in daily life, ranging from 
household appliances to cosmetics and medical devices. Therefore, leaching and release of PDMS 
oligomer is not uncommon. For instance, Gross using direct analysis in real time-mass spectrometry 
(DART-MS) detected the release of low to medium molecular weight oligomers from PDMS based 
appliances used on a daily basis 364. Similarly, Carter et al. have also reported the leaching of 
uncrosslinked PDMS oligomer from PDMS chips into microfluidic channels used in growing cells for 
organ-on-chip research. Such observations were attributed to the incomplete curing of the PDMS 
oligomers during microfluidic chip production 365. From a patient perspective, the presence of PDMS 
on the microneedle formulation may be lead concerns regarding the health risks associated with the 
deposition of the PDMS oligomer into the skin. Such an issue would be exacerbated if the microneedle 
formulations are used in delivery of the therapeutic for the management of long-term conditions such 
as cardiovascular diseases and diabetes. However, in the case of the BCC the management of the 
disease is usually short term which mitigates the likelihood of PDMS accumulation in the skin. 
Furthermore, the wide spread use of PDMS in the biomedical field owing to its good biocompatibility 
further reduces the concern associated with superficial PDMS contamination on the microneedle 
surface 366.   
5.5.5 Drug release study from microneedles into ex vivo porcine skin 
In the present work, the delivery of imiquimod from different microneedle patches into and across 
the skin was evaluated in comparison to the commercial imiquimod cream, AldaraTM. In order to gauge 
the delivery of imiquimod into and across the skin, in vitro permeation studies utilising Franz diffusion 
cells were carried out. Imiquimod was loaded into the microneedles by dissolving both the polymer 
and the drug along with the selected additive to form a polymer blend before casting the mixture into 




Figure 5-5(a) Drug loading from microneedle patches of different designs-obelisk and pyramidal  
(mean ± SD, n=8). (b) Amount of drug extracted from stratum corneum obtained from pool tape strips analysis 
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via HPLC after 24 h permeation study. (c) Amount of drug extracted from remaining skin obtained via HPLC 
analysis after 24 h permeation study. (d) Drug concentration within receptor fluid as a function of time during 
permeation study from Aldara™ and imiquimod loaded polymeric microneedles. Data are expressed as mean ± 
SEM for n = 6. Differences were calculated using one- way ANOVA, followed by Tukey’s post hoc test, and deemed 
significant at p < 0.05 
From Figure 5-5 (a) it is clear that by changing the design of the microneedle from pyramidal to obelisk 
while casting the same concentration of drug solution, it was possible to increase the drug loading 
from 150 µg to 300 µg. This is attributed to the volume of the moulds used in fabricating the 
microneedles. The obelisk microneedle mould has a total of 6 mm3 mould volume for the needle layer 
which is twice the mould volume of the pyramidal microneedle mould. Upon skin application 
imiquimod-loaded polymeric microneedles dissolved in the limited volume of the skin’s interstitial 
fluid to release drug into and across the skin layer. It was apparent that all the formulations evaluated 
were capable of delivering imiquimod into the stratum corneum, remaining skin and into the receptor 
fluid as shown in Figure 5-5 (b)-(d).  The delivery of imiquimod into the stratum corneum and 
remaining skin was statistically similar to that AldaraTM cream for the PVPVA, pHEAM and pAMPS 
microneedle (p > 0.05). By comparing the result from Figure 5-3 (c) and Figure 5-5 (b)-(c) it is possible 
to conclude that although PVPVA and pAMPS microneedles resulted in poor insertion efficiency in ex 
vivo skin tissue, the number of microneedles that managed to puncture and dissolved in the skin still 
resulted similar delivery of imiquimod relative to commercial cream  AldaraTM despite the patches 
having a lower drug loading than the 1000 µg of imiquimod administered from the 20 mg of AldaraTM 
cream.  
On the other hand, it was apparent that both the obelisk and pyramidal designs for imiquimod loaded 
pNAM microneedle patches resulted in the greatest amount of drug delivered into the stratum 
corneum and while only the obelisk design resulted in the greatest delivery into remaining skin. The 
differences in the amount of imiquimod delivered into the stratum corneum by both types of pNAM 
microneedles were of statistical significance (p<0.05) when compared to AldaraTM cream. In contrast, 
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both designs for the pHEAM microneedles delivered a statistically similar amount of the drug into the 
stratum corneum and remaining skin when compared to AldaraTM cream, despite displaying similar 
insertion efficiency to pNAM microneedles.  This may be attributed molecular weight of the pHEAM 
polymer as shown in Table 5-3 which is twice the molecular weight of pNAM, which could result in 
slower polymer dissolution over 24 hours relative to pNAM, resulting in incomplete imiquimod release 
from the microneedle patch. 
It is also worth noting that the amount of imiquimod administered from the pNAM obelisk 
microneedle patch was 300 µg.  The dose of imiquimod administered from this microneedle patch was 
much lower than the 1000 µg of imiquimod administered from the 20 mg of Aldara cream (5% w/w) 
that was applied to the skin area of 3.8 cm2, in the Franz cell, which is based on a clinical dose for 
AldaraTM cream for the treatment of BCC 314. Although the amount imiquimod administered was 
approximately three folds lower than the clinical dose of AldaraTM cream, the amount of imiquimod 
that was delivered into both the stratum corneum and remaining skin was significantly higher with the 
pNAM obelisk microneedles relative to AldaraTM cream (p < 0.05).  
Such enhanced permeation into the stratum corneum by both obelisk and pyramidal pNAM 
microneedles may also be attributed to the behaviour of the polymer upon interacting with the 
interstitial fluid in the skin. It has been highlighted that the microneedle channels that are formed 
within the stratum corneum during polymeric microneedle application behave as focal points for 
imiquimod to permeate laterally and to localise in the surrounding corneocytes, thus enhancing 
delivery to the upper layer of the skin 332. However, unlike the other polymers used in fabricating 
microneedles, pNAM has been shown to form a physical hydrogel that swells and doubles in size when 
the polymer comes into contact with fluid before undergoing dissolution 367.   The swelling of the 
pNAM polymer upon microneedle application was due to the formation of a physical hydrogel, 
resulting in enlargement of the microneedle channels. This ultimately results in larger focal points for 
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imiquimod to radiate laterally towards surrounding corneocytes, thereby enhancing the delivery of 
imiquimod into the stratum corneum. 
Such enhanced delivery to the skin surface maybe of great benefit in managing superficial BCC. 
However, in the management of nodular BCC the microneedle patch must also demonstrate the ability 
to permeate imiquimod beyond the stratum corneum and deeper into the skin 34. It was apparent that 
only pNAM obelisk microneedles resulted in the highest delivery of imiquimod into the remaining skin 
with such difference being statistically significant relative to the commercial control, AldaraTM 
(p>0.05). The observed enhanced delivery of imiquimod into the remaining skin may be attributed to 
the combinatorial effect of a higher drug loading with obelisk design relative to the pyramidal design 
coupled with the swelling behaviour of pNAM upon contact with interstitial fluid during microneedle 
application. The reliance on the swelling behaviour of pNAM alone in enhancing the delivery of 
imiquimod from the microneedle systems in this case was insufficient for enhancing the delivery of 
the drug into the remaining skin. This was exemplified by the amount drug delivered with the pNAM 
pyramidal microneedle, which was not greater than that delivered by AldaraTM cream.  
Figure 5-5 (d) shows the concentration of imiquimod detected in the receptor fluid over time for 
different microneedle formulation relative to AldaraTM. It can be seen that the concentration of 
imiquimod in the receptor fluid over time for most microneedle formulations were either statistically 
similar or lower when compared to AldaraTM over the course of 24 hours. This highlights that over the 
course of 24 hours, the microneedle patch resulted in either similar or even less (e.g., pHEAM obelisk 
and PVPVA pyramidal) imiquimod delivery across the skin while delivering a similar quantity of the 
drug into the remaining skin. However, in the case of pNAM similar imiquimod delivery into the 
receptor fluid was observed relative to AldaraTM cream, despite the greater intradermal delivery into 
the skin.  It is understood that the amount of drug detected in receptor fluid following Franz cell 
permeation studies are sometimes used to gauge the likelihood of systemic exposure following 
formulation administration to the skin  1.  Hence, it could be estimated that the likelihood for systemic 
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exposure to imiquimod following microneedle treatment is similar when compared to clinical dose of 
AldaraTM cream application. This suggests that should a patient with nodular BCC receive imiquimod 
loaded pNAM obelisk microneedle patches, the formulation will provide a simple application strategy 
to enhance the intradermal delivery of the drug into the skin. However, the likelihood of undesirable 
side effects associated with imiquimod systemic exposure from these patches will not be any greater 
than that associated with AldaraTM cream application.   
In addition, it is worth discussing the effect of drug partitioning from the delivery systems into ex vivo 
porcine skin as this may affect the overall drug distribution following the permeation study. Indeed, 
the permeation of drug molecules across the skin is essentially a passive diffusion process that is 
governed by Fick’s law of diffusion. During this process drug molecules partition from a region of high 
drug concentration (i.e., the delivery system) to a region on lower drug concentration (i.e., the skin 
tissue and the receptor fluid). Generally, the permeation of compounds across the skin are hindered 
by the lipophilic stratum corneum that acts as the main barrier to drug permeation 368. However, in 
this study, the barrier function of the stratum corneum have been circumvented through the use of 
polymeric microneedles thus enabling the delivery systems to be embedded directly within the 
hydrophilic epidermis and dermis. On top of that, it is known that the pH of the skin changes from  
pH 4.5 at the stratum corneum to pH 7-8 within the viable epidermis and dermis 51. Due to the 
presences of amine groups on the drug molecule, imiquimod display low solubility at neutral and basic 
pH. Therefore, this would suggest that imiquimod would have poor solubility within the epidermis and 
dermis and thus suffer reduced partitioning from the delivery system to the surrounding skin tissues. 
However, the overall process is far more complex as Wagner et al have demonstrated that the buffer 
solution within the receptor compartment of a Franz cell can permeate upwards into the  
skin 369. Thus, it can be postulated that the acetate buffer (pH 3.7) from the receptor compartment 
may have permeated upwards into the skin resulting in overall reduction in the pH of the epidermis 
and dermis. This reduction in pH within the epidermis and dermis would increase the solubility of 
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imiquimod and thus the overall partitioning of the drug into these layers of the skin. On top of that, 
the partitioning of imiquimod into the acidified epidermis and dermis will also compete with the 
partitioning of the drug into the aqueous receptor fluid which would ultimately affect the overall 
distribution of the drug in ex vivo skin tissue.  
It has been shown that the colocalisation of polymers with drug molecules may result in molecular 
interaction between the two species that mitigates the partitioning of the drug molecules into 
aqueous media 370.  Based on Figure 5-5, it could be hypothesised that presence of pNAM within skin 
particularly with the obelisk design relative to other polymeric microneedle systems resulted in strong 
molecular interactions between the polymer and the ionised imiquimod molecules via ionic hydrogen 
bonds. This interaction between pNAM and imiquimod reduces the propensity of the drug to partition 
out of the skin and into the aqueous receptor fluid resulting in enhanced drug retention in the skin. 
Also, it could not be ruled out that there will be some degree of imiquimod repartitioning back from 
the receptor fluid into the skin. However, as we have confirmed in our previous work that sink 
conditions were indeed maintained throughout the permeation study 35. Therefore, it could be 
postulated that the effect of repartitioning from the receptor fluid into the skin is minimal due to 
presence of sink condition.  
5.5.6 Drug release study in ex vivo human BCC tumour 
It was apparent that the quantitative results provided by HPLC analysis permitted comparison of the 
delivery efficiency of different microneedle formulations relative to the commercial control AldaraTM 
cream. From the HPLC analysis it was apparent that pNAM obelisk microneedles resulted in higher 
delivery of imiquimod into both the stratum corneum and remaining skin while resulting in similar 
transdermal delivery into the receptor fluid relative to AldaraTM cream. Nevertheless, HPLC does not 
provide any details on the dermal distribution of imiquimod and excipient from the delivered 
formulation. Complementary to the quantitative HPLC data, ToF-SIMS analysis of ex vivo human BCC 
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tissues treated with either AldaraTM cream or pNAM obelisk microneedles was conducted in order to 
evaluate the distribution of imiquimod within diseased tissues.  
Due to the discrepancy in healthy and diseased skin tissues, ex vivo human BCC tumours excised from 
patients attending Moh’s micrographic surgery were utilised in the permeation study. Such 
experimental design was selected as this would provide a better representation and estimation of 
imiquimod permeation into the tumour relative to healthy human or porcine skin. In addition, as there 
are a limited number of ex vivo BCC tumours, pNAM obelisk microneedles that resulted in the greatest 
delivery of imiquimod into the porcine skin were chosen for the drug release study into the tumour 
along with AldaraTM cream, which was chosen as a commercial control. 
Figure 5-6 shows ToF-SIMS secondary ion images from BCC tumour cross-sections analysed after a 24-
hour permeation study. Owing to the parallel detection capabilities of the ToF-SIMS, secondary ions 
originating from the BCC tumour tissue, pNAM polymer, substrate (glass slide) and imiquimod were 
detected and analysed. By monitoring the ion peaks from the ToF-SIMS spectra, visualisation of the 
localisation and distribution of these secondary ions was achieved. The fragment ion originating from 
phosphatidylcholine, C5H15NPO4+ was used to identify the BCC tumour as this fragment ion has been 
shown by Munem et al. and Nilsson et al. to be associated with the cancerous part of the BCC  
tissue 371,372. In previous work, it has been shown that the permeation of the imiquimod across the 
skin could be tracked by monitoring the molecular ion C14H17N4+ 35,68. By monitoring the fragment ion 
peak C5H9NO+, this enabled the detection of the localisation of the pNAM polymer within the BCC 
tumour as shown in Figure 5-6. The peak assignment for pNAM was validated by referring to the 
fragmentation pattern at m/z 99 with the reference spectra of pure pNAM on silicon wafer, as shown 




Figure 5-6 ToF-SIMS image of ex vivo human BCC sections from tumour that were treated with (a) AldaraTM cream 
(5% w/w imiquimod) alone (b) pNAM obelisk microneedles loaded with imiquimod after a 24-hour permeation 
study. This figure highlights the localisation of dissolved polymer and the release of imiquimod into the tumour 
when the ex vivo tumour was treated imiquimod loaded microneedles. C14H17N4+ indicated in green is the 
molecular ion for imiquimod, C5H15NPO4+ indicated in blue is the fragment ion for phosphatidylcholine used to 
identify the tumour tissue. C5H9NO+ indicated in red is the fragment ion pNAM polymer used to polymer within 
the tumour tissue. Si+ indicated in pink an inorganic ion of silicon which is used to identify the glass slide (the 
substrate used to mount the cross-sections). Scale bar: 500 µm. 
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It is apparent from Figure 5-6 that there is limited availability of imiquimod within deeper BCC layers 
when the molecule was delivered as a topical cream, AldaraTM. However, when imiquimod is delivered 
as a polymeric microneedle patch, improved delivery of imiquimod into both the upper and deeper 
layers of the BCC tumour was observed. Such observation is complementary to the HPLC analysis 
shown Figure 5-5 (b)-(c) that highlights greater delivery of imiquimod into the skin surface and 
remaining skin when the drug is delivered using pNAM obelisk microneedles relative to AldaraTM 
cream. Typically nodular BCC is much more difficult to treat as the tumour typically manifests from 
the skin surface and grows downward into the skin, to the depth of 400 µm below the skin surface 34. 
The ToF-SIMS analysis of BCC nodular tumour cross-sections from Figure 5-6 suggests that through 
the application of pNAM obelisk microneedle patch, it was apparent that imiquimod penetrated and 
permeated into the ex vivo BCC tumour the skin to a depth of greater than 600 µm resulting in 
imiquimod delivery into the deeper layer of the BCC tumour. 
In previous work it has been demonstrated for the first time in the microneedle field the capability to 
simultaneously detect the deposition of both drug and polymer from a dissolving microneedle patch 
within the skin in a label free manner owing to the parallel detection capability of ToF-SIMS 332.  In the 
current work, the polymer that is used in fabricating the microneedle patch is pNAM. By monitoring 
the fragment ion peak at m/z 99.04 it was possible to detect the localisation of the polymer within the 
tumour milieu post application as shown in Figure 5-6. By comparing this finding with the ToF-SIMS 
analysis of tumour cross-section from samples treated with imiquimod loaded microneedles in  
Figure 5-6, it was apparent that imiquimod was colocalised in the presence of pNAM polymer within 
the dermis following skin application. This leaves imiquimod which is embedded in a polymer matrix 
within the tumour. It was noted that there was more a concentrated layer of pNAM within the upper 
dermal layer that became progressively dispersed with tumour depth. The more concentrated layer 
of pNAM within the upper tumour layer was attributed to the formation of pNAM hydrogel within the 
skin. This is supported by the finding of Gorman et al. that showed from their work through the 
193 
 
synthesis of pNAM via photopolymerisation that the polymer behaves as a physical hydrogel, which 
swells over 120 minutes upon exposure to an aqueous environment 335.  
The swelling of the polymer into a physical hydrogel is attributed to the formation of intermolecular 
interactions between the pNAM polymers as well as the interaction between the polymer and the 
water molecules as shown in the schematic in Figure 5-7. Upon puncturing the stratum corneum, the 
microneedle is embedded in the water rich dermis. Here the polymeric microneedle begins to absorb 
water molecules which hydrates the polar hydrophilic acryloylmorpholine group pendant group of 
pNAM polymers leading to formation of a primary bound water layer. The formation of this primary 
bound water layer leads to polymer swelling, which exposes the hydrophobic region of the polymer 
(the backbone), which also interacts with water molecules via Van der Waals forces, which forms the 
secondary bound water layer leading to further swelling. This ultimately causes additional water 
molecules to imbibe into the needle structure due to osmosis leading to polymer swelling and dilution. 
However, the dilution process is opposed by transient physical interactions between the polymer 
chains leading to an elastic network retraction force 373. These physical interactions arising from 
polymer-polymer chain entanglement, hydrogen bonding arising from the nitrogen and oxygen group 
of the acryloylmorpholine pendant group as well as hydrophobic interactions between the polymer 
backbones culminates in formation of a physical hydrogels from the pNAM polymers 374.  
Evidence that supports the mechanism of swelling of the pNAM polymer was demonstrated by 
Gorman and co-worker 335. This was determined by measuring the water absorbance of the polymers 
over a period of 70 hours. The group discovered that pNAM absorbed water and swells to 
approximately double its dry weight within two hours upon exposure to excess water. Upon further 
dilution, the overall weight of the pNAM hydrogel started to decrease which indicate that the hydrogel 
is slowly undergoing dissolution. Gorman et al showed that dissolution curve of the pNAM hydrogel 
followed a second order exponential decay function with a dissolution rate constant of  
0.028 g-1min-1 335. The second order exponential decay exhibited by the pNAM polymer highlighted 
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that this class of polymer undergoes chain diffusion and disengagement as the main mechanism for 
hydrogel erosion as discussed by Chou and Koenig 375. In addition, evidence for swelling behaviour of 
pNAM based hydrogel have also been demonstrated by other research group by monitoring the 
changes in gel weight overtime upon immersion in excess distilled water 376,377. 
 
 
Figure 5-7 Schematic highlighting the mechanism of imiquimod release from pNAM polymeric microneedle. Upon 
application, the microneedle absorbs interstitial fluid leading to hydrogel formation. However, over time the 
polymer becomes diluted in the skin leading to hydrogel erosion which causes the release of the drug in the skin. 
However, the interaction of the drug with the polymer within the skin helps retain the drug intradermally 
mitigating transdermal release.  
However, prolonged exposure to the water rich environment of the dermis weakens these 
intermolecular interactions between the polymer chains as the individual pNAM polymer begins to 
form hydrogen bonds with the bulk water molecules within the interstitial fluid. This overall dilution 
process leads to polymer dissolution via chain disengagement and diffusion which culminates in 
hydrogel erosion 378,379. This can be seen in Figure 5-6; the lower layer of the ex vivo BCC tumour 
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treated with imiquimod loaded microneedles displayed lower intensity of C5H9NO+ ions which is 
specific to the pNAM polymer than the upper strata of the tumour highlighting the presence of a 
hydrogel erosion front. It has been described in the literature that the erosion of polymeric hydrogel 
matrix is the main mechanism in which hydrophobic drugs are released into an external medium which 
in this case is the dermal tissue of the BCC tumour 380. By comparing the signal from the molecular ion 
for imiquimod, C14H17N4+ and the signal arising from the fragment ion from pNAM, C5H9NO+ we can 
see some co-localisation of the imiquimod signal with the pNAM hydrogel erosion front. Therefore, in 
the current work it was demonstrated via ToF-SIMS analysis the existence of a hydrogel forming zone 
along with hydrogel erosion zone which leads to the release of imiquimod in the BCC tissue by 
monitoring the ions specific to the pNAM polymer and the drug. The co-localisation of imiquimod in 
the hydrogel erosion front causes the drug to encounter a region of enhanced viscosity due to the 
presence of the pNAM polymer within the BCC tissue 72,73. Such enhanced viscosity, attributed to the 
presence of polymer chains that have dissolved from the hydrogel layer, retards the permeation of 
drug molecules across the skin and into the receptor fluid, leading to enhanced localisation within the 
skin tissue. This may serve as an explanation why the concentration of imiquimod in the receptor fluid 
as shown in Figure 5-5 (d) is statistically similar to that of AldaraTM cream despite the greater 
intradermal delivery of imiquimod via pNAM obelisk microneedles. 
5.5.7 In vivo tumour study 
It was apparent that imiquimod loaded pNAM obelisk microneedles resulted in enhanced intradermal 
delivery of the drug into both ex vivo porcine skin tissue and ex vivo human BCC tumours. 
Subsequently, the efficacy of the formulation was evaluated in a mouse model for a cutaneous 
tumour. Prior to the in vivo tumour study, a dose tolerability study was conducted by applying drug 
loaded microneedle patch on healthy mice as shown Figure 5-8 (a) that were not challenged with any 
cutaneous tumour. This was conducted in order to evaluate the tolerability of the imiquimod loaded 
pNAM microneedle patches and to observe with increasing dose whether the microneedle patch 
would be tolerated and would not affect the overall health of the mice. It can be seen from  
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Figure 5-8 (b) that the mice suffered a reduction in body weight during the 24-hour microneedle patch 
application, however such effects were immediately reverse post patch removal. The reduction in 
body weight was attributed from the observation that the mice found it difficult to consume food and 
water when their bodies were wrapped with the patch and kinesiology tape.  Nevertheless, the ability 
of the mice to recover to more than their original body weight after being challenged with both 50 µg 
and 300 µg loaded microneedle patches suggests that the patches were indeed tolerated. This was 





Figure 5-8 (a) schematic highlighting the application on microneedle on a mouse treated with microneedle (b) 
Changes in mice body weight during dose tolerability study, data are expressed as mean ± SEM, n=3. (c) Changes 
in tumour volume for respective mice treatment group, data are expressed as mean ± SEM, n=10. Differences 
were calculated using one- way ANOVA, followed by Tukey’s post hoc test, and deemed significant at p < 0.05. 
Upon conducting the dose tolerability study, the anti-tumour effect of the imiquimod loaded pNAM 
patches were evaluated in vivo using subcutaneous B16F10 melanoma-bearing mice model. This 
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animal model was chosen as due to the lack of availability of an immunocompetent murine model for 
BCC. Several groups have attempted to develop a BCC xenograft model in nude mice has been met 
with very slow tumour uptake and growth 381. On the other hand, some success have been met when 
severely immunocompromised mice such as beige-nude or SCID-beige were used 382–384. However, 
these immunocompromised models would prove to be unsuitable to screen the efficacy of imiquimod 
loaded microneedle patch as part of the anti-tumoural activity of imiquimod relies on innate and the 
adaptive immune responses. Although imiquimod is not approved for melanoma therapy, it was 
previously shown to display an anti-tumour effect against a melanoma cell line 385,386. This could be 
attributed to some mechanistic similarities between the two types of skin tumours through which 
imiquimod exerts its antitumoural effects. Firstly, imiquimod may induce apoptosis in both type of 
skin tumours through the activation of CD95 surface death receptors which are present on both BCC 
and melanoma tumours. Upon binding to the receptor, imiquimod stimulate CD95 receptors to recruit 
several of proapoptotic factors including caspase-8 to form a death-inducing signalling complex. This 
complex then initiate a cascade of pro-apoptotic pathways by cleaving various intracellular proteins 
that culminate in cancer cell apoptosis in both BCC and melanoma cell lines 386,387. In addition, due to 
the lipophilic nature of imiquimod, the drug has been proposed to penetrate through the cell 
membrane and into the cytosol where the drug causes a marked shift of the Bcl-2/Bax-ratio favouring 
the formation of the pro-apoptotic protein Bax. The Bax protein then translocate to the mitochondria 
where the protein induces the release of cytochrome c into the cytosol leading to the activation of 
caspase-9. This cascade of reactions then result in the activation of further downstream executioner 
caspases that culminate in tumour apoptosis in both BCC and melanoma tumours 385,388. 
Following tumour implantation, treatments were performed on the melanoma-bearing mice 
respectively with tumour volume being recorded to compare the antitumoural efficacy between the 
treatment groups. Mice bearing the melanoma tumour that did not receive any treatment were 
selected as a negative control. From Figure 5-8 (c) it was apparent that there was no statistical 
difference between untreated control and unloaded pNAM microneedle patch treatment groups 
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(p>0.05). Similar observations have been reported by other researchers who found that the physical 
application of a microneedle patch alone without the delivery of any anticancer therapeutics did not 
result in any observable difference to the negative control 66,183. Collectively, these results suggest that 
the physical act of applying the patch did not result in any antitumoural effect.  From a safety 
perspective these observations also highlight that the mechanical application of microneedle alone to 
the tumour is safe and does not exacerbate tumour growth. 
In addition, from Figure 5-8 (c) it was apparent after four applications of the microneedle patch, no 
differences in tumour volume were observed, until two weeks after the last dose was applied. 
However, after two weeks, significant differences in tumour volume were observed between the 
imiquimod loaded pNAM microneedle patch treatment group and the controls. Coupled with the in 
vitro permeation data, this observation does give strong evidence that the application of imiquimod 
loaded pNAM microneedles to the tumour site on the mice led to successful release of the drug into 
the tumour tissue. The reduction in tumour growth in the imiquimod loaded pNAM microneedle is 
attributed to mode of action of imiquimod which stimulates toll-like receptors 7 (TLR-7) on resident 
dendritic cells, macrophages and monocytes in the skin leading to cytokine induction which leads to 
recruitment of plasmacytoid dendritic cells from the blood. In a melanoma mouse model,  
Drobits et al. have shown once these plasmacytoid dendritic cells are recruited to the tumour site, 
these cells secrete cytolytic molecules which then exert an antitumoural response on the  
melanoma 389. The delay in any observable tumour response after the last dose administered may be 
attributed to the time taken to recruit sufficient number plasmacytoid dendritic cells from the blood 
to the tumour site. 
In term of treatment efficacy, it appears that treatment with imiquimod loaded pNAM microneedles 
were only capable of slowing down tumour growth but failed to fully eradicate the melanoma. Similar 
observations have been made by other researchers that utilised a microneedle approach for the 
delivery of therapeutics into the B16 mouse melanoma tumour model 66,390. For instance, Pan et al. 
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discovered that the delivery of small interfering RNA that targets the signal transducer and activator 
of transcription 3 (STAT3), a protein involved in tumour malignancy, using dissolving microneedles 
were only able to slow down tumour growth instead of complete tumour eradication in B16 mouse 
melanoma tumour model 184. Similarly, Ye and co-workers observed that when the immune 
checkpoint inhibitor, anti-PD1 antibody that is used in the treatment of advanced melanoma was 
delivered using dissolving microneedles, complete tumour eradication was not achieved but the 
researchers observed a retardation in tumour growth. Nevertheless, such a delay in tumour growth 
was far more significant in comparison to mice in the control groups that received no treatment or 
mice that received treatment via intravenous administration of the anti-PD1 antibody 177.  By 
comparing the observations from these studies along with results from the current work, this 
highlights that complete tumour eradication in B16 mouse melanoma tumour model is indeed 
challenging and is attributed to highly aggressive nature of the tumour which makes complete tumour 
eradication very challenging 391. Nevertheless, the retardation in tumour progression does provide an 
indication that localised intradermal delivery of imiquimod using dissolving polymeric microneedles 
still provides some level of efficacy in the mice tumour model. 
With respect to the type of payload delivered, several groups have utilised and evaluated the 
effectiveness of different microneedle systems for the delivery of drugs used in BCC treatment. For 
instance, Jain et al. delivered the photosensitizer, 5-aminolevelunic acid, using carboxymethylcellulose 
coated stainless microneedles into Balb/c mice that were implanted with B-cell lymphoma cells as a 
skin tumour model. The group discovered that the combination of microneedle-based delivery of the 
photosensitizer followed with irradiation with red light at 633nm, resulted in significant suppression 
in tumour growth after 11 days. 175 Although this strategy proved efficacious, the two-step treatment 
may not be favourable by patients as they will need to attend the dermatology clinic in order to receive 
the light irradiation step. This additional step would also require the assistance of clinicians in 
administering the irradiation dose thus adding further cost to the therapy. In contrast, the use of 
imiquimod loaded pNAM microneedles that only require a one-step application under thumb pressure 
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would enable patients to self-administer the dose by themselves in the comfort of their home without 
the need of any healthcare worker. This offers a possibility for a cheaper overall treatment cost 
relative to the two-step treatment strategy developed by Jain and co-workers. 
On the other hand, Naguib et al. demonstrated the feasibility of using solid microneedles as a skin pre-
treatment via the poke-and-patch strategy to enhance the intradermal delivery of 5-fluorouracil to 
treat skin tumours. In their in vivo work using a mouse model with B16-F10 melanoma tumour, the 
group showed that topical application of 5-fluorouracil cream on microneedle-perforated skin 
resulted in significant tumour inhibition relative to the groups that receive no treatment or only 5-FU 
cream only 66. When comparing the microneedle systems used by Naguib et al. and Jain et al., the use 
of solid and coated microneedles will pose the issue of dangerous sharp waste disposal after 
microneedle application, which can be more prominent in poor resource settings. In contrast, this 
issue is not encountered with the imiquimod loaded pNAM microneedles after application, as the 
polymeric microneedles will have dissolved after 24 hours, leaving behind the backing layer, thus 
obviating the issue of sharp injury with needle reinsertion. 
5.6 Conclusions 
In conclusion, the current work highlights the design, fabrication and evaluation of a series of drug 
loaded polymeric microneedles of different designs and polymeric chemistries. These microneedle 
systems were developed as a drug delivery platform for the intradermal delivery of imiquimod for the 
treatment of nodular BCC. In vitro characterisation highlights that these microneedles were capable 
of breaching the skin down to the depth which nodular BCC typically resides. Permeation studies 
utilising Franz diffusion cells demonstrated that out of all the formulations developed, imiquimod 
loaded pNAM obelisk microneedles delivered the highest quantities of imiquimod into the stratum 
corneum and remaining skin relative to the commercial cream AldaraTM. This was achieved despite a 
3-fold lower drug loading, relative to the current clinical dose of AldaraTM cream used in BCC 
treatment. This ability of the polymeric microneedle to deliver the drug to the right target site despite 
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lower drug loading was also demonstrated in a ex vivo human BCC tumour. In addition, ToF-SIMS 
analysis of ex vivo human BCC tumour cross-sections highlighted the presence of embedded drug-
polymer matrix within tumour, which retains the drug within the tumour while reducing the 
permeation of the drug across the skin. Lastly, the in vivo tumour efficacy study using a mouse model 
for skin tumours highlighted that the microneedle was capable of delivering the drug into the tumour, 
resulting in a retardation in tumour growth. In summary, this work suggests that the drug loaded 
pNAM obelisk polymeric microneedles developed in this work may be of clinical utility for localised 
intradermal delivery of imiquimod. Such formulations may provide a less invasive intervention to 




5.7 Supplementary Figures 
 




Figure S5- 2 Microneedle length for all microneedle formulation fabricated. Data is expressed as  
mean ± SD, n=10. 
 
Figure S5- 3 (a) Respective polymeric microneedle fabricated without polyvinyl alcohol (PVA) resulting in 
microneedles with fractured tips post demoulding. (b) Optimised microneedle formulation via the addition of 




Figure S5- 4 Overlaid ToF-SIMS spectra of (a) pNAM microneedle before sputtering highlighting the presence of 
Si2C5H15O+ as a contaminant on the microneedle(b) pNAM microneedle after sputtering highlighting the absence 




Figure S5- 5 Overlaid ToF-SIMS spectra of (a) BCC tumour treated with pNAM polymeric microneedles (b) blank 
untreated BCC tumour (c) pure pNAM reference, showing the fragment peak of pNAM (C5H9NO+) at m/z = 99 as 
suitable marker to track the dermal distribution of the polymer within the skin.  
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Chapter 6 General Conclusions, Future Work and Clinical 
Translation  
6.1 General Conclusion 
Despite having a low likelihood to metastasise, BCC may induce substantial destruction to local tissues 
should the tumour be left untreated. The most effective treatment for BCC is Mohs’ micrographic 
surgery. Although this treatment strategy is effective, the surgical prerequisites are both time-
consuming and technical, which are major limitations of this surgical intervention 43,60–62. In addition, 
some patients would prefer a less invasive treatment option in which they could self-administer at 
home. One of these alternative treatments is topical therapy with AldaraTM cream  
(5% w/w of imiquimod). Despite imiquimod being one of the most efficacious drugs in the 
management of BCC the drug has a poor permeation profile and thus its use is limited to the 
management of the superficial variant of the cancer. 
The objective of this PhD project was to investigate and develop a drug delivery strategy using 
microneedles to improve the intradermal delivery of imiquimod for the treatment of nodular BCC. 
This objective was explored via two different strategies. The first approach involves investigating the 
use of commercial microneedles in combination with the commercially available AldaraTM cream. On 
the other hand, the second approach explored the reformulation of imiquimod into a dissolvable 
microneedle system. These strands of investigations and formulation development have led to a 
better understanding of how microneedles may be utilised as a drug delivery platform for the 
management of skin cancers such as nodular BCC. 
One of the key findings of this thesis includes the characterisation on the mechanical insertion of 
microneedles into the skin. It was discovered that biaxial strain indeed influences the penetration of 
microneedles into the skin. The two commercially microneedle systems investigated, Dermapen® and 
Dermastamp™ displayed different insertion force profiles with increasing skin strain. For all the strain 
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levels studied, it was evident that the Dermapen® required less insertion force than the 
Dermastamp™. In addition, the Dermapen® resulted in smaller variability in insertion efficiency and 
puncture force while resulting in deeper skin insertion than that of the Dermastamp™. The lower 
insertion force and deeper penetration conferred by the Dermapen® was attributed to the oscillating 
feature of the microneedle system which mitigates the effective frictional force encountered by the 
needle during skin application. Despite the better skin insertion profile displayed by Dermapen® 
relative to the Dermastamp™, such differences in penetration did not affect the permeation profile of 
imiquimod across the skin as shown in the ex vivo permeation study when a poke-and-patch approach 
was adopted. 
Moving forward, the effectiveness of the oscillating microneedle system, Dermapen, as a device to 
improve the intradermal delivery of imiquimod was investigated further. It was discovered that the 
approach in which the microneedles are used in combination with Aldara cream played a pivotal role 
in the intradermal delivery of imiquimod into the skin. It was evident that in order to successfully 
deliver imiquimod into the dermis, a patch-and-poke approach is superior to the conventional poke-
and-patch strategy. This is based on the ToF-SIMS analysis of porcine skin cross-sections post 
permeation studies that demonstrated limited dermal permeation when AldaraTM cream was applied 
to the skin that was pre-treated with the Dermapen. Such limited permeation was similar to that 
observed when the porcine skin was treated with AldaraTM cream alone. In contrast, when a patch-
and-poke strategy was adopted with the Dermapen® in combination with AldaraTM cream, we 
observed enhanced intradermal delivery of imiquimod into the dermis that persisted for up to  
24 hours. In addition, it was also highlighted that the oscillating function of the Dermapen for the 
patch-and- poke strategy, is a critical factor in providing successful intradermal delivery of imiquimod 
into the skin. This is because when the patch-and- poke strategy was adopted with the non-oscillating 
DermastampTM, we were unable to detect enhanced intradermal delivery of imiquimod into the skin. 
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The utility of using commercially available solid microneedle system coupled with the use of licensed 
imiquimod topical cream for treatment of BCC may be of great clinical value for nodular BCC patients 
who would prefer a less invasive intervention relative to surgery. However, the patch-and-poke 
administration is a two-step application process, which may decrease patient compliance and the 
adherence to the treatment. Furthermore, this step still involves topical cream application, which is 
often unfavourable for some patients due to poor cosmetic sensation upon administration. The 
propensity for the cream to spread to clothes and adjacent healthy skin is still a problem with the 
patch-and-poke strategy. Hence, there is an impetus to reformulate imiquimod into a dissolving 
microneedle system, which would allow for a one-step application. This simple one-step application 
would be a more preferred treatment option for patients in which they could easily self-administer at 
home.  
Therefore, this drug delivery strategy was explored by designing, fabricating, and evaluating the utility 
of drug loaded dissolvable polymeric microneedles for the intradermal delivery of imiquimod for the 
treatment of nodular BCC. PVPVA microneedles loaded with imiquimod were manufactured via a 
microfabrication and polymer casting technique. Permeation studies highlighted that the imiquimod 
loaded polymeric microneedles were capable of delivering similar quantities of imiquimod into the 
skin, despite a 6-fold lower drug loading, relative to the current clinical dose of Aldara™ cream used 
in BCC treatment. This permeation study showed that dissolvable polymeric microneedles were 
capable of delivering imiquimod to the right target site despite lower drug loading. This may be of 
economic benefit as less drug is wasted during administration while also mitigating the likelihood of 
side effects. In addition, analysis of skin cross sections treated with the microneedle patch highlighted 
the presence of drug-polymer matrix within the skin. This matrix helped retain the drug in the dermis 
while reducing the permeation of the drug across the skin. This finding corroborated the mechanistic 
understanding of how the embedded drug-polymer matrix following polymeric microneedle 
administration controls the release of drugs within the skin.  
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Moving forward we explored if using different microneedle designs coupled with the choice of 
different polymers may improve the delivery of imiquimod into the skin. This was explored in the final 
chapter of this thesis. Microneedle moulds of different microneedle architectures (obelisk and 
pyramidal) were produced using micromachining while three different hydrophilic polymers-pNAM, 
pAMPS and pHEAM were synthesised via free radical polymerisation reaction. The moulds were then 
used to manufacture different types of dissolving polymeric microneedle patches of different designs 
and chemistries. The polymeric microneedles were characterised via microscopy, fracture test and ex 
vivo skin insertion studies. ToF-SIMS analysis on microneedles was conducted and showed the 
homogenous distribution of drug and polymer distribution along the microneedle lengths in a label 
free fashion. In addition, the chemical sensitivity conferred by ToF-SIMS analysis allowed us to detect 
and visualise for the first time the presence of polydimethylsiloxane (PDMS) contamination along the 
polymeric microneedles. Drug release studies into ex vivo porcine skin was also conducted in 
comparison to the commercial cream, AldaraTM. It was discovered that microneedles fabricated from 
pNAM with an obelisk design resulted in significantly greater delivery of imiquimod into the skin 
relative to AldaraTM cream. This was further corroborated by the successful delivery of imiquimod 
using pNAM-based obelisk microneedles into human BCC tumours demonstrating the potential of the 
microneedle-based approach to treat BCC. In addition, the efficacy of the formulation was also 
evaluated and demonstrated in vivo using a rodent model for skin tumours with mice being treated 
with imiquimod loaded pNAM-based obelisk shaped dissolving microneedles showing a reduction in 
tumour growth as compared to the control groups. 
It was apparent that throughout this work that the application of ToF-SIMS imaging played a pivotal 
role in elucidating the dermal distribution of active and excipient following microneedle treatment. 
Conventionally, the most common and widely accepted method of assessing skin permeation typically 
involves HPLC. Despite the absolute quantitative data conferred by HPLC, this technique does not 
provide information pertaining to the dermal distribution of the drug and excipients within the skin. 
In contrast, imaging mass spectrometry techniques, such as ToF-SIMS, were capable of showing the 
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dermal distribution of active and excipients from the formulation within biological tissues (e.g., 
porcine skin tissue & human BCC tissue) in a label free fashion. This is evident from the ability to 
demonstrate the colocalisation of imiquimod and isostearic acid within microneedle channels 
following the patch-and-poke strategy in Chapter 3. In Chapter 4, this was also demonstrated by the 
ability to detect the presence a drug-polymer matrix within the skin. The existence of this drug 
polymer matrix helped provide evidence how dissolving microneedles conferred enhanced 
intradermal delivery of imiquimod whilst mitigating the movement of the drug across the skin into the 
receptor fluid. Lastly in Chapter 5, the detection of the presence of imiquimod along with the newly 
synthesised pNAM within an actual human BCC tumour further demonstrated the analytical power of 
ToF-SIMS in guiding formulation scientists on the fate and localisation of the active and excipients of 
the formulation following administration. It is worth emphasising that the ability of ToF-SIMS analysis 
to image the dermal distribution of drug, excipient within a biological tissue without the need for 
fluorescent reporter tags obviates the issues of altering the physiochemical properties of the molecule 
of interest that could lead to inaccurate estimation of the distribution of the molecule within biological 
tissues. 
6.2 Summary of significant results and method development from experimental chapter 
In general, a series of method development and optimisation has taken place across the experimental 
chapters which have led to the development and characterisation of the final polymeric pNAM obelisk 
microneedle system. In  Chapter 2 of this thesis, it has been shown that commercial microneedle 
systems such as the Dermapen® and the Dermastamp™, are capable of breaching the stratum 
corneum which led to the generation of microneedle channels within the skin. In order to evaluate 
and quantify these insertion profiles between the two systems, various insertion studies were 
developed and utilised. Firstly, this chapter highlights the development of a novel biaxial stretch rig 
that was used to investigate the effect of skin strain on microneedle insertion into the skin. The 
development of such device highlighted that the Dermapen® required less force for microneedle 
insertion into the skin for all skin strains investigate while displaying superior insertion reproducibility 
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relative to the Dermastamp™. This chapter also highted the utilisation of the in vitro Parafilm M® 
insertion study as a simple and inexpensive method to evaluate and estimate the microneedle 
penetration prior to ex vivo porcine skin insertion. In addition, this chapter also featured the 
development and utilisation of the dye binding study as a method to estimate microneedle insertion 
depth into ex vivo skin. Through the use of these insertion tests, it was shown that the Dermapen® 
possessed superior insertion profile relative to the DermastampTM in puncturing the skin down to a 
depth of ≈ 600 µm which nodular BCC typically resides. The insertion tests utilised in this chapter were 
later employed as to estimate and quantify microneedle insertions later chapters. Overall, Chapter 2 
of this thesis identified that the Dermapen® was indeed the superior commercial microneedle system 
relative to the DermastampTM.  
In Chapter 3 of this thesis, the utility of Dermapen® in enhancing the delivery of imiquimod into the 
skin was explored further. It was shown that post-treatment of the skin with the Dermapen® after 
AldaraTM application, known as “patch-and-poke”, was superior to the conventional “poke-and-patch” 
strategy in enhancing the intradermal delivery of imiquimod into the skin. However, such 
improvement in intradermal delivery of imiquimod was not apparent when the “patch-and-poke” 
strategy utilised a non-oscillating microneedle applicator, the DermastampTM. Enhancement in 
intradermal delivery of imiquimod via the “patch-and-poke” approach was visualised through  
ToF-SIMS analysis of skin cross-sections that were cryosection through partial OCT embedding. The 
application of ToF-SIMS analysis within this chapter expanded upon the method developed by Al-
Mayahy et al. 68 by exploring the capability of this analytical method to track the co-localisation of 
both active (imiquimod) and excipient (isosteric acid) within skin tissues. The result obtained within 
this chapter demonstrated for the first time the ability to track both active and excipients from a 
microneedle treatment in a label free fashion.  The methodology developed within this chapter was 
later used to analyse the colocalisation of drug and other excipients such as polymers within the skin 
as demonstrated in Chapter 4 and Chapter 5. 
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It has been highlighted in Chapter 4 that there is an impetus to reformulate imiquimod into a dissolving 
microneedle system due the limitation associated with the “patch-and-poke” strategy. Therefore, 
Chapter 4 of this thesis highlighted the development and optimisation of the methodology to produce 
dissolving microneedles via the use of micromachining and micromoulding. A dissolving polymeric 
microneedle system was fabricated through the use of a commercially available polymer, PVPVA that 
has never been used in microneedle production before. The microneedle system developed was 
capable of delivering similar quantities of imiquimod intradermally, despite a 6-fold lower drug 
loading, relative to the current clinical dose of AldaraTM cream used in BCC treatment. This chapter 
also highlighted the importance of incorporating plasticiser such as PEG 400 during microneedle 
production as this mitigate the likelihood of microneedle fracturing during the demoulding stage. The 
knowledge of incorporating of plasticisers such as PEG 400 into polymeric microneedle formulations 
was later applied to the development of other polymeric microneedle systems in Chapter 5. The 
parallel detection capability of ToF-SIMS demonstrated in Chapter 3 was further explored and utilised 
in Chapter 4 by tracking the colocalisation of both drug and polymer within the skin tissue. This was 
the first study within the microneedle field that demonstrated the capability to simultaneously detect 
the deposition of both drug and polymer from a dissolving microneedle patch in a label free fashion.  
The advances and method optimisations developed in the earlier chapters were then applied to 
Chapter 5. In this final experimental chapter, a series of novel polymers that has never been used in 
microneedle fabrication were synthesised. These polymers are similar to PVPVA used in Chapter 4 
because they are also hydrophilic. This enabled the polymers to be dissolved into aqueous solutions 
which are then used to formulate dissolving microneedles via the same micromachining and 
micromoulding process developed in  Chapter 4. Based on the knowledge gained from Chapter 4, each 
of the microneedle formulation developed in  Chapter 5 incorporated plasticisers such as PEG 400 and 
PVA to help mitigate the propensity of needle fracture during microneedle demoulding. This enabled 
the production of intact and sharp microneedles on a clean and smooth base. The Parafilm M® and 
dye binding study that was developed and optimised in Chapter 2 were applied to characterised the 
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series of polymeric microneedle developed in this chapter. These insertion tests showed that the 
pNAM obelisk microneedles displayed the best insertion depth and efficiency out of all the polymeric 
microneedles developed. In addition, the pNAM obelisk microneedle was capable of delivering 
imiquimod into ex vivo human BCC tumours while also demonstrating efficacy in vivo using a rodent 
model for skin tumours. The capability of the ToF-SIMS analytical method developed  
Chapter 3 was further demonstrated in Chapter 5 through the detection of the presence of imiquimod 
along with the newly synthesised pNAM within an actual human BCC tumour. Indeed, there is a series 
of method development and optimisation throughout the earlier chapters within this thesis. These 
methods are later applied to the final series of experiments in  Chapter 5. Such methodologies enabled 
the development and characterisation of a series of imiquimod loaded polymeric microneedles. Out 
of all the polymeric microneedles developed within this body of work, it was identified that the pNAM 
obelisk microneedles was capable of achieving the highest intradermal delivery of imiquimod into the 
skin. The pNAM obelisk microneedles developed may be of therapeutic value for the treatment of 
nodular BCC in patients who would prefer an alternative treatment to surgery.  
6.3 Future Work 
The results presented within this thesis explored the utility of microneedles as a drug delivery platform 
to enhance imiquimod delivery into the skin for the treatment of nodular BCC. The successful 
permeation enhancement of imiquimod into the skin through the use of solid microneedles via the 
patch-and-poke approach along with the reformulation of imiquimod into dissolvable microneedles 
demonstrated the clinical potential that microneedles could have in managing dermatological 
conditions such as skin cancers. Such treatment can easily be self-administered by patients thus 
mitigating the clinical burden imposed by the disease on the healthcare system. Moving forward, there 
are some recommendations that can be carried out to further improve our mechanistic understanding 
on the insertion profile, drug release behaviour and efficacy from the microneedle systems developed. 
In addition, these future works could also help refine the microneedle systems developed in order to 
further improve the efficacy for the management of nodular BCC. 
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In Chapter 2 in this thesis, skin insertion studies using ex vivo porcine skin was utilised to investigate 
the effect of biaxial strain (stretching) on the insertion of commercial cosmetic microneedles system 
into the skin. This experimental set-up proved to be a valuable tool in distinguishing the insertion 
profile (insertion efficiency and force needed for insertion) from two different commercial 
microneedle systems. It would be of great heuristic value to use such experimental set-up to elucidate 
the effect of biaxial strain on the insertion profile of polymeric microneedle patches fabricated from 
different polymers with different geometries. Such information will help us understand if the insertion 
profile of microneedle patches is dependent on polymer chemistry and needle design. The different 
skin strain generated may mimic the effect of biological variability of the skin arising from anatomical 
locations and aging. 
In Chapter 3 of this thesis, we demonstrated via ToF-SIMS label free imaging that using the patch-and-
poke approach with the Dermapen® in combination AldaraTM resulted in co-localised delivery of both 
imiquimod and isostearic acid. As it has been discussed in Chapter 3, although isostearic acid has been 
traditionally used as a surfactant in most topical and cosmetic products, the fatty acid surfactant has 
been shown by Walter et al. to display pharmacological properties independent of the immune-
mediated response induced by imiquimod 286. In addition, it has also been highlighted by Walter et al. 
that the presence of isosteric acid is pertinent to the overall efficacy of AldaraTM cream. However, in 
Chapter 4 and Chapter 5 we have reformulated imiquimod into dissolvable microneedles in the 
absence of isostearic acid. Due to the poor water solubility of isostearic acid, the fatty acid was not 
incorporated into the aqueous drug and polymer blend during the fabrication of dissolvable polymeric  
microneedle 392.  
Therefore, it is suggested that a potential research avenue that warrants further investigation is to 
identify a way of reformulating both imiquimod and isosteric acid into a single dissolvable microneedle 
system. One strategy that could be used is to first reformulate both imiquimod and isostearic acid into 
solid lipid nanoparticle which is then incorporated into dissolving microneedle systems. This solid lipid 
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nanoparticle-based dissolving microneedles strategy have been explored by Permana et al. and has 
been shown to be successful in delivering the antifilariasis drugs doxycycline, diethylcarbamazine and 
albendazole intradermally 393. The co-delivery of both imiquimod and isostearic using solid lipid 
nanoparticles may prove to be more efficacious that the delivery of imiquimod alone using dissolving 
microneedles.  
In addition, it has been reported that the incorporation of drug molecules and biologics into 
microneedle systems such as dissolving, coated and hydrogel forming microneedles enhances the 
stability of therapeutics. This is attributed to the interaction of the therapeutics with the polymer 
matrix that results in reduced molecular mobility of the incorporated molecules. The restricted 
molecular mobility results in reduced kinetics of possible chemical and physical degradation pathways, 
leading to improved stability. The interaction of the drug molecules with polymers through hydrogen 
bonding also results in the formation of a stabilisation shell around the incorporated therapeutic, 
which mitigates dehydration induced changes during storage. Nevertheless, long-term stability 
studies of the microneedle formulations developed in the current work will need to be done in order 
to establish the stability of the formulations long-term. When conducting these stability studies, it is 
suggested that both the stability of the incorporated therapeutic along with the mechanical properties 
of the overall microneedle patches during long term storage would need to be evaluated. This is 
because the hygroscopic nature of hydrophilic polymers used in this work could have adverse effects 
on the needle structure and subsequently, the ability of the microneedle array to successfully 
penetrate the skin. Further studies into these effects could help establish the viability of the 
microneedle patches after prolonged storage. 
These stability studies should also be complemented with research looking into appropriate primary 
packaging for microneedles. As dissolving and hydrogel forming microneedle are deemed “self-
disabling” once the formulations are exposed to liquid or humid environment, it is necessary that the 
packaging in which these microneedles are stored confer protection against such environmental 
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factors. Work that looks into these primary packaging would be imperative and would help the 
transition of microneedle technology from a laboratory setting to patients.  
In Chapter 5 of this thesis, the efficacy of imiquimod loaded microneedle patches was evaluated in 
B16 melanoma model in HHDII/HLA- DP4 mice. Although imiquimod has been shown to be efficacious 
in slowing down tumour growth in the mouse model for melanoma, it is acknowledged that the use 
of this animal model may not be an accurate animal model to predict the efficacy of the formulation 
developed for BCC 389. One of the challenges in developing formulation for BCC is the lack of good and 
accurate pre-clinical animal models for BCC. Tumour xenograft models are the standard used in 
assessing the efficacy of new treatments at the pre-clinical stage. However, it has been shown that 
successful and reproducible human BCC xenograft implantations in mice model have been attempted 
but have been met with little success. These animal models yielded low tumour uptake and growth 
making these models unsuitable to evaluate formulation efficacy 381. Some level of success have been 
achieved when these xerographs are implanted in severely immunocompromised murine models such 
as beige-nude, SCID-beige mice or NOD/SCID mice 382–384. However, these immunocompromised 
models may not be suited to screen the efficacy of imiquimod loaded microneedle patch as part of 
the anti-tumoural activity of imiquimod relies on the innate and the adaptive immune responses. 
Therefore, future work in establishing an immunocompetent mouse model for BCC would pertinent 
in order to evaluate the efficacy of these imiquimod loaded microneedle patches for BCC treatment. 
The ideal BCC animal model ought to be orthotopic, have short tumour latency, display similar tumour 
profile to humans, predictable growth rate as well as capable of producing identical tumour replicates 
for formulation screening and evaluation. 
It has been highlighted that one of the mechanisms for imiquimod induced antitumour response is via 
the innate and the adaptive immune responses. Another research avenue worth exploring is to carry 
out imaging mass spectrometry analysis on tumours from mice that have not been treated with 
imiquimod microneedles and those who have received treatment with imiquimod microneedles. By 
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doing so we can observe the change in the metabolic and immune profile of the local tumour milieu 
following the administration of the imiquimod loaded microneedles. However, as most of the immune 
response mediated my imiquimod leads to the production of proteins and peptides such as 
interleukins, TNF-α, interferon-α and granulocyte colony-stimulating factor, it is postulated that ToF-
SIMS imaging may not have the sensitivity and mass-resolving power needed to detect such proteins. 
However, with the recent development and introduction of the Hybrid-SIMS also known as the 3D 
OrbiSIMS, such analysis would be achievable. The Hybrid-SIMS is equipped with an OrbitrapTM mass 
analyser that confers the instrument with a mass-resolving power of >240,000 at m/z 200 and mass 
accuracy <1 p.p.m. Such resolving power would permit the detection and analysis of ions with 
enhanced sensitivity in comparison to the ToF-SIMS analysis conducted in the present work. In 
addition, Passarelli et al. has shown that the Hybrid-SIMS may also be used to image the drug 
distribution down to single cell analysis 394. Such approach could be extended to single cell analysis of 
both tumour cells and immune cells within the tumour milieu following the treatment with imiquimod 
loaded dissolving microneedles. This would permit us to establish the changes in both metabolic and 
immune profile within the tumours prior and post-treatment. Nevertheless, such analysis would need 
rigorous optimisation and validation before such analysis and tumour profiling could be achieved. 
The results within this thesis have shown that microneedles indeed provide a viable approach to 
enhance the delivery of imiquimod for the treatment of skin tumours such as BCC. When developed 
further as suggested by these future works, this drug delivery platform could prove to be of great 
clinical value in the management of BCC, which could lessen the burden of skin cancers on 
dermatologist workload while providing a simple and effective treatment in which patients could self-
administer the medicine at home. In summary, this future work would aid the development and 
clinical translation of these dissolving microneedle systems. However, before such a transition into 
clinical settings could occur, some translation challenges would need to be considered and addressed. 
Such translational hurdles are discussed in the last section of this chapter. 
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6.4 Clinical Translation and future perspectives 
At the time of writing this thesis there are no commercially available dissolvable microneedle systems 
for clinical application on the market. The microneedle product, which is closest to FDA approval is a 
formulation of zolmitriptan, that is delivered transdermally via drug-coated microneedle arrays. The 
microneedle system known Qtrypta™, owned by Zosano Pharma is anticipated to be approved for 
clinical use by 2021 for acute migraine attacks as the proprietary formulation successfully 
demonstrated efficacy, safety and tolerability in phase 2 and 3 clinical trials. Nevertheless, the lack 
microneedle products on the market at the moment for clinical use highlights that there are indeed 
several translation hurdles that are currently hindering the progression of microneedle systems from 
bench to bedside. 
One of the factors that needs to be acknowledged and considered is the need to incorporate a 
feedback system into the microneedle products developed. This would provide end-user the 
confidence and certainty that the microneedle patches have been successfully inserted into the skin. 
Through engagement with potential end-users, Donnelly and co-workers have identified that this is 
one of the major hurdles in translating microneedle systems into clinical practice 395. Several attempts 
to incorporate a simple feedback mechanism into microneedle systems have been explored by several 
researchers. Norman et al. reported the use of a simple, low-cost snap-based device that provides 
audible feedback upon microneedle application. The group discovered that there was a significantly 
higher end-user preference for microneedle systems that incorporated the audible snap-based 
feedback system relative to microneedle systems that did not have this function 396. Furthering this, 
Vicente-pérez et al. explored the use of a low-cost pressure-indicating sensor film (PISF), Pressurex-
micro® Green attached to the backing layer of microneedle patches. This acts as a feedback system to 
indicate successful microneedle insertion. The film undergoes a colour change when a pressure of 
greater than 18.6 Ncm−2 has been applied to the skin, which is sufficient for successful microneedle 
insertion 309. Therefore, if the microneedle systems developed in this project were to be translated 
into clinical practice for the treatment of nodular or even superficial BCC, the incorporation of a simple 
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feedback system (e.g. snap-based device or even colour changing backing layer) would provide 
reassurance to the patient that they have administered the anticancer medicine accurately. 
Sterility will be another factor to consider in the translation of dissolvable microneedle products into 
clinical practice. From a commercial standpoint, the choice of the sterilisation method will be critical 
as this will ultimately impact the cost of the final product. McCrudden et al. was the first to explore 
the method of sterilisation of microneedle patches. They discovered that using terminal sterilisation 
techniques such as steam autoclaving and dry sterilisation resulted in substantial irreversible damage 
to dissolving and hydrogel-forming microneedle systems 313. This is attributed to the hygroscopic 
nature of the hydrophilic polymers used in fabricating these polymeric microneedle systems. 
Furthering this, Swathi et al. explored the effect of gamma irradiation on dissolving microneedles. 
Four different dissolving microneedles systems fabricated from sodium carboxymethyl cellulose 
(CMC), polyvinylpyrrolidone (PVP) K30, PVP K90 and sodium hyaluronate (HU) were explored. Upon 
exposure to gamma irradiation, it was discovered that CMC and PVP K30 microneedles were affected 
by this mode of sterilisation resulting in poor mechanical properties and needle architecture. 
However, the appearance, properties and release profile of PVP K90 and HU were unaffected by the 
dose of gamma irradiation used 397. In comparison, the current work utilised hydrophilic polymers to 
fabricate dissolvable microneedle systems. It is anticipated that these microneedle systems would be 
susceptible to irreversible damage should steam autoclaving or dry sterilisation are utilised as a 
method of terminal sterilisation since the polymers used in the current work are also hydrophilic. It is 
proposed that the PVPVA microneedles and pNAM microneedles fabricated might be more suited to 
be sterilised via gamma irradiation. However, this should be accompanied by further testing to 
evaluate if the appearance and release profile of these systems have been altered post-sterilisation. 
Should this method of sterilisation also be deemed unsuitable, then it is likely that aseptic 
manufacture would be the way to produce these microneedles. 
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Another factor to consider is the possible scale-up of the manufacturing process of these dissolvable 
microneedles. With regards to the production method used in this study, which involved 
centrifugation and polymer blend casting, such methodology would be most suited for lab-based 
research and is not suitable for the manufacture of patches at a commercial scale. This is because 
laboratory-based procedures are typically difficult to scale-up, with issues revolving around cost-
efficiency of mass manufacture as well as turnaround time.  
 Therefore, a method to produce large quantities of dissolvable microneedle patches ought to be 
investigated. Such production would be imperative particularly when large number of microneedle 
patches are needed during phase 2 and 3 clinical trials and ultimately for commercial manufacture 
when the products have gained regulatory approval. The use of aqueous drug-polymer blend casting 
method used in this work could be potentially be translated into the scalable roller system 
manufacturing method developed by Lutton et al. 299. The use of the roller system would provide a 
potential scale-up manufacturing method at a commercial scale, enabling the transition from 
laboratory to industry manufacture and subsequent clinical practice. 
Another major hurdle to consider would be the need to establish standardised quality control tests to 
evaluate the properties and performance of microneedle-based medical products at the final stage of 
mass production. Indeed, there are strict guidelines and pharmacopoeial standards that a medicine 
would need to meet prior to release for human use. However, such guidelines and standards are yet 
to be established for microneedle-based formulations. It is anticipated that such standards and tests 
will emerged once microneedle-based medicine are commercialised as such tests are typically derived 
from products that have been approved by regulatory bodies as part of a manufacturer’s submitted 
dossier. The development of such guidelines and standardised tests would also aid researchers within 
the field on the choice of experiments that ought to be done when developing new microneedle 
systems. Despite the uncertainties with regards to standardised quality control tests, considerable 
strides have been made in this direction. For instance, the FDA has recently published draft guidance 
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on “microneedling” for cosmetic applications 398. It is predicted that this draft guidance would act as 
a foundation to develop guidelines for microneedle-based product for medical applications in the 
future. This is further corroborated by establishment of PATH Center of Excellence for Microarray 
Patch Technology, a non-profit, international health organisation working on progressing microneedle 
technology for effective and safe clinical use. Recently, PATH has released information detailing their 
four-year initiative in propelling the development of microneedle-based drug delivery system for 
clinical use 399. As an emerging pharmaceutical technology, microneedles display considerable 
advantages such as being patient friendly, easy to apply and remove, minimally invasive and painless. 
The versatility and diversity in microneedle designs allow the device to be tailored to nature of the 
disease intended to be treated. Such advantages may have a significant clinical impact in the 
foreseeable future. However, before commercialisation and transition into clinical practice can take 
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